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This study was aimed at investigating the effect of inhibiting SRPK1 in leukaemic cells. It 
was also aimed at exploring the potential utility of combining conventional leukaemia 
chemotherapy (such as imatinib) with compounds that inhibit SRPK1. 
SRPK1 is best known for its role in the phosphorylation of serine/argenine rich proteins 
(SR-proteins) which are responsible for constitutive and alternative mRNA splicing. 
Studies have associated elevated levels of SRPK1 with tumour growth, proliferation and  
invasiveness with inhibition resulting in decreased tumour growth and altering the 
choice of alternative splice site. 
Imatinib mesylate and azacytidine remain the drugs of choice for the management of 
chronic myeloid leukaemia (CML) and acute myelogenous leukaemia (AML)  
respectively. Studies have shown that both imatinib and azacytidine are able to reduce 
the growth of proliferating Bcr/Abl+ and AML cells principally through the induction of 
apoptotic cell death.  
SRPK1 was inhibited using the small molecule inhibitor SPHINX. SPHINX was combined 
with either  imatinib in a CML cell line (K562) or azacytidine in an AML cell line (Kasumi-
1) for up to 72hrs. Results suggest that the SPHINX compound affects the ability of SRPK1 
to phosphorylate its substrates in all three cell lines (TK6, K562 and Kasumi-1).  Inhibition 
of SRPK1 was  found to reduce cell viability in Kasumi-1 cells and at higher concentration,  
affect K562 cell viability consistent with the work of Sanidas et al.,(2010). There was also 
an indication that SRPK1 could be regulating its own expression through a feedback loop 
in a cell line-dependent manner. 
Studies with imatinib mesylate and azacytidine showed that both imatinib mesylate and 
azacytidine are able to reduce cell growth and viability in a dose and time-dependent 
manner. On combining them with SPHINX, a combination of azacytidine and SPHINX had 
an additive effective on Kasumi-1 cells but not with imatinib mesylate in K562 cells. 
Results also showed that imatinib affected the alternative splicing  of caspase 9 
favouring a pro-apoptotic isoform, caspase 9a. Imatinib mesylate alone also caused an 
apparent reduction in the expression of SRPK1, CLK1 and SRSF1, suggesting that 
pathways imatinib affects cell signalling pathways that regulate the expression of these 
oncogenic splice factor kinases and splice factors. In summary, this thesis presents 
xvi 
 
evidence that targeting SRPK1 could potentially provide therapeutic benefit in the 
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CHAPTER 1  
Introduction 
1.1 Haematopoiesis 
The blood system is established and maintained by self-renewing haematopoietic stem 
cells found in the bones marrows of adult humans. This process known as 
haematopoiesis is the process by which circulating blood stem cells called 
haemocytoblasts go on to become committed progenitor cells giving rise to erythroid, 
megakaryocytic, granulocytic, monocytic, basophilic, eosinophilic, or lymphoid lineages 
over the course of a lifetime (Kondo et al., 1997; Akashi et al., 2000) (Figure 1.1). An 
earlier study suggests that not all haematopoietic stem cells become committed to a 
lineage as some cell which express high levels of interleukin-7 (IL-7) neither adopt 
erythroid or megakaryocyte lineage fates (Adolfsson et al., 2005). The process of cell 
differentiation in haematopoiesis is mediated by transcription factors (TFs) (AML-1, 
GATA-2), cytokines (such as granulocyte–macrophage CSF(GM-CSF) receptors, 
interleukins (ILs), interferons) and other factors (Ikros, Hox, Notch) with variable level of 
expression of these molecules observed at different stages of cell differentiation (Klug 




Figure 1.1: Stages of cell differentiation in haematopoiesis. Pluripotent haematopoietic 




While this process is tightly controlled to achieve stability and homeostasis, genetic 
alteration which can be in the form of variation, mutation and deletion in this process 
could result in disease conditions (Owen et al., 2008). For example, germline mutation 
of the RUNX1 gene leading to its deficiency cause familial platelet disorder and 
predisposes an individual with such mutation to myeloid leukaemia (Owen et al., 2008). 
Deficiency of the RUNX1 gene also correlates with deficiency in megakaryocyte colony 
formation thus, implicating RUNX1 as a regulator of megakaryopoiesis. This links RUNX1 
haploinsufficiency and predisposition to malignant haematological conditions (Owen et 
al., 2008) possibly due to increased circulating haematopoietic progenitor cells and 
defective T- and B-lymphocyte development observed in mice deficient of AML-
1/RUNX-1 (Ichikawa et al., 2004).  
Further studies suggests that bone marrow tumour microenvironment is initiated by 
pro-inflammatory cues within the bone marrow and is responsible for the maintenance 
of ALL precursor cells at the expense of normal hematopoietic cells, through aberrant 
expression of NF-кB induced by intrinsic and extrinsic factors (Enciso et al., 2016).   It is 
also known that an interplay between genetic and epigenetic changes is responsible for 
the development of B-cell acute lymphoblastic leukaemia. These changes lead to 
excessive production of malignant B-lymphoid precursor cells within the bone marrow 
(BM) (Pelayo et al., 2012; Purizaca et al., 2012). 
Failure in the differentiation of immature cell into myeloid or lymphoid cell is a 
characteristics of blast phase in chronic myeloid leukaemia (CML) (Hehlmann, 2012).  A 
study has shown that although the blast phase CML is driven by genetic instability and 
additional mutation through the BCR-ABL fusion gene, cross-talk between the signalling 
network involving Sonic hedgehog (Shh), Wnt, Notch and Hox are responsible for blast 
transformation of CD34+ CML cells (Sengupta et al., 2007). Interestingly, 
haematopoietic stem cell transcription factors; most of which are DNA binding proteins 
such as RUNX1, TEL/ ETV6, SCL/Tal1, and LMO2 have been linked to leukaemia-
associated somatic mutations and translocations in patients. The result is deregulation 
of the locus or generation of chimeric fusion proteins (Golub et al., 1995; Krivtsov et al., 
2006; Regha et al., 2015). These findings suggest the role dysregulation in both 
biochemical and molecular pathway during haematopoiesis plays in the initiation of 




1.2.1 Definition, types and classification 
Leukaemia results from the proliferation of an abnormal clone of haematopoietic stem 
cells that has become insensitive to regulatory, differentiation and apoptotic signal (Chu 
et al., 2012). These cells are known to multiply at the expense of normal haematopoietic 
cells (Lee et al., 2007). Signs of leukaemia are commonly related to the leucocytes 
infiltrating the lymphatic nodes and organs. However, most patients will present with 
symptoms related to bone marrow failure such as spontaneous bruising or abnormal 
bleeding, recurrent infection due to neutropenia or symptoms relating to severe 
anaemia (Grigoropoulos et al., 2013). Leukaemia is known to have a poor prognosis 
(Huang et al., 2014). It could result in osteolytic bone destruction, impaired 
haematopoiesis, and progressive renal failure (Allegra et al., 2010). Despite the 
advancement in understanding the molecular pathogenesis of leukaemia, improvement 
in therapy and introduction of novel drugs, most patients will relapse (Allegra et al., 
2010). Relapse in leukaemic cancers is a common event and has been associated to the 
heterogeneous nature of the tumour cells due to genomic instability and accumulation 
of multiple mutations (Schlenk et al., 2008; Casado et al., 2013). Such heterogeneity 
disrupts the homeostasis of the signalling network which is maintained by complex 
crosstalk and feedback (Sugawara et al., 1998; Kahlert et al., 2014). Therefore, 
regulation of protein signalling networks in leukaemic cells is difficult to predict, as it is 
also difficult to predict the influence of oncoproteins on the cells, as well as determine 
the most effective method to reverse the adverse effects of these oncoproteins on the 
cell (Quail and Joyce, 2013; Bailey et al., 2018). For example, the RUNX1/ETO 
oncoprotein responsible for leukaemic transformation in AML.  In a complex network, 
RUNX1/ETO downregulates several DNA repair proteins such as BRCA2 and ATM and 
increase the phosphorylation of TP53 gamma H2AX (γH2AX) (Forster et al., 2016). 
The EVI1 (ecotropic viral integration site 1) oncoprotein is a transcriptional regulator 
with an essential role in haematopoiesis. Overexpression of EVI1 in acute myeloid 
leukaemia (AML) confers extremely poor prognosis through transcriptional regulation, 
signalling, and epigenetic modifications by interacting with DNA, proteins and protein 
complexes (White et al., 2013).  Other oncoproteins which are well characterized and 
associates with complex protein-protein network driving leukemogenesis include the 
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MYC (Yun et al., 2018), BCR-ABL oncoproteins (p210 and p230) (Hantschel et al., 2014), 
the RAS family proteins (Liang et al., 2006) and the tyrosine kinases which are activated 
in this network (Scheijen and Griffin, 2002). 
Leukaemia’s are either of pre-B cell or pre-T cell phenotype, meaning that they exhibit 
cell surface markers of normal pre-B and pre-T cells and appear to be clonal outgrowths 
of normal precursor cells whose differentiation has not progressed but stopped at a 
particular stage (Aziz et al., 2015). Leukaemic cells are capable of extravasation since 
they are blood cells.  There are mounting evidence that common genetic mutation in 
leukaemia such as translocations involving t(12;21)TEL-AML1, t(8;21)AML1-
ETO, inv(16)CBFB-MYH11 occur prenatally evidenced by its presence in neonatal blood 
spots at birth in children who contract leukaemia later in life (McHale et al., 2003; Zuna 
et al., 2011). Further studies have shown that mutations associated with leukaemia 
increase susceptibility to the condition but do not result in the acquisition of the disease 
itself (Mori et al., 2002). This is true for TEL-AML1 and AML1-ETO, the most common 
translocations for ALL and AML, respectively suggesting that a percentage of normal 
individuals carry preleukaemic clones (Mori et al., 2002; Zuna et al., 2011). 
Classification of leukaemia is based on cell type and stage of leukocyte differentiation. 
Leukaemia classification can either be acute or chronic. Leukaemia is said to be acute 
when the proliferating blood cells are immature white blood cells or cells in blast phase. 
Whereas the proliferation of mature cells is considered chronic. Further classification is 
based on the origin of the leukaemic cells. Leukocytes are usually of lymphoid origin and, 
hence, leukaemic cells can be classed as T-cell or B-cell leukaemia whereas, neutrophils, 
basophils, eosinophils and monocytes which are of myeloid origin are classed as myeloid 
leukaemia (Grigoropoulos et al., 2013). 
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The World Health Organization (WHO) in 2016 revised haematopoietic and lymphoid 
tissue related neoplasms. The revision (Table 1.1) reflects the opinion of 
haematopathologists, haematologists, geneticists and oncologists and incorporates 
updated data to include new clinical, prognostic, morphologic, immunophenotypic and 
genetic characteristics (Arber et al., 2016). 
 
    Table 1.1. Summary of WHO classification of myeloid neoplasms and acute 


















leukaemia (CML) (for 
example, neutrophils, 
eosinophils, basophils
Myeloproliferative Neoplasms (MPN)  
o Chronic Myeloid Leukaemia (CML), BCR-ABL11+  
o Chronic Neutrophilic Leukaemia (CNL)  
o Polycythaemia Vera (PV)  
o Primary Myelofibrosis (PMF) 
 PMF, prefibrotic/early stage  
 PMF, overt fibrotic stage  
o Essential Thrombocythemia (ET)  
o Chronic Eosinophilic Leukaemia, not otherwise specified (NOS) 
o MPN, unclassifiable  
o Mastocytosis 




Myelodysplastic syndromes (MDS)  
 
o MDS with single lineage dysplasia  
o MDS with ring sideroblasts (MDS-RS) 
 MDS-RS and single lineage dysplasia 
 MDS-RS and multi-lineage dysplasia 
o MDS with multi-lineage dysplasia 
o MDS with excess blasts  
o MDS with isolated del(5q)  
o MDS, unclassifiable  
o Provisional entity: Refractory cytopenia of childhood  
o Myeloid neoplasms with germ line predisposition 
 
Acute Myeloid Leukaemia (AML) and related neoplasms 
  
o AML with recurrent genetic abnormalities  
 AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1  
 AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-
MYH11 
 APL with PML-RARA  
Myeloid/Lymphoid Neoplasms with eosinophilia and rearrangement of 
PDGFRA, PDGFRB, or FGFR1, or with PCM1-JAK2 
 
o Myeloid/Lymphoid Neoplasms with PDGFRA rearrangement 
o Myeloid/Lymphoid Neoplasms with PDGFRB rearrangement 
o Myeloid/lymphoid Neoplasms with FGFR1 rearrangement 
o Provisional entity: Myeloid/Lymphoid Neoplasms with PCM1-JAK2 
Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN)  
 
o Chronic Myelomonocytic Leukaemia (CMML)  
o Atypical Chronic Myeloid Leukaemia (aCML), BCR-ABL1- 
o Juvenile Myelomonocytic Leukaemia (JMML)  
o MDS/MPN with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T)  
o MDS/MPN, unclassifiable 
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 AML with t(9;11)(p21.3;q23.3);MLLT3-KMT2A  
 AML with t(6;9)(p23;q34.1);DEK-NUP214  
 AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, 
MECOM  
 AML (megakaryoblastic) with t(1;22)(p13.3;q13.3);RBM15-
MKL1 
 Provisional entity: AML with BCR-ABL1  
 AML with mutated NPM1 
 AML with biallelic mutations of CEBPA  
 Provisional entity: AML with mutated RUNX1  
o AML with myelodysplasia-related changes  
o Therapy-related myeloid neoplasms  
o AML, NOS  
 AML with minimal differentiation  
 AML without maturation  
 AML with maturation  
 Acute Myelomonocytic Leukaemia  
 Acute Monoblastic/Monocytic Leukaemia  
 Pure erythroid leukaemia 
  Acute Megakaryoblastic Leukaemia  
 Acute Basophilic Leukaemia  
 Acute panmyelosis with myelofibrosis  
o Myeloid sarcoma  
o Myeloid proliferations related to Down syndrome  
 Transient Abnormal Myelopoiesis (TAM) 
  Myeloid leukaemia associated with Down syndrome 
Blastic plasmacytoid dendritic cell neoplasm  
 
Acute leukaemia’s of ambiguous lineage  
 Acute undifferentiated leukaemia  
 Mixed phenotype acute leukaemia (MPAL) with 
t(9;22)(q34.1;q11.2); BCR-ABL1  
 MPAL with t(v;11q23.3); KMT2A rearranged  
 MPAL, B/myeloid, NOS  
 MPAL, T/myeloid, NOS 
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B-Lymphoblastic Leukaemia/Lymphoma  
 
o B-lymphoblastic leukaemia/lymphoma, NOS  
o B-lymphoblastic leukaemia/lymphoma with recurrent genetic 
abnormalities  
 
o B-lymphoblastic leukaemia/lymphoma with t(9;22)(q34.1;q11.2);BCR-
ABL1  
o B-lymphoblastic leukaemia/lymphoma with t(v;11q23.3);KMT2A 
rearranged  
o B-lymphoblastic leukaemia/lymphoma with t(12;21)(p13.2;q22.1); 
ETV6-RUNX1 B-lymphoblastic leukaemia/lymphoma with hyper-
diploidy 
  
o B-lymphoblastic leukaemia/lymphoma with hyp-odiploidy 
 
o B-lymphoblastic leukaemia/lymphoma with t(5;14)(q31.1;q32.3) IL3-
IGH 
o B-lymphoblastic leukaemia/lymphoma with t(1;19)(q23;p13.3);TCF3-
PBX1  
o Provisional entity: B-lymphoblastic leukaemia/lymphoma, BCR-ABL1–
like 
o Provisional entity: B-lymphoblastic leukaemia/lymphoma with iAMP21 
T-Lymphoblastic Leukaemia/Lymphoma  
o Provisional entity: Early T-cell precursor Lymphoblastic Leukaemia 




1.2.2  Prevalence and statistics 
According to Cancer Research UK (CRUK), leukaemia is the 12th most common cancer in 
the UK with about 9,900 new cases of leukaemia reported each year. The incident rate 
is higher in male than in females. It is projected that the incidence rate of leukaemia will 
rise by 5% between 2014 and 2035 to 19 cases per 100,000 people while the mortality 
rate will rise by 18%. The Caucasian population are known to be more affected than 
Black or Asian populations. Current statistic on leukaemia incidence and survival 
according to CRUK are shown in Figure 1.3 and 1.4.  
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More comprehensive data compiled from several databases was recently published by 
Adalberto et al., (2018) (Table 1.2). The collected data was consistent with reports that 
leukaemia is more common in males than female. Australia and New Zealand were 













































































Figure 1.3. UK leukaemia incidence rate per 100,000 population by sex 
from 1993 to 2015. Increase rate in leukaemia in all age group. Age 
standardized (AS) incidence rate in males and females between 1993-1995 
and 2013-2015 was 15% and 14% respectively (adapted from CRUK). 
 
Figure 1.4. Survival rate of leukaemia in England and Wales between 2010- 
2011. Chart showing overall survival at 69%, 52% and 46% for one, five and ten 
years from the time of diagnosis (adapted from CRUK). 
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lymphoblastic leukaemia (ALL) subtype was more prevalent. In adults, subtypes were 
found to be diverse. European and North American adults had a relatively higher 
incidence of chronic lymphoblastic leukaemia (CLL) whereas, adults in South American, 
Caribbean, Asian and African had higher rates (Adalberto et al., 2018). 
                Table 1.2. Summary of finding on the global incidence of leukaemia  
Continent/ region Sex Incidence rate 
Australia and New Zealand Males 11.3 
 Females 7.2 
North America Males 10.5 
 Females 7.2 
Western Europe Males 9.6 
 Females 6.0 
Western Africa Males 1.4 
 Females 1.2 
                                                                                                          Adalberto et al., 2018 
 
It has been observed that adults have a higher incidence of CML, AML, myelodysplastic 
and myeloproliferative syndrome when compared to children (Adalberto et al., 2018). 
Whereas childhood leukaemia is more prevalent in B and T-cell acute lymphoblastic 
leukaemia (ALL). The former subtype which has shown a higher incidence in adults are 
of myeloid origin and are derivative of precursor cells critical in innate immunity rather 












1.2.3 Aetiology and Pathogenesis  
The table below summarises some factors which are thought to increase the risk of 
developing leukaemia. 
 
     Table 1.3. Genetic and environmental risk factor implicated in leukaemia 
Environmental factors 
 Radiation and electromagnetic exposure 
 Chemical exposure e.g. benzene 
 Viral infection e.g. human T-cell lymphoma virus (HTLV-1), Epstein-Barr virus 
(EBV) 
 Therapy-related predisposition e.g. radiotherapy and chemotherapy 
 
Congenital and inherited syndromes 
Inherited predisposition factors 
 Fanconi anaemia 
 myelodysplasia 
 Neurofibromatosis 
DNA repair defects 
 Bloom syndrome 
 Li-Fraumeni syndrome 
 Ataxia-telangiectasia 
Chromosomal associated syndrome 
 Down syndrome 






 Family history 
 Preventable cases e.g. lifestyle 
 
Extensive review by Buffler et al., 2005. 
 
As mentioned earlier, in adults there was a higher incidence of leukaemia of myeloid 
origin, myeloid cells are derivatives of precursor cells critical in innate immunity rather 
than adaptive immunity (Abbas et al., 2005). Cells involved in innate immunity are 
known to produce large number of enzymes (e.g., myeloperoxidase) that can produce 
cytotoxic mediators as part of their normal function. The cytotoxic mediator produced 
can activate environmental chemicals (e.g., benzene), reactive oxygen and nitrogen 
species through chronic inflammation that can reach the bone marrow and produce 
genotoxic intermediates (van der Vliet et al., 1997; Eiserich et al., 1998). Benzene is a 
known culprit in leukaemia and lymphoma development as well as causes haemopoietic 
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defects (Hayes et al., 2000; Lan et al., 2004). Myeloperoxidase in the bone marrow 
activates benzene metabolites to nucleophilic compounds causing DNA damage 
(Wiemels et al., 1999; Eastmond et al., 2005).  Bioactivated benzene metabolite, 
hydroquinone (BAHQ) has also been shown to inhibits topoisomerase-II (Topo II) in vitro 
and in vivo during the DNA binding stage and at the closed clamp stage in the catalytic 
cycle thereby interfering with either binding of Topo II to the DNA or the release of 
synthesized DNA.  This could result in DNA breakage, chromosomal aberration and 
leukaemic-associated chromosomal translocation in bone marrow (Eastmond et al., 
2001; Mondrala and Eastmond, 2010). 
A recent study using a genome wide association study and meta-analysis found a 20-
fold increased risk of acute lymphoblastic leukaemia (ALL) in children with Down 
syndrome (DS).It also demonstrated distinct somatic features, 
including CRLF2 rearrangement in approximately 50% of cases with susceptibility loci for 
single nucleotide polymorphisms in IKZF1, CDKN2A, ARID5B and GATA3 which was 
independent of DS-ALL subtype (Brown et al., 2019). Knockdown of IKZF1 resulted in 
increased cell proliferation in lymphoblastoid cell lines (Brown et al., 2019). Lifestyle 
factors such as smoking and increased BMI associated with obesity have been identified 
as risk factors for other cancers and leukaemia (Poynter et al., 2016). Owing to the 
conflicting results published, a meta-analysis of a pool of existing data found an 
association between being overweight and obesity with increased incidence of AML (Li 
et al., 2017). However, they only found an association between acute promyelocytic 
leukaemia (APL) with short overall survival (OS) and high risk of differentiation syndrome 
but not with AML (Li et al., 2017). Among the several mechanisms which have been 
suggested through which obesity can increase susceptibility and promote cancer is the 
activation of free radicals through mitochondrial and tissue stress which are capable of 
inducing DNA damage by release of reactive intermediates (Inoue and Kawanishi, 1995; 
Collado et al., 2012). Through the production of leptin and adiponectin which are 
adipokines, obesity promotes cancer cell proliferation and survival via activation of PI3K, 





1.2.4 Chronic Myeloid Leukaemia (CML) 
Chronic Myeloid Leukaemia (CML) is a myeloproliferative disorder of transformed 
haematopoietic stem cells and progenitors such as common myeloid progenitor and 
granulocyte-macrophage progenitor cells (Jamieson et al., 2004). CML is characterized 
by a balanced and reciprocal translocation of chromosome t(9;22)(q34;q11) with 
resultant fusion of the breakpoint cluster region protein (BCR) and Abelson Murine 
Leukaemia viral oncogene homolog 1 (ABL1) (Figure 1.5) (Li et al., 1999). The resultant 
BCR-ABL fusion gene is commonly referred to as the Philadelphia (Ph) chromosome 
(Tough et al., 1961; Nowell, 2007) and is found in over 90% of CML patients. The initial 
phase of CML is characterised by expansion of premature myeloid precursors and 
mature cells which have the capacity to differentiate normally.  
Studies (Daley et al., 1990; Li et al., 1999) suggests that three main types of BCR-ABL 
protein are formed depending on the breakpoint (Figure 1.5). A breakpoint that occurs 
in introns 1 or 2 of ABL and in cluster region (M-bcr) of BCL between exon 13 and 14 (b2) 
or exon 14 and 15 (b3) produce BCR-ABL fusion gene that is transcribed into b2a2 or 
b3a2 mRNA (where b = BCL gene and a = ABL gene). The resultant fusion protein, 
p210BCR-ABL is 210kDa, and sufficient for the malignant transformation of CML and 
responsible for the phenotypic characteristics such as elevated WBC, splenomegaly and 
anaemia observed in the chronic phase of CML. Atypical causes are those resulting from 
BCR-ABL transcripts involving ABL exon a3 instead of a2, e1a2 encoding a protein about 
190kDa, p190BCR-ABL and BCR exon 19/ABL exon a2 (e19/a2) encoding a larger protein of 
about 230kDa, p230BCR-ABL. A study (Sawyers et al., 2002) suggested that although these 
fusion proteins differ in their BCR component, they express the same level of c-ABL 













Functional domains (Figure 1.6) in the BCR-ABL protein that could be responsible for the 
cellular transformation in leukaemia have been identified (Pendergast et al., 1991).  In 
the ABL portion, the Src-homology domain 1 and 2 (SH1 and SH2) and the actin-binding 
domain have been named. While in the BCR portion, the coiled-coil oligomerization 
domain (aa-1-63), the Grb-2 binding site (Tyr-177) and the phosphoserine/threonine-
rich SH2 binding domain have been identified to aid cellular transformation (Pendergast 
et al., 1991; McWhirter et al., 1993; Fredericks and Ren, (2013).     
                       
Figure 1.5. Schematic representation of BCR and ABL gene, translocation and resultant 
protein. Boxes represent exons while connecting horizontal lines represents introns. A. 
Breakpoints in the ABL gene are indicated by the arrows and occur at intron 1 or 2 of the 
ABL gene. B. BCR alternative first (e1’) and second (e2’) exon. Breakpoints in BCR occur 
within the cluster region (m-bcr, M-bcr and µ-bcr) shown by the double-headed 
horizontal arrows. C. Represents the structure of the various BCR-ABL mRNA transcript 
which are formed and in accordance with the position of the BCR breakpoint. Breaks in 
m-bcr gives rise to mRNA molecule with e1a2 junction. Breaks in M-bcr generate fusion 
transcripts with a b2a2 or a b3a2 junction, respectively. Breakpoints in µ-bcr, result in 
BCR-ABL transcripts with an e19a2 junction. (where: I = intron; e=exon; b=BCL gene 






   
 
 
                  
 
 
The resultant BCR-ABL fusion protein exhibits a constitutively active tyrosine kinase 
activity because of autophosphorylation of the activation loop via SH2 binding 
(Hantschel et al., 2014). The tyrosine kinase activity of the chimeric protein is found 
exclusively in the cytoplasm of the cell complexed with several cytoskeletal proteins 
(Figure 1.7) (Puil et al., 1994; Raitano et al., 1995). The constitutively active tyrosine 
kinase activity and the interaction with cytoskeletal proteins underlie the mechanism of 
induction and pathophysiology of the leukaemic phenotype.  The cytoskeletal proteins 







Figure 1.6. Schematic illustration showing the functional domains of BCR-ABL protein 
using the p210BCR-ABL example. Shown on the BCR portion is the coiled-coil domain, Grb-
2 binding site, the phosphoserine/threonine-rich SH2-binding domain, the rho-GEF 
domain. The ABL portion consist of the regulatory src-homology regions SH3 and SH2, 
the SH1 tyrosine kinase domain, the nuclear localization signal (NLS) and the DNA and 
actin binding domain (Adapted: Salesse and Verfaillie, 2002). 
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In CML, the abnormal cells function adequately, allowing a mild initiation of the disease; 
a benign chronic phase (CP). This then progresses to an accelerated phase (AP), which is 
more difficult to control and characterised by an enlarged spleen and increased number 
of blast cells. The final stage of CML is the acute or blast crisis (BC) phase characterised 
by blast cells domination of the bone marrow and blood. At the blast phase, CML 







Figure 1.7. Basic representation of the signalling pathway of the BCR-ABL proteins. 
Activation of the RAS-JAK/STAT-PI-3 pathways and the FAK complex (actin, paxillin and 
integrin) which are multi-protein structures that link the extracellular matrix (ECM) to 
the cytoplasmic cytoskeleton result in increased cell proliferation, differentiation and 
decreased apoptosis in CML progenitor cells. Binding of these proteins to adaptor 
protein such as GRB2, CBL, SHC, and CRKL result in their activation. BAP-1 denotes 
BCR-associated protein 1; GRB2: growth factor receptor-bound protein 2; CBL: casitas 
B-lineage lymphoma protein; SHC: SRC homology 2-containing protein; CRKL: CRK-
oncogene-like protein; JAK-STAT: Janus kinase-signal transducers and activators of 
transcription; FAK: focal adhesion kinase, SOS: son-of-sevenless and GEF: GDP-GTP 
exchange factor (Adapted: Salesse and Verfaillie, 2002).  
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           Table 1.4. The Role of signalling pathways and transcriptional factors  
           dysregulated in response to BCR-ABL activation 
Pathway       Role Effectors 
Wnt/β-catenin -HSCs self-renewal  





Notch -Interaction between leukemic, HSCs, 
and BM niche  
-CML advanced stages 
 
ϒsecretase 
PI3K/AKT/mTOR  Normal haemopoiesis PI3K  
AKT 
mTOR1/2 
JAK/STAT  -Normal haemopoiesis 




FoxO/TGF-β  -Expression of genes involved in cell 
growth, proliferation and differentiation  




PML -Critical role in haemopoiesis 




                     Abbreviations: CML, chronic myeloid leukaemia; HSC, hematopoietic stem cells; BM, bone marrow.  
                     PI3K, phosphoinositide 3-kinase; PML, promyelocytic leukaemia; PP2A, protein phosphatase 2A;  
                     TGF-β, transforming growth factor-β. (Jilani et al., 2008; Naka et al., 2010) 
 
 
Diagnosis of CML is through a basic blood test which looks for elevated peripheral WBC 
count that is dominated by granulocytes.  A confirmation is achieved by examination of 
the bone marrow, which shows a large proportion of matured white cells when 
compared to the blast cells. Bone marrow aspiration is also useful for staging between 
phases. Chromosomal abnormalities can be identified in bone marrow samples using 
fluorescence in-situ hybridization (FISH) and reverse transcriptase polymerase chain 
reaction (RT-PCR) technique (Schoch et al., 2002; Jabbour and Kantarjian, 2018). The 
FISH analysis relies on co-localization of large genomic probes specific for BCR and ABL 
genes. The error margin for a false positive test is between 1-5% depending on the probe 
used (Jabbour and Kantarjian, 2018). PCR can be either qualitative or quantitative. A 
qualitative assessment provides information about the presence of BCR-ABL transcript 
whereas, quantitative PCR assesses the amount of transcript present.  Qualitative PCR 
is preferred in the diagnosis of CML whereas quantitative PCR is best used to monitor 
the amount of residual disease (Jabbour and Kantarjian, 2016; 2018). Both FISH and PCR 
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techniques can also be used to assess response to treatment and differentiate CML from 
other myeloproliferative diseases with similar presentation (Schoch et al., 2002).  
A cost-effective chemiluminescence clinical diagnosis method has been recommended 
by Xu and colleagues (Xu et al., 2016). WHO has outlined criteria for CML diagnosis listed 
in Table 1.5 (Arber et al., 2016). 
 
Chronic phase (CP) CML 
 Cytogenetic evidence of Ph+ chromosome in peripheral blood or 
bone marrow  
 Examination of haematological cells from bone marrow (BM) 
aspiration with less than 10% blast cells 
Acute phase (AP) CML (diagnosed if any one or more of the following exist) 
 Persistent or increasing WBC (>10 x 109/L), unresponsive to chemo or 
radiation therapy 
 Persistent or increasing splenomegaly, unresponsive to chemo or 
radiation therapy 
 Persistent thrombocytosis (>1000 x 109/L), unresponsive to chemo or 
radiation therapy 
 Persistent thrombocytopenia (<100 x 109/L) unrelated to chemo or 
radiation therapy 
 20% or more basophils in the peripheral blood 
 10%-19% blasts in the peripheral blood and/or bone marrow 
 Any new clonal chromosomal abnormality in Ph+ cells that occurs 
during therapy 
Tyrosine kinase inhibitor (TKI) response criteria  
 Hematologic resistance to the first TKI (or failure to achieve a 
complete hematologic response to the first TKI)  
 Any haematological, cytogenetic, or molecular indications of 
resistance to two sequential TKIs 
 The occurrence of two or more mutations in BCR-ABL1 during TKI 
therapy 
 
BC CML (diagnosed if any one or more of the following exist)  
 ≥20% of peripheral blood or bone marrow cells are blasts  
 Onset lymphoblast in the peripheral blood or bone marrow cells 
Table 1.5. WHO haematological/cytogenetic criteria for the diagnosis of CML                      




Earlier treatment and or management of CML was initially based on cytoreductive 
therapy such as hydroxyurea.  This method of therapy only provides temporary disease 
control but does not limit disease progression with a median survival of about 45months 
from diagnosis. Later immunology-based therapy was introduced which, includes the 
use of interferon alpha (IFN-α) (Hehlmann et al.,1994). This proved to be superior to 
cytoreductive therapy with an increase in the median survival rate of 60months from 
diagnosis and patients going into complete cytogenic remission (Allan et al., 1995; 
Bonifazi et al., 2001). 
The use of allogeneic haematopoietic stem cell transplant (HSCT); a process in which 
stem cells from a matching donor is infused into a recipient to re-establish 
haematopoietic function, offered effective and lasting curative potential for patients 
with CML. However, this method was less applicable than alternative therapies due to 
the challenge in finding a suitable donor, the morbidity of the procedure, tissue rejection 
known as graft versus host disease (GvHD) and the age of the recipient (McGlave et 
al.,2000; Curtler et al., 2001). Further challenges in the use of HSCT as a lasting solution 
is the theory of “bystander effect”. A theory in which the naïve haematopoietic stem 
cells transplanted are reprogrammed within the new host microenvironment and 
becomes cancerous (Shen et al., 2012). This has been blamed on the total body 
irradiation (TBI) required for conditioning regimen (Shen et al., 2012).  
The use of tyrosine kinase inhibitors (TKI), which function by blocking adenosine 
triphosphate (ATP) binding sites in the BCR-ABL kinase proved efficacious in patients 
who were nonresponsive to IFN-α (Kantarjian et al., 2002a). The first TKI, imatinib 
became the front-line drug for the management of CML (O’Brian et al., 2003; Baccarani 
et al.,2009). Imatinib, when administered at a standard daily dose of 400mg/day in a 
patient, is relatively tolerated but not without side effects which include nausea, 
oedema, and diarrhoea (Druker et al., 2001).  Following its success with an estimated 
progression-free survival of 90% in 5years (Kantarjian et al., 2002b), the newer 
generation of imatinib analogue; nilotinib, dasatinib, and bosutinib has been developed 
and approved by the FDA as front-line treatment of patients with newly diagnosed CML 
in chronic phase (CP) (Talpaz et al., 2006; Kantarjian et al., 2007; Cortes et al., 2011). 
This newer generation of drugs was developed to solve the problem of resistance with 
imatinib due to mutations in the BCR-ABL ATP binding site (Talpaz et al., 2006; Kantarjian 
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et al., 2007; Cortes et al., 2011). Patients who develop the T315I “gatekeeper” mutation 
display resistance to all currently available TKIs except ponatinib (O’Hare et al., 2009). 
Individuals with the advanced disease do not respond to imatinib and hence, are offered 
induction chemotherapies such as etoposide, cytarabine and carboplatin with the hope 
of restoring patients to the chronic phase. Kuroda et al., (2013) argues that molecular 
remission (which is a complete remission with no evidence of the disease in the blood 
and or bone marrow using sensitive monitoring test such as PCR) is rarely achieved even 
when haematological and cytogenetic remission is achieved. This is due to the protective 
effect conferred on these cells by the extensive network of BCR-ABL1 gene with a normal 
haematopoietic and signalling pathway (Kuroda et al., 2013). Allogeneic stem cell HSCT 
remains an important therapeutic option for patients with CML-CP who have failed at 
least two TKIs, and for all patients in CML advanced phases (Jabbour et al., 2011). 
Studies have shown that combining kinase inhibitor with cytoreductive drugs could 
improve the efficacy of TKI in overcoming the challenge of mutation in the BCR-ABL1 
oncogene (Fava et al., 2015). Combination of imatinib and interferon has been 
suggested to improve the cytogenic response (Palandri et al., 2008; Fava et al., 2015). A 
phase III randomized study combining imatinib and peginterferon alfa-2a obtained a 
higher rate of major molecular response (MMR) (i.e., a BCR-ABL RNA level ≤0.1%) 
(Preudhomme et al., 2010). Another study found that co-treatment with imatinib and 
amiloride re-sensitized BCR-ABL1 T3151 mutant cells to imatinib treatment by 
modulating alternative splicing (Cheng et al., 2011). These studies suggest that 
combined kinase therapy in CML treatment may offer a better cytogenic response. 
1.2.5 Acute myeloid leukaemia (AML) 
Acute myeloid leukaemia (AML) is a heterogeneous malignancy that is characterized by 
exaggerated growth or clonal expansion of blast cells (myeloid progenitors) in the bone 
marrow and peripheral blood (Narmala et al., 2010). This results in haematopoietic 
insufficiency with or without leucocytosis (Narmala et al., 2010). It was earlier reported 
that 40-50% of patients with AML do not have clonal chromosomal aberration (Schlenk 
et al., 2008). In recent years, with the advances in technology, several acquired genetic 
mutation and deregulated gene expression profiles have been identified.  The 
cytogenetic risk for AML has been classed as favourable prognosis, intermediate 
prognosis and poor prognosis and have been summarized in Table 1.6. Two classes of 
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somatic mutations have been observed in AML. Class I includes mutation that activates 
the signal transduction pathway; mainly the FMS-related tyrosine kinase 3 gene (FLT3) 
and RAS family of viral oncogenes (Schlenk et al., 2008). While class II involves mutations 
that affects transcriptional factors and components of the transcriptional co-activation 
complex e.g. mutations in CCAAT/enhancer binding protein α gene (CEBPA), myeloid–
lymphoid or mixed-lineage leukaemia gene (MLL) and nucleophosmin gene (NPM1) 
(Schlenk et al., 2008).  There has also been a report on an early acquisition of somatic 
mutation in genes encoding epigenetics modifiers such as DNMT3A, ASXL1, TET2, IDH1 
and IDH2 (Ley et al., 2010; Rocquain et al., 2010). 
 
 





Balanced structural rearrangements; 
t(15;17) (q22;q 12-21) 
t(8; 21) (q22; q22) 






Balanced structural rearrangements 
 t(9 ;11)(p22 ;q23)  
 
Unbalanced structural rearrangements  
del (7q), del (9q) , del (11q) , del (20q) 
 
Numerical aberrations  





       Balanced structural rearrangements; 
Inversion (3)(q21q26)/t (3 ;3)(q21 ;26) 
t(6 ;9)(p23 ;q34) 
t(6 ;11)(q23 ;p13,1) 
 




 -5, -7 




Another sub-classification of AML using M0-M7 has been described. M0 and M1, 
immature myeloblastic; M2, mature myeloblastic; M3, promyelocytic; M4, 
myelomonocytic; M5, monocytic; M6, erythroleukaemia; and M7, megakaryocytic 
based on the different cell types observed in the blood and bone marrow (Bennett et 
al., 1985; Basharat et al., 2019).   
Following the WHO update, the European leukaemic network has published a more 
comprehensive cytogenetic/mutational prognostic stratification and is described by 
Döhner et al., (2017) in Table 1.7. 
 
Table 1.7. Update summary of AML genetics/mutational prognostic stratification 
Prognosis Genetic abnormality 
Favourable t(8;21)(q22;q22.1);RUNX1-RUNX1T1 
Inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 
Mutated NMP1 without FLT3-ITD or with FLT3-ITDlow (allelic ratio 
<0.5); Biallelic mutated CEBPA 
Intermediate Mutated NPM1 and FLT3-ITDhigh 
(allelic ratio ≥0.5) 
Wild-type NPM1 without FLT3-ITD or with FLT3-ITDlow (without 
adverse-risk genetic lesions) t(9;11)(p21.3;q23.3); MLLT3-KMT2A 
Cytogenetic abnormalities not classified as favourable or adverse 
Adverse t(6;9)(p23;q34.1); DEK-NUP214 t(v;11q23.3); 
KMT2A rearranged t(9;22)(q34.1;q11.2); 
BCR-ABL1 inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM 
(EVI1) -5 or del(5q); -7; -17/abn(17p) 
Complex karyotype (three or more unrelated chromosome 
abnormalities), 
Monosomal karyotype (defined by the presence of 1 single 
monosomy) 








Development of AML has been associated with exposure to benzene, ionizing radiation, 
chemotherapy and inherited syndrome such as Fanconi anaemia and Downs syndrome 
(Tsai et al., 2014).  The statistical record for AML incidence in the UK is approximately 
3.9 and 5.2/100,000 in females and males accounting for 43% and 57% respectively 
(CRUK) with a diagnostic median age of 75years (Cartwright et al., 2002; Bhayat et al., 
2009). AML is more common in older people than children and adolescent (Bhayat et 
al., 2009). The five years relative survival rate in England is 16% and 14% respectively for 
women and men compared to 18% and 15% reported for available data for Europe 
(CRUK). Techniques such FISH, PCR, flow cytometry and array technology, which can 
detect gain and loss of genetic materials can be used for the diagnosis of AML (Döhner 
et al., 2010). 
 
1.2.6 AML therapy and management 
 
Due to the wide range of cytogenetic and mutational events that occur in AML, 
treatment is based on presentation. Intensive chemotherapy (IC) is often employed in 
30-60% of the elderly with adverse prognosis but results in poor performance and 
treatment-related mortality of about 10-25% (Burnett et al., 2007). Overall survival (OS) 
when IC is feasible is 13months. Low-dose cytosine arabinoside (LDAC), the 
farnesyltransferase inhibitor tipifarnib, and gemtuzumab ozogamicin have shown 
improved outcome with patients going into remission but without improvement in OS 
(Burnett et al., 2007; Burnett et al., 2013). 
 
Older patients with AML and high-risk myelodysplastic syndrome (MDS) who have never 
received treatment showed increased therapy response with clofarabine. However, OS, 
relapse and treatment co-morbidity were unchanged when compared to patients who 
had LDAC treatment (Burnett et al., 2013). Sapacitabine alone, a nucleoside analogue, 
has also been used in a randomized study in older patients with no improvement in OS 
when compared to LDAC alone. Both Sapacitabine and LDAC were found to result in a 
similar outcome except for sapacitabine whose side effect was well tolerated (Burnett 
et al., 2015). Barasertib showed an OS of 8.2 months against 4.5 months with LDAC but 
with more toxic effect. The population for this study was notably small at 74 (Kantarjian 
et al., 2013).  
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Volasertib, a selective inhibitor of polo-like kinase (Plks) which is responsible for mitotic 
checkpoint regulation and cell division in a phase 2 trial, was found unsuitable for 
intensive induction therapy when compared to LDAC (Dohner et al., 2014). Although a 
significant increase in event-free and OS rate were achieved when combined with LDAC, 
volasertib led to an intolerable increase in the frequency of adverse effect (Dohner et 
al., 2014).  
 
Azacytidine, a DNA methylation inhibitor administered at 75mg/m2/d in a phase-III trial 
significantly prolonged OS in patients with intermediate and high-risk myelodysplastic 
syndrome. Patients for this study were classified using the French American British (FAB) 
classification with one-third meeting the WHO definition of AML at ≥20% BM blasts 
(Fenaux et al., 2010; Dombret et al., 2015). In phase I/II trial, azacytidine was combined 
with midostaurin; a broad-spectrum tyrosine kinase inhibitor of both wild type and 
mutated FLT-3 type. The result showed better response and longer median remission 
duration in patients who have not been previously exposed to FLT3 inhibitor and 
previously transplanted (Strati et al., 2014). On Table 1.8 is listed the current regiment 





















Table 1.8. Summary of therapeutic efficacy of drugs used for AML in older patients 
Regimen    Complete         




Intensive chemotherapy  50-60 6–12 
LDAC  10-25 6 
Azacytidine in low-blast count AML   25 24.5 
Azacytidine in AML >30%  25 12.1 
Decitabine in AML >30% bone 
marrow blast 
18 7.7 
Clofarabine 38 11.4 
Sapacitabine  37 7.9 
Barasertib  35 8.2 
Volasertib (+ LDAC)  31 8 
Tipifarnib  8 3.6 
Midostaurin (+Aza)  2 NA 
Quizartinib  54 <12 
Vorinostat (+LDAC) 46 NA 
Gemtuzumab Ozogamicin 30 11 












1.3   Constitutive and alternative Splicing 
 
RNA splicing is a post-transcriptional modification required for the maturation of RNA. 
There are two types of splicing events; constitutive splicing (Figure 1.7A) in which all 
introns are removed and exons are joined together (Ding and Elowitz, 2019) while 
alternative splicing (Figure 1.8B-F) is a regulatory mechanism of post-transcriptional 
mRNA processing that selectively removes or retains introns, which allows for multiple 
expression of several mRNAs from a single gene. The result is the generation of two or 
more proteins from a single gene (Liu et al., 2017; Bush et al., 2017). Other processes 
through which multiple mRNA transcript can be generated apart from alternative 
splicing are alternative polyadenylation and alternative promoter usage (Pecci et al., 
2001; Hilgers, 2015). The close coupling of constitutive splicing with transcription (Fong 
and Zhou, 2001) is thought to serve as a signal-processing filter that regulates the 
amount of mature mRNA depending on the rate of transcription (Ding and Elowitz, 
2019). There are indications that constitutive splicing provides several possible functions 
including intron-enhanced transcriptional efficacy (Brinster et al., 1988), increased 
retention of intronic miRNAs and other non-coding RNAs in constitutively spliced introns 
(Rodriguez et al., 2004; Rearick et al., 2011) and could reflect or promote the 
evolutionary selection of new phenotypes (Lev-Maor et al., 2007). Thus, constitutive 
splicing could be playing roles beyond isoform diversification.  
An earlier study suggests that the size of an intron determines whether an exon is 
constitutively or alternatively spliced. The study found that when intron size is between 
200 and 250 nucleotides, the splice sites across the introns are not recognized resulting 
in exonic splice site recognition with inclusion of weak exonic splice site (Fox-Walsh et 
al., 2005). Other factors such as the exon and intron architecture have been shown to 
influence the choice of splice site such that large exons result in exon skipping but could 
be included when flanked by small introns (Fox-Walsh et al., 2005; Roy et al., 2008). This 
suggests that constitutive splice-site recognition is more efficient in small exons and 
introns. 
It is estimated that 90-95% of human genes are alternatively spliced (Wang et al., 2008). 
It is also apparent that alternative splicing plays a role in physiological functions and 
developmental processes and in recent times has been found to aid the progression of 
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several diseases such as cancer, neurological conditions like Alzheimers, vascular defects 
of the eyes and metabolic disorders (Climente-González et al., 2017; Han et al., 2018; 
Batson et al., 2017; Wong et al., 2018). A proteomic mapping performed on human 
tissue identified several new protein-coding regions in genes due to alternative splicing 
and selection of an alternative splice site thus indicating that alternative splicing also 
contributes to proteomic complexity (Kim et al., 2014). Alternative splicing can modify 
the properties of the encoded protein which affects the stability, binding pattern, 
cellular localization and activity (Bush et al., 2017). With a better understanding of the 
regulatory mechanism of alternative splicing, studies are now geared toward 










Figure 1.8. Representation of constitutive and alternative splicing. 
Alternative splicing of pre-mRNAs occurs when an exon is skipped, intron 
retained, an alternative 3’- (acceptor) or 5’- (donor) sites are used and from 
selection of mutually exclusive exons. Exons (rectangles) are connected by 
introns (black lines).  Broken lines depict regions which are spliced (adapted: 
Li et al., 2007). 
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1.3.1 Precursor messenger RNA (Pre-mRNA) splicing by spliceosome 
Pre-mRNA splicing is a process whereby the intron sequence is identified and excised 
from pre-mRNA with the ligation of adjoining exons (Figure 1.7). Binding of the splicing 
machinery to the splice site results in the assembly of the spliceosome. Splicing is 
catalysed by the spliceosome, which is a large ribonucleoprotein complex formed from 
an assembly of five small nuclear ribonucleoproteins (snRNP) (Makarov et al., 2002).  
Each snRNP is composed of a single uridine-rich small nuclear RNA (snRNA U1, U2, U4, 
U5, and U6) (shown in Figure 1.9) and multiple proteins such as the U1 specific proteins, 
SR-proteins and U2AF protein required for RNA-protein interaction during the splicing 
process (Makarov et al., 2002; Saulière et al., 2006). 









Figure 1.9. Illustration of the mechanism of spliceosome assembly. Representative pre-
mRNA showing binding site. GU sequence is binding site for U1snRNP, AG sequence is 
binding site for U2AF splice factors and the branchpoint sequence (A) which is binding site 
for U2 snRNP. Inactive Complex B formed from combination of the U1, U2 snRNP with the 
pre-assembled tri-snRNP. Activated Complex B is formed after dissociation of U1 and U4.  
Formation of a lariat intron and excision of the intron result in complex C and matured 
mRNA. Dissociated snRNP are recycled into the system (Adapted: Wahl et al., 2009).  
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During the initiation of splicing, there are characteristics of the RNA which determines 
spliceosome assembly and includes;  
 Recognition of the 5’ and 3’ splice site (5’ss and 3’ss) that determine the 
exon-intron and intron-exon boundaries. 
 The polypyrimidine tract binding protein (PTB/hnRNP I) which recognizes 
short motif such as UCUU and UCUCU associated with the polypyrimidine tract 
upstream of the 3’ss of alternative exons  
 The branchpoint sequence (BPS) which provides activity site for the 
2’hydroxyl group during the first transesterification reaction. 
The mechanism of spliceosome assembly (Figure 1.9) begins with the U1 snRNP 
recognising the 5’ splice site. The U1 snRNP is recruited together with SR proteins by 
RNA polymerase II and ensure the coupling of splicing to transcription and they are co-
transcriptionally deposited on the 5′ splice sites of nascent transcripts (Staknis, and 
Reed, 1994; Das et al., 2007). The co-transcriptional deposition of SR proteins on 
nascent pre-mRNA transcripts contributes to genome stability and prevents the 
formation of R-loops due to hybridization of the neosynthesized RNA to the 
complementary strand of the DNA template (Li and Manley, 2005). The U2 snRNP 
recognises functional 3’ splice site by base pairing with the branch-point sequence (Shao 
et al., 2014).  This pairing between U2 and BPS requires the assistance of auxiliary splice 
factors like U2AF due to the degenerate nature of the branch point sequence (Zhang et 
al., 1992). The U2AF heterodimer consist of two subunit U2AF65 and U2AF35 which 
binds the polypyrimidine tract downstream of the BPS and the AG dinucleotide, 
respectively (Singh et al.,1995; Valcárcel et al., 1996). This result in the stability of the 
branch point. SR proteins such as SF1 interact with U1 snRNP and the 35kDa subunit of 
the heterodimeric factor, U2AF, bridging the gap between U1 and U2AF snRNP (Wu and 
Maniatis, 1993). This pre-spliceosome assembly is the earliest splicing-specific complex 
to form and is known as complex E. Conversion of complex E to complex A involves an 
ATP-dependent association of U2 snRNP at the branchpoint sequence of the intron 
(Shao et al., 2014). The tri-snRNPs U4/U6/U5 which forms the A complex associates with 
U1 and U2 snRNPs and pre-mRNA forming the pre-catalytic B complexes. Following this, 
U5 snRNP interacts with the 5’ and 3’ splice site, leading to the destabilization and 
dissociation of the U1 and U4 snRNPs association and activating the B complex. The U5 
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snRNP binds to the 5’ splice site and U6 associates with U2 snRNPs resulting in the 
U2/U5/U6 complex. With the activation of the B complex and looping of the spliced 
intron, complex C is formed, and splicing is processed. Intron is spliced out and a 
matured mRNA is formed. U2/U5/U6 complex then dissociates and is recycled. 
These signals responsible for recruitment of the spliceosome are thought to be 
recognized multiple times during the spliceosome assembly to coincide with the internal 
rearrangements resulting in the assembly of spliceosome complexes (Lim and Hartel, 
2004; Schneider et al., 2010). A critical step in the mRNA splicing is the recruitment of 
pre-assembled tri-snSNP U4/U6/U5 to Complex A which interacts with 5’ and 3’ SS to 
form the pre-catalytic Complex B. Formation of activated Complex B result from 
structural and conformational changes of the pre-catalytic Complex B This step is 
associated with the release of U1 and U4 and the hydrolysis of ATP and GTP catalysed 
by Brr2 and Snu114 proteins, respectively (Häcker et al., 2008). The splicing reaction is 
completed by Complex C whose formation is catalysed by activated Complex B 
(Wickramasinghe et al., 2015). The kinetics of splicing involves two esterification 
reaction. The first which results in the formation of a lariat structure after the 2′OH 
group of the branch adenosine of the intron carries out a nucleophilic attack on the 5′ss. 
This results in cleavage at this site and ligation of the 5′ end of the intron to the branch 
adenosine. Next, the 3′OH group of the 5′ exon attacks the 3′ss, leading to the ligation 
of the 5′ and 3′ exons and formation of the mRNA with a corresponding release of the 
intron (Will and Lührmann, 2007). 
      
1.3.2  Regulation of constitutive and alternative splicing by regulatory elements (SRE) 
and splice factors 
 
Spliceosome assembly is highly dynamic, and tightly controlled in its rearrangement, 
(Makarov et al., 2002) as splicing errors involving a single nucleotide either by addition 
or removal will affect the open reading frame (ORF) of an mRNA resulting in the use of 
alternative splice site (Krawczak et al., 1992; 2007). To overcome such error, snRNAs 
target specific phosphate bonds for cleavage once the spliceosome is assembled. The 
spliceosome, however, needs to be able to recognize the correct splice site. This is aided 
by regulatory cis elements known as exonic and intronic splicing enhancers (ESEs and 
ISEs) and exonic and intronic splicing silencers (ESSs and ISSs) (Will and Lührmann, 2007). 
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Exons contain short and classical splice site sequences, whereas, introns contain 
numerous pseudo splice sites which have sequence similar to a true splice site (Sun and 
Chasin, 2000; Lim and Burge, 2001). Since splicing needs to be precise and definite, the 
cis-regulatory elements (ESEs and ISEs; ESSs and ISSs), which either promote or inhibit 
the inclusion of an exon or intron or the use of adjacent splice site, regulate this process 
by recruiting trans-acting splice factors that activate or suppress recognition of a splice 
site or spliceosome assembly (Chasin, 2007). 
It has been shown that ESEs function by recruiting serine/arginine (SR) protein family 
members such as SRSF1 and SRSF2 (previously known as SC35) which bind to the RNA 
recognition motif (RRM) domains on the N-terminal of the ESEs and mediates protein-
protein interaction that facilitates spliceosome assembly (Graveley et al., 1998). The 
heterogenous nuclear RNA proteins (hnRNP) are class of protein associated with 
heterogenous nuclear RNA (hnRNA or pre-mRNA). These were found to be associated 
with the splicing machinery where they act as splice repressors.  The splice repressors 
of the hnRNP class often bind the ESSs. hnRNP such as PTB (hnRNP I) can act by blocking 
interaction between U1 and U2 snRNPs causing skipping of the exon (Sharma et al. 2005) 
while hnRNP A1 either displace U1 snRNP or binds on either side of the exon forming a 
loop (Nasim et al. 2002;). Both ESEs and ESSs have been identified based on their 
enrichment and depletion from the authentic exon sites so that exons which are 
constitutively spliced have abundant ESEs bound to it. Similarly, there are fewer ESSs 
bound to authentic exons (Fairbrother et al., 2002). The abundance of ESEs in 
constitutively spliced exons suggested that while enhancers play a dominant role in 
constitutive splicing, silencers play more prominent role in alternative splicing 
(Fairbrother et al., 2002; Wang et al., 2004). 
ISEs such as the G-triplet (GGG) have been well characterized and are found in clusters. 
They enhance the recognition of adjacent 5’ and 3’ splice site (McCullough and Berget 
2000). Intronic C-A repeats are known to enhance splicing of upstream exons through 
binding of hnRNP L (Hung et al. 2007). Some neuron-specific ISEs such as YCAY (Y=C or 
U) and UGCAUG have been identified which are responsible for brain-specific splicing 
event and recognized by the brain and muscle-specific factor Fox-1 and Fox-2 (Wang et 
al., 2012).  
32 
 
It is known that the SR-proteins, a family of splice factors with a characteristic serine-
arginine (SR)-rich domain, play a critical role in the assembly of the spliceosome and 
interact with regulatory elements and cofactors during splicing. SRSF1 is known to 
regulate the use of 5’ss which does not involve the binding of SRSF1 to ESE via hyper-
phosphorylation by CDC-like kinase 1 (CLK1) and serine-rich protein kinase-1 (SRPK1) 
(Bourgeois et al., 2004). The study suggests that SRSF1 acts by increasing the 
recruitment of U1 snRNP to the 5’ss by interaction with the U1-70k subunit with the 
alternate use of proximal 5’ss (Bourgeois et al., 2004).  An earlier study has also reported 
a novel tri-snRNP-specific 27K SR-protein, which is thought to be phosphorylated by the 
snRNP associated kinase, is responsible for the recruitment of the tri-snRNP (U4/U6/U5) 
during spliceosome assembly (Fetzer et al., 1997). SRPK2 has been associated with the 
tri-snRNP via stabilization of PRP28 (DDX28), which is required for the formation of the 
B-complex whereas, SRPK1 is associated with the U1 snRNP in spliceosome assembly 
(Mathew et al., 2005). Another protein kinase, the pre-mRNA processing factor 4 kinase 
(PRP4K or PRPF4B), through phosphorylation of PRP6 and PRP31, has been shown to 
interact with pre-mRNA splicing factor PRP6, copurify with U5 snRNP and regulate the 
U4/U6/U5 tri-snRNP assembly during B complex formation (Dellaire et al., 2002; 
Schneider et al., 2010). 
1.3.3 Aberrant alternative splicing in cancer 
Considering the increased likelihood of the choice of alternative splicing event and the 
resemblance between a true and pseudo splice site, it is not unlikely that the splicing 
machinery can be hijacked and manipulated resulting in diseases such as cancers. The 
consequence of which, results in aberrant splicing through the choice of an alternative 
pseudo-splice site. Alternative splicing can occur in untranslated 3’ and 5’ regions (UTR) 
of mRNA resulting in altered mRNA stability and translation efficiency (Hughes 2006). 
Aberrant splicing can also result in the introduction of premature stop codon which can 
render mRNA transcript inactive, alter protein function or result in an encoded protein 
with an antagonistic function (Solier et al., 2005).  
 
Changes in alternative splicing have been observed to affect several aspects of 
tumorigenesis to include cell cycle control of tumour growth, migration and 
proliferation, cell apoptosis, tumour metabolism and angiogenesis (Inoue and Fry, 2015; 
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Mavrou et al., 2014; Christofk et al., 2008). In recent times, studies have continued to 
show that alternatively spliced gene can be used for diagnostic and prognosis purposes, 
as well as therapeutic targets in malignancies (Amin et al., 2011; Mavrou et al., 2014). 
For example, inhibition of SRPK1 using a small molecule inhibitor, SPHINX, result in 
alternative splicing of VEGF to its anti-angiogenic isoform, thus, inhibiting growth of 
blood vessel in models of choroidal angiogenesis in vivo (Batson et al., 2017) 
 
Breast cancer has been associated with aberrant splicing of the TP53, BRCA1 and PTEN 
genes (Okumura, et al., 2011), and CDC25 encoding phosphatase (Albert, et al., 2011). 
In ovarian cancer, the growth factor receptor-bound protein-7 (GRB7) has been 
identified to be alternatively spliced and its spliced variant GRB7v function as an adaptor 
for extracellular signalling ligand responsible for cell proliferation (Wang, et al., 2010). 
In colon cancer, tissue inhibitor of metalloproteinase-1 (TIMP-1) and cell adhesion 
molecule CD44 are alternatively spliced and increase the metastatic potential of colon 
cancer cells (Usher et al., 2007; Gotley et al., 1996). A wide variety of genes (BCL2L1, 
CD44, VEGFA, CCND1) with spliced variants were found in lung cancer that confer 
increased proliferation and resistant to apoptosis to tumour cells (Cheung et al., 1998; 
Nguyen et al., 2000; Shabnam et al., 2004; Li et al., 2008). Other splicing events, which 
have also been observed, include CLK1 (Simon, et al., 2018), VEGFA (Mavrou and Oltean, 
2016), BCL2L2 (Mercatante et al., 2001 and ERG (Hagen et al., 2014) splicing in prostate 
cancer, Caplin-3 in melanoma and Kruppel-like factor-6 (KLF6) in liver cancer (Hanoun et 
al., 2010). 
It is evidenced that isoform switches resulting from translation of alternative spliced 
gene or use of alternative reading frame affect protein-protein interactions in cancers 
due to loss or gain of the functional domain. Loss of function has been observed in 
NFE2L2 (Goldstein et al., 2016) when alternatively spliced and consequently, activates 
an alternative mechanism for oncogenesis when interacting with a negative regulator 
such as KEAP1 (Goldstein et al., 2016; Climente-González et al., 2017). 
1.3.4 Aberrant alternative splicing in leukaemia 
Aberrant splicing has also been reported in leukaemic cancers and has been shown to 
drive leukaemogenesis. For example, DNA methyltransferase 3A (DNMT3A) and its 
transcripts (DNMT3A2; DNMT3A4) are known to be key players in haematopoietic cell 
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differentiation and proliferation (Božić, et al., 2018). An alternative spliced variant of 
transcript DNMT3A2; DNMT3A2V when overexpressed has been shown to delay cell 
proliferation whereas a mutated isoform DNMT3A2V R882H promotes cell proliferation 
in haematopoietic cell. A switch from DNMT3A1 to DNMT3A2V is implicated in the 
pathophysiology of AML (Lin, et al., 2017). Further RNA-seq analysis of AML has shown 
variations in isoform levels of key genes (such as MYB, BRD4 and MED24) known to be 
involved in leukaemogenesis following inhibition of SRPK1 (Tzelepis et al., 2018). 
 
In Philadelphia positive (Ph+) pre-B-lymphoblastic leukaemia and ALL cells, aberrant 
splicing induced by BCR-ABL1 gene has been found in IKAROS; a transcription factor 
belonging to the zinc-finger family, with the resultant isoform (IK6) exerting a negative 
dominant effect on early lymphoid commitment of B-cells (Klein et al., 2006). Increased 
expression of IK6 isoform correlates with the high percentage of blast cells in ALL and 
TKI resistance (Klein et al., 2006; Iacobucci et al., 2008). 
An earlier study (Liu et al., 2012) has found differential expression of the gene (CENPE, 
SLC4A1, WT1 and E2F7) responsible for the cell cycle in K562, a CML cell line. However, 
a reversed gene expression level was observed with genes which were previous 
upregulated (E2F7, WT1, CCNE2 and CHEK2) becoming downregulated due to imatinib-
induced alternative splicing of the T-box transcription factor (TBX3) (Liu et al., 2015). A 
similar experiment has found a change in splicing in Bclx protein with the anti-apoptotic 
variant, Bcl-xL showing increased expression after treatment with imatinib in K562 cell 
line (Liu et al., 2012). 
 
A key gene c-Myb involved in the regulation of proliferation and differentiation in 
several cells including haematopoietic cells (Emambokus et al., 2003) has been found to 
be alternatively spliced with its spliced variant highly expressed in leukaemia and 
implicated in leukaemic cell transformation (Zhou et al., 2011).  Expression of c-Myb 
variant correlated with poor survival in a cohort of B-ALL samples (Zhou et al., 2011). 
The alternative spliced Myb variants are formed using alternate exon 8A,9A.9B.10A,13A 
and 14A.  The levels of these spliced variant transcripts were shown to be regulated 





1.4 Serine/arginine-rich (SR) proteins 
 
An essential class of splicing regulators is the serine/arginine (SR) family of proteins. SR 
proteins are a highly conserved family of splicing factors and regulators which contain 
an arginine/serine (RS)-rich domain. The SR protein have a characteristically organized 
structure which contain one or two N-terminal RNA-recognition motifs (RRM), C-
terminal rich in arginine and serine (RS) dipeptides repeats (Krainer et al., 1990; Fu and 
Maniatis, 1992). Using the mAb104 monoclonal antibody, specific for phosphoepitopes, 
members of the SR protein family were identified and classed as a family (Roth et al., 
1991). Members of the ‘classical’ SR protein family has been designated splice factor, 
serine/arginine (SRSF) 1-9 and 11. These differs either in the presence or absence of the 
RRMH, the zinc knuckle and the number of arginine/serine repeats (Figure 1.10) 
(Boucher et al., 2001).  
                        
              
Figure 1.10. Schematic showing structural organization of the common 
human SR proteins. RRM, RNA recognition motif; RRMH, RRM 
homology; RS, arginine/serine-rich domain; Zn, Zinc knuckle (Shepard 




Localization of SR proteins are in ‘speckles’ which are subnuclear structures found in the 
interchromatin region of the nucleoplasm of mammalian cells from where the SR 
proteins are mobilized during active transcription (Cazalla et al., 2002). 
SR proteins have been shown to determine and regulate splice-site selection during 
constitutive and alternative splicing (Chandler et al., 1997), a function performed by the 
RRM while the RS domain mediate protein-protein interaction in several steps during 
spliceosome assembly (Kohtz et al., 1994; Tronchère et al., 1997). They have also been 
implicated in crucial aspects of mRNA metabolism including export, localization, 
translation, and nonsense-mediated decay (NMD) (Krainer et al. 1990; Cáceres et al., 
1998; Sanford et al.,2004). Another study reports that SR proteins binds noncoding RNAs 
and exhibit positional RNA binding during regulated alternative splicing events (Bradley 
et al., 2014). The choice of alternative promoter and polyadenylation site selection are 
also affected by levels of SR proteins (Bradley et al., 2014). SR proteins act as activators 
during alternative splicing by binding to exonic splicing enhancers (ESEs) in pre-mRNA 
and recruiting the splicing machinery to the splice site through RS-domain-protein 
interaction (Bradley et al., 2014). 
Other essential function of the SR protein in cell viability and embryogenesis has been 
demonstrated in cultured cell and xenograft study using mice with germline deletion of 
Srsf1, Srsf2 and Srsf3 resulting in cell death and early embryonic death in mice 
respectively (Jumaa et al., 1999; Wang et al., 1996, 2001; Xu et al., 2005). In contrast 
Srsf10 null mice were observed to have severe cardiac defect to include septa defect 
and myocardial thinning (Feng et al., 2009). These findings underline the key role played 
by SR proteins in early development and active gene transcription. 
The role of SR proteins in splice site selection and spliceosome assembly is regulated by 
their phosphorylation. In vitro phosphorylation of RS domain affects both protein-
protein and protein-RNA interactions and prevents nonspecific binding during early 
spliceosome assembly (Xiao and Manley, 1997; Tacke et al., 1997). Dephosphorylation 
on the other hand, results in the resolution of the splice machinery and release of 
processed RNA (Cao et al., 1997). Thus, suggesting that phosphorylation-
dephosphorylation cycle of the RS domain of SR proteins play a role during the splicing 
cycle. Further supporting the effect of phosphorylation on the function of SR protein is 
evidenced by the intracellular and intranuclear trafficking mediated by RS domain 
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phosphorylation (Yeakley et al., 1999) and suggests the regulation of SR proteins by 
specific kinases.  
Protein kinases which have been well characterized and specific for SR protein are the 
SRPK and CLK families of kinases. Kinases belonging to these two families are structurally 
distinct, are differentially expressed and exhibit different substrate specificities (Gui et 
al., 1994; Colwill et al., 1996).  
 
1.5 CDC-like kinase-1 (CLK1) 
 
1.5.1 Structure and function of CLK1 
CDC-like kinase-1 (CLK1) is a member of an evolutionarily conserved group of kinases. 
There are four CLKs in humans, termed CLK1-4. It is widely expressed and can 
phosphorylate protein substrates at serine, threonine and tyrosine residue (Moeslein et 
al., 1999). CLK1 was first identified by Ben-David et al., (1991) where it was closely 
associated with protein kinases involved in the regulation of the cell cycle.  The human 
CKL1 gene consists of 13 exons. Its full-length protein consists of 484 amino acids (aa) 
with the first 130aa constituting a regulatory region required for CLK1 interaction with 
SR proteins. The remaining amino acids forms its catalytic domain (Uzor et al., 2018). 
Within the motif HTDLKPEN, CLK has a threonine where most other kinases have 
arginine (Ben-David et al., 1991). The CLK consist of 19 amino acid (19-aa) inserts in 
between the HTDLKPEN and highly conserved DFG motif relative to other protein 
kinases (Ben-David et al.,1991; Hanks et al., 1998). The CLKs can phosphorylate both 
Arg-Ser and Ser-Pro dipeptides common in all serine-rich proteins ((Aubol et al., 2013). 
Localization of CLK1 is mainly in the nucleus where its function is to phosphorylate SR 
proteins and facilitate the release of SR proteins from nuclear speckles during splicing 
and regulation (Aubol et al., 2013). High level of CLK1 is thought to inhibit the 
recognition of splice sites by SR proteins and regulate SRPK1 nuclear presence (Aubol et 
al., 2016). Phosphorylation and activation of the protein-tyrosine phosphatase 1B (PTP-
1B) is achieved with the action of CLK1 resulting in fold increase of phosphatase activities 
in HEK-29 cells in vivo (Moeslein et al., 1999) 
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It is suggested that CLK1 is required for cell cycle progression as inhibition or depletion 
of CLK1 results in cell death or G1/S phase arrest due to a defect in mitosis (Dominguez 
et al., 2016). 
1.5.2 Regulation of CLK1 expression and activity 
Studies on the regulation of CLK1 expression appear to be sparse. An earlier study has 
suggested that CLK1 is regulated through its pre-mRNA splicing yielding a catalytically 
active CLK1 and a truncated inactive polypeptide (CLK1T) (Duncan et al., 1997). This was 
further demonstrated in a recent study, which showed that CLK1 auto-regulates itself 
through exon-4 skipping and intron-4 retention in the presence of environmental or 
biological stress by altering the balance between its full length and truncated form Uzor 
et al., 2018).  
 
Aubol et al., (2016; 2018) has shown that mobilization of SRSF1 from the nuclear speckle 
by SRPK1 is enhanced by CLK1 and this, in turn, result in fold increase in the level of CLK1 
in the nuclei as it forms a complex with SRPK1.  In a similar study, it was observed that 
human CLK1 activity is dependent on CLK1 concentration (a concentration fold change 
which was associated with its quaternary structure). It was also observed that the N-
terminus of CLK1 is necessary for speckle location of CLK1 and induces oligomerization, 
which determines CLK1 substrate specificity (Keshwani et al., 2015) 
1.5.3 Molecular interactions of CLK1 
The association of CLK1 with SRPK1 in the mobilization of SR proteins, during pre-mRNA 
splicing is well described (Figure 1.11). The release of SR protein from nuclear speckles, 
following phosphorylation, requires the CLK1-SRPK1 hetero-kinase complex (Aubol et 
al., 2016). It is also reported that this process results in the nuclear regulation of SRPK1 














Like the association between CLK1 and SRPK1, another protein kinase Prp4 has been 
shown to interact with CLK1 carboxylic terminus resulting in phosphorylation of Prp4 
arginine/serine-rich domain by CLK1 (Kojima et al., 2001). The protein kinase PTP-1B 
which is required for regulation of intracellular protein phosphorylation is itself 
enzymatically activated by CLK1 phosphorylation (Moeslein et al., 1999). Myelin basic 
proteins and Histone H1 have also been identified as CLK1 substrates. 
There are also indications that CLK1 may interact with some apoptotic genes such as 
Caspase, MCL-1, BCL-X and Survivin as inhibition of CLK1, using the benzothiazole TG003, 
one of the first established inhibitors of CLKs (Muraki et al., 2004) was found to alter 
levels of pro and anti-apoptotic isoforms of these genes (Uzor et al., 2018). 
 
1.5.4 The role of CLK1 in cancer 
 
With the critical function of CLK1 synergizing with SRPK1 in the release of SR protein and 
consequent regulation of SRPK1 (Aubol et al., 2016) during alternative mRNA splicing, 
and its role in cell cycle regulation and progression (Dominguez et al., 2016), it is not 
Figure 1.11: Schematic diagram showing CLK1-SRPK1 interaction during SR protein 
phosphorylation for the initiation of pre-mRNA splicing. CLK1 bounds to the RNA 
recognition motif (RRM) of SR protein and phosphorylates SR protein. With the nuclear 
import of SRPK1, SRPK1-CLK1 complex is formed which recruits the U1 snRNP to the splice 
site. With the attachment of U1 snRNP to the splice site, complete phosphorylation and 
release of SR protein from nuclear speckle, splicing is initiated (Adapted: Aubol et al., 2016). 
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surprising that CLK1 could play a role in carcinogenesis. Varying levels of CLK1 have been 
found in different cancers with the overexpression indicative of poor disease prognosis 
and survival (Dominguez et al., 2016). Silencing of CLKs in MCF7 breast cancer cells and 
MCF10 female xenograft mice using shRNA plasmid or lentivirus has been shown to 
inhibit breast tumour growth indicated by expression of smooth muscle epithelium 
(Yoshida et al., 2015) as well as a change in the splicing pattern of epithelial-
mesenchymal transition (EMT) genes such as ENAH gene (Yoshida et al., 2015). CLK1/4 
has also been shown to regulate alternative splicing of tumour suppressor gene TP53 in 
breast cancer where it influences the choice of alternatively spliced p53β and p53Ƴ 
isoforms (Marcel et al., 2014; Czubaty and Piekiełko-Witkowska, 2017). 
 
In lung cancer, CLK1/4 prevents the stimulation of hypoxia-induced angiogenesis 
through reduction of an alternatively spliced isoform of tissue factor (asTF), which is 
known to stimulate the expression of proangiogenic genes (Eisenreich et al., 2013). A 
recent study also showed that CLK1 is upregulated in PC3 prostate cancer cell lines and 
inhibition of CLK1 in prostate cancer significantly resulted in decreased expression of 
anti-apoptotic caspase 9b isoforms (Bowler et al., 2018). 
 
CLK1 has also been implicated in therapy-related resistance due to its direct regulation 
of the SPF45 human splice factor (Liu et al., 2013). Knockdown of CLK1 using siRNA was 
found to degrade SPF45 with consequent reduction in SPF45-induced exon 6 exclusion 
from Fas mRNA (Liu et al., 2013) implicating CLK1 as a druggable target. 
There are insufficient data on the role of CLK1 in leukaemia and blood-related 
malignancy. One study found that upregulation of CLK1 and other members of the CLK 
family have been observed in hexamethylene-bis-acetamide (HMBA)–induced 
erythroleukaemia cell differentiation and, thus it is implicated in the erythroid cell 
transformation in leukemogenesis (García-Sacristán et al., 2005).  
Owing to the fact that the effect of CLK1 in carcinogenesis is related to its role in 
alternative splicing of TNF-stimulating genes (TSGs) and oncogenes and with the 
established role alternative splicing play in tumorigenesis and cancer progression, it is 
therefore, arguable that the control of alternative splicing in cancers through 
manipulation of splice factors and their kinases such as SRPK1 and CLK1, could be key in 
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the treatment and management of most cancer types where aberrant splicing is key to 
progression and metastasis. 
1.5.5 CLK1 as a therapeutic target 
As the search for targeted therapeutics with high efficacy and minimal side effect 
continues, the use of small molecule inhibitors against protein molecules and their 
substrates has continued to increase. This has shown prospect as some of these 
molecules have moved on to clinical trials (extensive review by Gatzka, 2018).  Targeting 
protein kinases involved in alternative splicing is gaining grounds and an emerging 
therapy due to the key role they play in gene regulation. As such, several molecules are 
currently being developed targeting the CLK1 and the CLK family of kinases such as CLK2 
and CLK4 (Araki et al., 2015; Iwai et al., 2018). 
Mounting evidence continues to show that targeting the CLKs significantly affect tumour 
behaviour and significantly change splicing. Araki et al., (2015) showed that CLK 
inhibition leads to modulation in ribosomal protein kinase, S6K splicing, splicing 
alterations in several genes and protein depletion for multiple genes including those 
involved in tumour growth and survival pathways such as endothelial growth factor 
receptor (EGFR), eukaryotic translation initiation factor 3 (EIF3D) and poly (ADP-ribose) 
polymerase (PARP). A similar finding was also published by ELHady et al., (2017) in which 
CLK1 and CLK4 led to the depletion of EGFR, histone deacetylases (HDAC1) and S6K1 
kinase in cancer cells. 
A study investigated 169 cell lines, of which, 19 were haematological cancers and 150 
were solid tumours.  The results showed that a reduction in CLK-dependent 
phosphorylation, led to alternate skipping of exons in CLK-regulated genes, increased 
apoptosis and growth suppression both in vitro and in vivo, of which, MYC-driven 
cancers were found to be the most sensitive (Iwai et al., 2018). 
Compound screening has identified CC-671 as a potential and selective inhibitor of 
CLK1/2 in triple-negative breast cancer. Mechanism of action of this compound involves 
the inhibition of SRSF4 through reduced phosphorylation which resulted in the selection 




1.6  Splice factor kinase-1 (SRPK1) 
 
1.6.1 Structure and function of SRPK1 kinase 
The serine/arginine-rich protein-specific kinase-1 (SRPK1) belongs to a family of protein 
kinases which phosphorylates RS-domain of proteins rich in serine/arginine repeats. 
Members of this kinase family (SRPK1 and SRPK2) are known to be conserved in 
eukaryotes (Yun and Fu, 2000). The human SRPK1 gene is located on chromosome 
6p21.2-p21.3 (Figure 1.12A) (Wu et al., 2013). Like most protein kinases, SRPK1 is 
characterized by two conserved kinase domains separated by a spacer sequence; an 
accessory domain (Figure1.12B) (Ding et al. 2006; Zhong et al., 2009).  
The accessory domain is known to regulate SRPK1 cytoplasmic-nuclear shuttling as 
deletion of the accessory domain results in exclusive nuclear localization (Wang et al., 
1998; Zhong et al., 2009). This observation suggests the role of SRPK1 in spliceosome 
assembly and in the mediation of trafficking of splice factors and subsequent 
phosphorylation of SR proteins during constitutive and alternative splicing in 
mammalian cells (Zhou et al., 2012). A further study has also shown that the accessory 
domain in addition to stabilizing the catalytic loop is essential for protein substrate 
phosphorylation by increasing the exchange rate in the glycine-rich and activation loop 
which drives phosphoryl transfer from ATP (Plocinik et al., 2011).  
The N-terminus and C-terminus of this kinase are not known to be conserved and are 
thought to play an auxiliary role (Ngo et al., 2005).  Deletion of the N- and C-terminal 
does not inactivate the kinase catalytic activity (Ngo et al., 2007). However, another 
study demonstrated that the N-terminus stabilizes the docking groove of the kinase 
domain which enhances high-affinity binding and efficient phosphorylation of its 
substrate, the SR proteins (Ngo et al., 2005). Consequently, deletion of the N-terminus 
reduces SR-protein recognition and binding affinity (Plocinik et al., 2011).  
X-ray structures of SRPK1 reveal an insert for mitogen-activated protein kinase (MAPK) 
which connects helices αG and αH, a loop connecting helices αF and αG and a docking 
groove generated by the MAPK insert which contains eight amino-acid residues (191-
198) (Ngo et al., 2007).  Contrary to other proteins, which require regulation by diverse 
mechanism, SRPK1 and its family members are constitutively active and require no post-
translational modification or additional subunits for optimal activity (Ngo et al., 2007). 
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This is because SRPK1 has a relatively short activation loop that lacks a reversible 
phosphorylation site, allowing for a stable conformation and access of substrates to the 
constitutively active site (Ngo et al., 2007).  
The presence of a short activation loop in addition to the malleability of the activation 
loop, and the ability of the kinase catalytic loop to extract hydroxyl hydrogen (OH-) from 
the substrate serine; a critical step for phosphorylation, has been shown to be 
responsible for the maintenance of a constitutively active conformation for SRPK1 (Ngo 
et al., 2007).  
Other family members of the SRPK family have been identified that are expressed in the 
nervous system (SRPK2) and muscle cells (SRPK3) respectively. In addition, a spliced 
isoform of SRPK1 known as SRPK1a, which result from the inclusion of 513bp segment 
is exclusively expressed in the testis (Sanidas et al., 2010; Nikolakaki et al., 2001). This 
implies that the members of this kinase family have their distinct cellular localization 
and functions in different cell types (Nakagawa et al., 2005; Zhou and Fu, 2013). 
        
 






Figure 1.12 Gene location and protein structure of SRPK1. Structure of chromosome 6 
showing the location of the SRPK1 gene on p21.2-p21.3 (A). Structure of full length SRPK1 
protein (B). The accessary domain (AD) located between aa 256-474 is flanked at both end by 
N-terminal (aa 227-255) and C-terminal (aa 474-489) and divides the kinase domain into two 




1.6.2  Regulation of SRPK1 activity 
The accessory domain (AD) of SRPK1 has been shown to affect the localization of SRPK1 
Zhong et al., 2009. An earlier study has shown that deletion of the accessory domain 
results in SRPK1 being sequestered in the nucleus (Wang et al., 1998; Zhong et al., 2009). 
It is possible that the AD function as a cytoplasmic anchor for SRPK1. The accessory 
domain of SRPK1, in part, regulates its function by providing a binding surface for 
chaperone complex assembly. Plocinik et al., (2011), in an X-ray diffraction study, 
discovered that although the AD is large with about 200 amino acid, it lacks a stable 
structure and proposed that the bulk of the AD which has been previously described 
constitute a large intrinsically disordered region in SRPK1.  It suggests that this region 
could provide a large unstructured surface for chaperones which are known to bind to 
unfolded proteins (Plocinik et al., 2011).  
Chaperones, which have been identified are the heat shock family and co-chaperones 
Hsp40/Hsp70 and Hsp90/Aha1(Zhong et al., 2009) (Figure 1.13). While Hsp40 targets 
region outside the accessory domain, Hsp90 targets the accessory domain (Zhong et al., 
2009). Chaperone complex assembly is initiated by the binding of Hsp40/Hsp70 to SRPK1 
followed by the binding of Hsp90 and Aha1, a co-chaperone (Figure 1.13). Formation of 
SRPK1/chaperone/co-chaperone complex also ensures the folding of SRPK1 into its 
active conformation and protects it from proteasome degradation. This model has been 
validated in an experiment which showed that inhibition of the chaperone Hsp90 ATPase 
activity resulted in dissociation of the chaperone complex and SRPK1 nuclear localization 







1.6.3  Molecular interactions of SRPK1 
Like other protein kinases, SRPK1 interacts with several molecules, which either serve 
as a substrate or control its association with substrates. Such interactions result in the 
regulation of their activity either directly or indirectly. Phosphorylation of SR proteins by 
SRPK1 results in nuclear import of SR-proteins and their localization into nuclear 
speckles. 
 In relation to SRPK1 phosphorylation of SR proteins, SRPK1 also interacts with the splice 
factor protein kinase CLK1. SRPK1 forms a complex by interacting with the RS-domain in 
the N- terminus of CLK1 in a mechanism to release the phosphorylated SR protein (Aubol 
et al., 2016 and 2018). 
SRSF1 is a member of the SR protein family which has been extensively studied and 
strongly phosphorylated by SRPK1. SRSF1 has two RRM and an RS domain of about 50 
amino acids. It is known that SRPK1 interacts with about 10-12 amino acids of the RS 
Figure 1.13. Model for SRPK1 regulation showing the binding of chaperone and co-
chaperone proteins to SRPK1. Signalling such as those required for transcription result in 
dissociation of SRPK1 from the chaperone molecules and it’s binding to SR-protein with 
nuclear translocation which results in transcription and constitutive and alternative splicing 
(Zhong et al., 2009). 
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domain (Plocinik et al., 2011); an interaction which produces high-affinity binding which 
is considered critical for the regulation of the extent to which SRSF1 is phosphorylated 
(Ngo et al., 2007; Plocinik et al., 2011).  Phosphorylation of SRSF1 by SRPK1 has been 
shown to be in C- to N-terminal direction irrespective of the presence (SRPK1-FL) or 
absence of N-terminal (SRPK1∆N) and spacer domain (SRPK1∆S) (Plocinik et al., 2011). 
Cellular interactions of SRPK1 with SRSF1 affects several pathways including those 
involved in apoptosis and cell proliferation (Anczuków et al., 2012) as well upstream 
signalling pathways of MYC and PI3K such as S6K1 and BIN1 (Karni et al.,2007).  Studies 
(Amin et al., 2011; Oltean et al., 2012) have also shown that SRPK1 and its key substrate, 
SRSF1 is part of an essential pathway responsible for the regulation of the alternative 
splicing of vascular endothelial growth factor (VEGF) into pro-/anti-angiogenic isoform 
in renal epithelial cells (podocytes) and in colon carcinoma cells. These studies further 
demonstrate that a knockdown of SRPK1 increased levels of VEGF anti-angiogenic 
isoform and prevents tumour growth in xenograft by reducing micro-vessel density. A 
similar finding has been observed in a study using prostate cancer cell line PC3 (Mavrou 
et al., 2014). Furthermore, interaction of SRPK1 with the Wilms’ tumour-1 (WT1) has 
resulted to hyper-phosphorylation of SRSF1 and hence splice shift in VEGF to 
proangiogenic isoform (Amin et al., 2011).  
Studies (Wang et al., 2014; Chang et al., 2015) suggests that SRPK1 is a downstream 
target of activated protein kinase-B (Akt/PKB). The studies showed that SRPK1 interacts 
and modulates the Akt pathway through recruitment of pH domain leucine-rich repeat 
protein phosphatase (PHLPP), an Akt phosphatase. SRPK1 was shown to induce Akt 
activation by interfering with PHLPP mediated dephosphorylating of Akt, which suggest 
that SRPK1 could be a regulator of Akt. A positive feedback mechanism between SRPK1 
and Akt was also suggested where elevated SRPK1 induced activation of Akt and the 
activated Akt then binds and stimulates SRPK1 auto-phosphorylation (Chang et al., 
2015). 
Also, SRPK1 has been shown to regulate epidermal growth factor (EGF) activation; a 
proto-oncogene which is upregulated in tumour cells and capable of activating several 
oncogenic pathways in cancers (Zhou et al., 2012). This study suggests that EGF can be 
activated by SRPK1 via the phosphatidylinositol-3-kinase/protein kinase-B (PI3/Akt) 
pathway other than the well-known downstream mammalian target of rapamycin 
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(mTOR) pathway to induce large splicing response in the nucleus (Zhou et al., 2012). 
Supporting this finding is a mass spectrometry analysis of SRPK1 phosphopeptides 
showing multiple phosphorylation sites, which could be induced by EGF or Akt (Zhou et 
al., 2012). There are also indications that down-regulation of SRPK1 or CLK1 blocks EGF 
stimulation of nuclear SRSF1 mobilization (Aubol et al., 2018).  
Since SRPK1 has been shown to display both cytoplasmic and nuclear localization (Aubol 
et al., 2016), it is speculated that SRPK1 may have other substrates which drive its 
cellular function even though it is known to be highly specialised to target SR proteins 
and related splicing factors (Aubol et al., 2013). 
Other named possible substrate of SRPK1 are viral proteins. Nuclear import of herpes 
simplex virus-1 protein, ICP27 due to interaction with SRPK1, was found to reduce 
splicing activity with subsequent intron-less viral mRNA formed (Sciabica et al., 2003).  
In hepatitis B virus (HBV) infected cells, SRPK1 phosphorylates the viral protein which 
results in the encapsulation of the viral genetic material (Zheng et al., 2005). This was 
further evidenced by the failure in encapsulation of Sindbis virus following inhibition of 
SRPK1 by a small molecule, SRPIN340 (Fukuhara et al., 2006). The E1^E4 protein of 
human papillomavirus 1(HPV-1) has also been named as a substrate for SRPK1, where it 
inhibits SRPK1 phosphorylation of viral SR protein thus, regulating posttranscriptional 
processing of viral transcript by SR protein (Prescott et al.,2014). 
In addition, phosphoprotein such as human P1 protamine has been identified as 
substrates for SRPK1. SRPK1 phosphorylation of human P1 protamine results in its 
exchange with histone H1 and H3 during the process of spermiogenesis 
(Papoutsopoulou et al., 1999). 
 
1.6.4 The role of SRPK1 in cancer 
 
Interestingly, upregulation of SRPK1 has been observed in prostate cancer (Mavrou et 
al., 2014), glioma (Wu et al., 2013), colon cancer (Amin et al., 2011), breast cancer (van 
Roosmalen et al., 2015) and hepatocellular carcinoma (Zhou et al., 2013). It is also 
apparent that the role and expression of SRPK1 in different cancers are heterogeneous 
and not yet entirely clear (Zhou et al., 2013). While SRPK1 upregulation has been 
observed to promote tumour growth, progression, metastatic dissemination in prostate, 
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breast and hepatocellular cancers, and an indication for chemo-resistance in cancers 
with the proangiogenic phenotype (Oltean et al., 2012; Mavrou et al., 2014; van 
Roosmalen et al., 2015). Tumours of germinal origin have shown progressive and 
metastatic dissemination characteristics following downregulation of SRPK1 with 
associated cisplatin resistance (Krishnakumar et al., 2008; Wang et al., 2014). van-
Roosmalen and colleagues have associated high levels of SRPK1 with poor prognosis, 
tumour aggressiveness, dissemination and distant metastases in breast cancer and have 
suggested SRPK1 as a potential target for drug therapy (van Roosmalen et al., 2015). 
That SRPK1 is a druggable target has already been demonstrated as its inhibition blocks 
angiogenesis and tumour growth in vivo (Amin et al., 2011; Mavrou et al., 2014). 
 
1.6.5  SRPK1 in leukaemia 
 
The complexity of protein network involved in molecular signalling and its interaction 
with kinases and other molecules has become the target in leukaemia therapy due to 
their role in genomic instability and dysregulation of these signalling pathways in 
leukaemia (Paulsen et al., 2009). Research into molecular and cellular mechanisms can 
provide clues on the behaviour of leukaemia cells and possible therapeutic interventions 
(García-Sacristán et al., 2009; Jang et al., 2008; Paulsen et al., 2009).  
The need to maintain cell homogeneity and homeostasis in leukaemia has implicated 
SRPK1 as candidate for drug targeting due to its involvement in wide cellular interaction 
responsible for pre-mRNA splicing (Sanidas et al., 2010; Zhou et al., 2012), angiogenesis 
(Amin et al., 2011; Oltean et al., 2012), cell survival and proliferation (Sanidas et al., 
2010) even in leukemic cells. A study using K562 CML demonstrated that SRPK1 is highly 
expressed in erythroid and lymphoid cells and associated increased expression of SRPK1 
to cell proliferation and tumour grade (Sanidas et al., 2010). Another review suggests 
that repression of SRPK1 in acute myelogenous leukaemia (AML) could modify the 
choice of a splice site in VEGF (Mohamed et al., 2014). The mechanism is such that 
repression of SRPK1 results in hypo-phosphorylation of SRSF1 and hence, the selection 
of 3’ proximal (pro-angiogenic) splice site during VEGF splicing (Oltean et al., 2012; 
Mohamed et al., 2014). Several studies (Daub et al., 2002; Hishizawa et al., 2005; Zheng 
et al., 2005; Fukuhara et al., 2006;) have shown that SRPK1 is able to interact with viral 
protein associated with several viral diseases which include the human T-cell leukaemia 
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virus 1. Thus, the pharmaceutical targeting of SRPK1 could benefit not just leukaemia 
and other cancer treatments, but also antiviral treatments, 
 
1.6.6 SRPK1 and leukaemia therapy 
 
There has been increasing interest towards targeting SRPKs in the management of 
several cancers as SRPKs have shown increased expression in tumours of the pancreas, 
colon, breast as well as viral-induced T-cell leukemic cells (Fukuhara et al., 2006). More 
so, experiments using several cell line models (U87, CaCo2 MiaPaCa2, HL60) have also 
shown diminished activities in pathways relating to cell proliferation, invasion, 
migration, and increased apoptotic potential and sensitivity to common 
chemotherapeutics following inhibition of SRPK1 (Hayes et al., 2007; al., 2011; Wu et 
al., 2013; Siqueira et al., 2015). Earlier studies have demonstrated increased expression 
of SRPK1 as an indication for resistance to chemotherapeutic agents such as oxaliplatin, 
gemcitabine and cisplatin using HT29 colon cancer cell and K562 leukaemic cell lines 
(Plasencia et al., 2006; Sanidas et al., 2010). In myeloma, combined therapy of 
bortezomib, a proteasome inhibitor and thalidomide, a cell cycle inhibitor has been 
investigated which only showed improved progression-free survival (PFS) on long-term 
administration but not overall survival (OS) with increased toxicity even in a high-risk 
patient with cytogenic profile t(4;14).   
Over time, second-generation proteasome inhibitors and immunomodulatory agent 
such as pomalidomide, alkylphospholipid (an Akt inhibitor) perifosine and heat shock 
protein (HSP) inhibitors have undergone varying level of clinical evaluation in leukaemia 
(Anderson et al., 2007; Mitsaides et al., 2009; Allegra et al., 2011). In phase III clinical 
trial by Palumbo et al., (2010) combined bortezomib-melphalan-prednisone-
thalidomide (VMPT), which combines a proteasome inhibitor, alkylating agent, immune 
cells and cell cycle respectively was used followed by maintenance with bortezomib-
thalidomide (VMPT-VT). This was compared with bortezomib-melphalan-prednisone 
(VMP) treatment alone in untreated multiple myeloma patients who are ineligible for 
autologous stem-cell transplantation. Patients showed only three years of overall 
survival (OS). This was not free of toxicity relating to cardiologic and thromboembolic 
event which result in treatment-related death of 4% of the 38% who completed the 
therapy. It was shown that the inclusion of thalidomide greatly improved the efficacy of 
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the treatment (Palumbo et al., 2010). The current regimen for the management of 
leukaemia is not without toxic side effects, which have affected therapy as most of these 
drugs were found to have reduced potency at lower doses (Palumbo et al., 2010).  
Drug-like imatinib mesylate, a tyrosine kinase inhibitor which was developed since the 
1990s to specifically target the breakpoint cluster region (BCL/ABL+) fusion protein in 
CML has remained the first line treatment for this condition. Although not curative, 
imatinib is only known to manage the condition through inhibition of cell proliferation 
and induction of apoptosis (Liu et al., 2015) with up to 37% discontinuing the therapy 
due to suboptimal response or tolerance (Jangamreddy et al., 2013). 
Following increased treatment failure and relapse in patients with leukaemia in novel 
therapeutic regimens, investigations are further targeted towards specific signalling 
pathways that are known to be deregulated (for example, constitutively activated) in 
leukemic cancers (Allegra et al., 2011). The evidence strongly suggests that targeting 
splice factor kinases in leukaemic patients could prove to be beneficial. There is however 
very little work on targeting SRPK1 as a novel method in improving existing drugs in 
leukaemia treatment. The aim of this thesis is to explore the potential benefits of 
combining SRPK1 inhibition with the effect of existing leukaemic drugs. 
 
1.7 Hypothesis and aims 
 
1.5.1. Hypothesis 
Targeting SRPK1 in leukaemia will enhance the efficacy of conventional chemotherapy. 
1.5.2. Aims and objectives 
The aims of this research are; 
Aim A 
To investigate the consequences of targeting SRPK1 in K562 and Kasumi-1 leukaemic 
cells. 
This will be achieved through the following specific objectives; 
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i. Investigate the effect of SRPK1 chemical inhibition using small molecule 
inhibitors such as SPHINX and its knockdown using small interfering RNA (siRNA) 
on leukaemic cell growth, proliferation and apoptosis (chapters 3 and 4). 
ii. Investigate the effect of SRPK1 chemical inhibition and knockdown on the 
alternative splicing of a panel of apoptotic genes; BCL2L1, APAF1 and CASPASE 9 
(chapters 3 and 4). 
Aim B 
To investigate the potential of combining conventional chemotherapeutic drugs 
(imatinib mesylate and azacytidine) with SRPK1 (and for comparison CLK1 inhibition) in 
leukaemic cells; 
This will be achieved using the following specific objectives; 
i. Treat leukaemic cell lines (K562 and Kasumi-1) with established 
chemotherapeutic drugs; Imatinib mesylate and azacytidine and observe the 
effect on cell activities such as cell growth, proliferation and apoptosis (chapter 
4). 
ii. Combine SPHINX and TG003 treatment with conventional chemotherapeutic 
drugs to see if it augments their effects (chapter 4).  
iii. Investigate the effect of this combination on the alternative splicing of a panel 












2 Materials and methods 
 
2.1 Cell and tissue culture 
Human lymphoblastic cell line, TK6, chronic myeloid leukaemia cell (Phil+), K562 and 
acute myeloblastic leukaemic cell line, Kasumi-1 were used in this experiment which 
targets the effect of SRPK1 on these cell lines. Cells were purchased from the European 
Collection of Authenticated Cell Cultures (ECACC). All three cell lines are suspension cells 
and were cultured using RPMI-1640 culture medium with L-glutamine from (Sigma 
Aldrich, UK). Culture media was further supplemented with 10% foetal bovine serum 
(Sigma Aldrich, UK) for TK6 and K562 cell lines while Kasumi-1 cells were cultured in a 
20% foetal bovine serum enhanced media. Cells used were between passage six to 
nineteen. Sub-culturing of all three cell lines involves the collection of the cell 
suspension into a centrifuge tube and centrifuged at 106 x g for 5mins. Following 
centrifugation, the supernatant was aspirated and discarded, and cell pellets were re-
suspended in an appropriate volume of fresh media. Cells were seeded at densities of 
5x105 – 1.0x106 in a T25 flask and were sub-cultured every 48hours.  All cell lines used for 
this experiment were incubated at 5% CO2 at 37oC. 
 
2.2 Cell viability and growth count 
 
Cell count and viability were determined using basic trypan-blue stain.  Ten microlitre of 
cell suspension was diluted with an equal amount of 0.4% trypan-blue dye in a ratio of 
1:1. Using a haemocytometer counting chamber, an aliquot of the stained cell is viewed 
and counted under a microscope at x10 magnification. Cells which absorbed the dye and 
stain blue were considered non-viable/dead. Alternatively, the Luna FL automated cell 
counter (Logos Biosystems, France) was used and result compared to manually counted 














2.3 Chemical inhibition of splice factor kinases 
 
Either TK6, K562 or Kasumi-1 cell line was treated with SRPK1 specific small molecule 
inhibitors 5-methyl-N-[2-(morpholin-4-yl)-5-(tri-fluoromethyl)phenyl] furan-2-
carboxamide commonly known as SR Protein Inhibitor X (SPHINX) which was purchased 
from Enamine (Kiev, Ukraine). SRPK1 chemical inhibitors were dissolved in 100% sterile 
dimethyl sulfoxide (DMSO) (Sigma Aldrich, UK) soluble at 25mM. Using culture media, a 
serial dilution of 10nM, 100nM, 1µM, 10µM was prepared. The equivalent of the 
amount of DMSO (1%) in each dilution was used as positive control while negative 
control was represented by an untreated cell culture. The experimental setup involved 
seeding 1.0x106/ml of cells in a T25 culture flask for each treatment. The experimental 
setup was done in duplicate. Cells were incubated for the period of treatment up to 
72hrs. 
Similarly, K562 and Kasumi-1 cell were also treated with 1-(3-ethyl-5-methoxy-2, 3-
dihydrobenzothiazol-2-ylidene) propan-2-one, known as TG003, a competitive inhibitor 
for CLK1. The experimental setup was like those of SPHINX treatment although the 
concentration of TG003 up to 50µM was used to determine the inhibitory concentration. 
The subsequent experiment was performed using the highest concentration of 50µM. 
𝑐𝑒𝑙𝑙 𝑣𝑖𝑎𝑏𝑖𝑙𝑡𝑦 =
𝑙𝑖𝑣𝑒 𝑐𝑒𝑙𝑙
𝑙𝑖𝑣𝑒 + 𝑑𝑒𝑎𝑑 𝑐𝑒𝑙𝑙𝑠
 
𝐶𝑒𝑙𝑙 𝑐𝑜𝑢𝑛𝑡 (𝑁) =  𝑥 𝑦 × 𝑎 ×  𝑏 ×  𝑐 
where;  
x=Total live cell count; y= Number of grids counted (4); a= Dilution factor; b=Fixed 




              
 
 
2.4 Treatment with chemotherapeutic drugs 
 
Imatinib mesylate (Gleevec, formally; STI571) is an orally bioavailable mesylate salt of 
Imatinib which a multi-target inhibitor of Abl-Bcr+. The tyrosine kinase inhibitor, [N-(4-
methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl)-4-(4-methylpiperazin-1-
yl)methyl)benzamide methanesulfonic acid] was the drug of choice for K562 treatment. 
Whereas, 4-amino-1--D-ribofuranosyl-1,3,5-triazin-2(1H)-one; azacytidine, a DNA 
methyltransferase inhibitor was used to treat Kasumi-1 cells. Both drugs were sourced 
from Selleckchem. The initial dose of imatinib and azacytidine treatment was up to 
20µg/ml and 1.5µg/ml respectively. These were later maintained at 3-5µg/ml and 
750ng/ml respectively corresponding to the peak serum concentration when a standard 
clinical dose of 400mg and 75mg/ml/m2 is administered to a patient. 
 
Figure 2.1: Structure and chemical formulae for SRPK1 and CLK1 small 
molecule inhibitors.   
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2.5  Caspase-3 colorimetric assay 
 
To determine Caspase 3 activity in all leukaemic cell lines, caspase-3 colorimetric assay 
kit sourced from Abcam (ab39401) was used. The protocol used were those provided by 
the manufacturer. Cells were treated with kinase inhibitor or drug of choice for the 
treatment duration. At the end of the treatment period, cells were collected in a 
microcentrifuge tube, pelleted and lysed using the lysis buffer provided. Extracted 
proteins were quantified using the Bradford assay method. Aliquot of 1.5mg/ml of 
extracted protein was transferred into a 96-well plate in triplicates (x3). Appropriate 
volumes of a cocktail mixture containing 2x reaction buffer, dithiothreitol (DTT) and a 
labelled substrate, DEVD-p-nitroaniline (DEVD-p-NA) was added to each well. Plates 
were incubated at 37OC for one hour, protected from light.  Spectrophotometric 
detection of the chromophore p-nitroaniline after cleavage was read at 405nm 
corresponding to caspase-3 activity in the cells. Caspase-3 activity was determined by 




2.6.1 Examination of cell morphology using acridine orange fluorescence stain 
The compound 3, 6-Bis(dimethylamino) acridine hydrochloride zinc chloride double salt 
also known as acridine orange hemi (zinc chloride) salt; is a cell-permeable, nucleic acid 
selective dye that emits green fluorescence when bound to dsDNA and red fluorescence 
when bound to ssDNA or RNA (Sigma Aldrich). Since it is a cationic dye, it also enters 
Figure 2.2: Structure and chemical formula for imatinib mesylate and 
azacytidine.   
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acidic compartments such as lysosomes which in low pH conditions, will emit orange 
light. Twenty thousand of K562 cells were collected post-treatment into a 
microcentrifuge tube and spun at 106 x g for 10minutes. The supernatant was aspirated 
and discarded. The cell pellet was re-suspended in 150µL of sterile phosphate buffered 
saline (PBS) and transferred into a cytofunnel. The cytofunnel which has a microscope 
slide attached was spun at 20,000 x g for 8minutes in a Cytospin 4 (Thermo Scientific). 
Cells were then fixed using 90% methanol for 10mins and air dried.  
For staining, slides were dipped in fresh phosphate buffer (0.66% (w/v) potassium 
phosphate mono-basic + 0.32% (w/v) sodium phosphate dibasic, at pH 6.4-6.5) to 
rehydrate and stained in a solution of acridine orange (0.12 mg/ml in phosphate buffer; 
Sigma Aldrich, UK) for 45 seconds. Removal of excess stain was achieved by dipping 
slides in two changes of fresh buffer for 10 minutes and 15 minutes, respectively. Post-
staining, slides were air dried and stored away from light. Microscopic examination of 
slides using phosphate buffer as a mountant. Slides were analysed using the Nikon 
Eclipse 80i (upright) fluorescence microscope. Nuclei morphology was analysed using a 
BG-12 excitation filter and 0-530nm barrier filter under x40 magnification. Scoring was 
achieved by manually counting 2,000 cells per slide. 
2.6.2  Examination of cell morphology using caspase 3/7 fluorescence stain 
Cells pre-treated with a combination of kinase inhibitor and chemotherapeutic agent 
were stained with the ThermoFisher scientific CellEventTM Caspase 3/7 green detection 
reagent. The detection reagent was diluted (1:100) in PBS. Twenty thousand pelleted 
cells were suspended in 150µl of the reconstituted reagent and allowed to stand for 
45minutes at room temperature away from light. Counterstaining was done using the 
Hoechst at a 1:5000 in PBS for one minute after which cells were transferred into a 
cytofunnel (Fisher Scientific, UK) and spun onto a microscope slide using the cytospin 4 
(Thermo Scientific, UK) at 20,000 x g for 8minutes. Air drying of slides was in the dark. 
Slides were mounted using Mowiol aqueous mounting media (24g Glycerol, 9.6g 
Mowiol, 24ml Ultra dH20 and 48ml 0.2M Tris-HCl, pH 8.5). The Nikon Eclipse 80i 
fluorescent microscope was used for imaging. Nuclei morphology was analysed using a 
BG-12 and FITC excitation filter and 0-530nm barrier filter under X40 magnification. 
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The principle of action is such that the caspase 3/7 green detection reagent which is a 
four-amino acid peptide (DEVD) is activated in apoptotic cells following cleavage of the 
peptide (Thermofisher). This enables the dye to bind to DNA producing a bright green 
fluorescence emission of about 530nm. 
 
2.7 RT-PCR and Agarose gel electrophoresis 
 
2.7.1  RNA isolation and DNase treatment 
The Agilent absolute RNA miniprep kit (cat: 400800) and its protocol for total RNA 
isolation were adapted. Post treatment, cells were transferred into a microcentrifuge 
tube and centrifuged (Beckman Allegra x-22R, Rotor: F2402H) at 9,650g for 5minutes. 
Cell pellets were lysed using a reconstituted lysis buffer containing a 1:100 dilutions of 
β-mercaptoethanol and the lysis buffer. Homogenization of cells was achieved either by 
vortexing for a minute or passing solution through a 21guage needle. Up to 700µl of the 
cell homogenate was transferred to a pre-filter spin column placed in a receptacle and 
spun at 9,650g for 5min. The spin column was discarded while the filtrate retained. An 
equal amount of 70% ethanol was added to the filtrate and vortexed until mixed 
thoroughly. Up to 700µl of the filtrate was then transferred to an RNA binding spin 
column seated in a sterile receptacle and spun at maximum speed for a minute. The 
filtrate was discarded, and the spin cup which contains the bound RNA was retained. 
For DNase treatment, 600µl of 1x low-salt wash buffer was added into the RNA binding 
column and spun at maximum speed for 3mins. A constituted aliquot of DNase digestion 
buffer and reconstituted RNase buffer was added to the matrix of the spin column and 
incubated at 37oC for 15mins. This was followed by several washes with 1x high and low 
salt wash buffer. Purified RNA was eluted in 30µl of elution buffer into a micro-
centrifuge tube following a 2minute incubation at room temperature. The final product 
was stored in -20 or -80oC. The total RNA concentration was determined using a 
Nanodrop spectrophotometer (Thermo Fisher Scientific, USA). 1.5µl of each RNA sample 






2.7.2 Complimentary DNA (cDNA) synthesis 
Post RNA extraction, cDNA synthesis was performed using the ProtoScript first strand 
cDNA synthesis kit protocol described by New England Biolabs (NEB). Two micrograms 
(2µg) of RNA for each treatment category was collected in a 0.5ml sterile 
microcentrifuge tube. In each tube, a cocktail (2µl of a mixture of random primer and 
oligodT at a 1:1, 4µl of 2.5mM dNTP) was added and brought to a final volume of 16µl 
with nuclease-free water (Qiagen). This was followed by incubation at 70oC on a heat 
block for 5mins. The reaction product was spun down and held immediately on ice. 
While on ice, another cocktail (2µl of 10x M-MLV reverse transcriptase buffer, 1:1 mix 
of 2x reverse transcriptase and RNA inhibitor; NEB, UK) was added to the tube followed 
by incubation at 42oC for one hour. The transcriptase enzyme was deactivated at 90oC 
for 10 mins and the final product stored at -20oC.  
 
2.7.3 Standard PCR and Agarose gel electrophoresis 
 
Following cell treatment with chemical inhibitors, RT-PCR was carried out to measure 
the levels of SRPK1, and the alternative splicing of the gene of interest, which included 
Caspase 9, Bcl-x, APAF-1, CLK1 and VEGF. Beta-actin (β-actin) was also amplified and 
used to determine the quality of the cDNA as well as a loading control. Table 2.1 
describes all primer sequence used for standard PCR and the annealing temperatures 




2.7.4  Primer sequences and design 
 
 
Gene name Primer sequence/ length Alignment  Tm(0C) Amplicon length (bp) 
SRSF protein kinase 1 (SRPK1) 
NM_003137 
F: TTCCTCAACTGTAGGTCAGTCATTC (25) 
R: TGTTCTTGCTCTTGTTCATCTTCAC (25) 
F :1329 – 1353  
R :1430 – 1403  
49 102 
Beta – actin (β-actin) 
NM_001101 
F:  TTAAGGAGAAGCTGTGCTACG (21) 
R: GTTGAAGGTAGTTTCGTGGAT (21) 
F: 719 – 739  
R: 924 – 904  
52 206 
Vascular endothelial growth 
factor A (VEGF-A) 
NM_001025366 
F:  GTAAGCTTGTACAAGATCCGCAGACG (26) 
R: ATGGATCCGTATCAGTCTTTCCTGG (25) 
 
F: 1616 – 1641 
R: 1814 – 1790  
54 199 
Vascular endothelial growth 
factor A (VEGF-A165b)  
NM_001171629 
F:  GGCAGCTTGAGTTAAACGAACG (22) 
R: ATGGATCCGTATCAGTCTTTCCTGG (25) 
 
F: 1562 – 1583  
R: 1625 – 1601  
52 64 
Vascular endothelial growth 
factor A (VEGF-A165b)  
NM_001033756 
F:  GGCAGCTTGAGTTAAACGAAC (21) 
R: ATGGATCCGTATCAGTCTTTCCTGG (25) 
 
F: 1560 – 1580  
R: 1623 – 1599  
52 64 
BCL2 like 1 (BCL2L1) xl  F:  CATGCCAGCAGTGAAGCAAG (20) F: 627 – 646 53 351 
60 
 
NM_138578 R:  GCATTGTTCCCGTAGAGATCC (21) R: 977 – 957  
BCL2 like 1 (BCL2L1) xs  
NM_001191 
F:  CATGCCAGCAGTGAAGCAAG (20) 
R:  GCATTGTTCCCGTAGAGATCC (21) 
F: 857 – 876 
R: 1018 - 998 
53 162 
Apoptotic peptidase activating 
factor 1 (APAF1)  
NM_013229 
F:  CAGCTGATGGAACCTTAAAGC (21) 
R: GTCTGGTCATCAGAAGATGTC (21) 
F: 2829 – 2849 
R: 3258 – 3238  
48 430 
Apoptotic peptidase activating 
factor 1 (APAF1)  
NM_001160 
F:  CAGCTGATGGAACCTTAAAGC (21) 
R: GTCTGGTCATCAGAAGATGTC (21) 
F: 2829 – 2849 
R: 3129 – 3109 
48 301 
Caspase 9 Variant alpha (CASP9α) 
NM_001229 
F: GCTCTTCCTTTGTTCATCTCC (21) 
R:  CATCTGGCTCGGGGTTACTGC (21) 
F: 220 – 240 
R: 961 – 941  
50 742 
Caspase 9 Variant beta (CASP9β) 
NM_001278054 
F:  GCTCTTCCTTTGTTCATCTCC (21) 
R: CATCTGGCTCGGGGTTACTGC (21) 
 
F: 450 – 470  
R: 741 – 721  
50 292 
CDC like kinase 1 (CLK1), Exon 4 
retention 
NM_004071 
F: (1FB) CAAGGATGTGAACCTGGACATCGC (24)  
R: (3RB) CTCCTTCACCTAAAGTATCAAC (22)  
F: 339 – 362  
R: 606 – 585  
48 268 
CDC like kinase 1 (∆CLK1), Exon 4 
skipping 
F: (1FB) CAAGGATGTGAACCTGGACATCGC (24)  
R: (3RB) CTCCTTCACCTAAAGTATCAAC (22) 
F: 339 – 362  




                               
     




CDC like kinase 1 (∆CLK1x), intron 
4 retention 
NM_004071 
F: (2FB) GGAGGGTCACCTGATCTGTCAG (22) 
R: (3RA) CTGCTACATGTCTACCTCCCGC (22)  
F: 530 – 551  
R: 663 – 642  
57 516  
CDC like kinase 1 (CLK1x), intron 4 
skipping 
NM_004071 
F: (2FB) GGAGGGTCACCTGATCTGTCAG (22) 
R: (3RA) CTGCTACATGTCTACCTCCCGC (22)  
F: 530 – 551  
R: 663 – 642  
57  134 
          Table2.1: Forward (F) and reverse (R) primer sequences for all human genes amplified using standard PCR.  





First, a gradient PCR was performed to determine the optimum annealing temperature 
(Tm/0C) for each primer, and these are shown on Table 2.1. General cycling conditions 
for all primers are as follows; denaturation at 95°C for 30 seconds, elongation at 68°C 
for 1minute and final extension was at 68°C for 5minute. A total of 35 cycles at 95°C for 
15 seconds was performed. PCR amplicons were electrophoresed on a 2% agarose gel 
using 1x tris-acetate-EDTA (TAE) buffer at 95V for 45minutes. Gels were stained with 
0.01% of 10µg/ml ethidium bromide (Sigma Ltd, UK). A 100bp DNA ladder (NEB, UK) was 
loaded alongside the PCR products to determine amplicon size. 
Image acquisition from gels was performed using the LI-COR Odyssey FC imaging system 
(USA) at 600nm. 
2.7.5 Normalization of RT-PCR 
To ensure that the level of gene expression observed was due to experimental 
treatments, gels were analysed using LI-COR odyssey FC software (Image studio Lite 5.2) 
that measured RT-PCR band densities. Obtained values were normalized to β-actin for 
the same treatment. Final values were exported to GraphPad statistical software 
(version 7). Corresponding graphs were generated for each RNA and their splice 
variants. Splice variants were plotted as the percentage of splice inclusion (PSI-Ѱ). Data 
were presented as mean ± 95% confidence interval (CI).  
 
2.8  SDS-PAGE and immunoblotting 
 
2.8.1 Protein extraction and quantification 
Proteins were extracted from cells using the radioimmunoprecipitation assay (RIPA) lysis 
buffer (10 mM Tris-Cl (pH 8.0), 1mM EDTA, 1% Triton X-100, 0.1% sodium deoxycholate, 
0.1% SDS, 140mM NaCl). Post-treatment harvested cells were suspended in ice-cold lysis 
buffer (0.1mL per 1 x 106 cells) supplemented with protease inhibitor (1:1000) (Roche 
Diagnostics, UK) for 30minutes. This was followed by centrifugation at 3000 x g at 4oC 
for 10minutes.  Supernatant which contained proteins were aspirated into a clean sterile 
microcentrifuge tube and held on ice for quantification. 
 
Protein samples were diluted in a 1:1 ratio with nuclease free water for quantification. 




bovine serum albumin (BSA) was prepared in the following concentrations: 2 mg/ml, 1 
mg/ml, 0.5 mg/ml, 0.25 mg/ml and 0.125 mg/ml. The working solution was prepared 
using the Pierce BCA suggested dilution of 50:1 (BCA reagent A: BCA reagent B). An 
aliquot of 200µl of the working solution was added to each well of a 96well plate 
containing the sample to be quantified. The plate was incubated in the dark for 
30minutes. All samples including controls were prepared in duplicates and read at 
560nm on a plate reader (Fluostar Optima, BMG lab tech, Germany). Absorbance values 
were exported into an excel sheet (Microsoft) where a standard curve was generated, 
and protein concentration determined using the graph equation generated. Final 
protein concentration was brought to 20µg/µl using sterile water and were mixed with 
2x Laemmli buffer (Sigma, UK) in 1:1 dilution. The mixture was then boiled at 100oC for 
5minutes before being held on ice for loading into gels. 
2.8.2 Acrylamide gel 
Proteins were separated on a 10% acrylamide gel. Each gel contains 30% (v/v) 
acrylamide mix (29:1; acrylamide: bis-acrylamide) (Sigma Aldrich), 1.5M resolving buffer 
(18.17g tris and 100ml diH2O; pH 8.8), distilled water, 10% (w/v) ammonium persulphate 
(AP) (Sigma Aldrich) and tetramethylethylenediamine (TEMED) (Sigma Aldrich). This 
cocktail was carefully loaded on to the pre-assembled casting trays using a pasture 
pipette and allowed to set for 15-20mins. A 5% acrylamide stacking gel was then added 
to overlay the separating gel and a 10-well comb was inserted and allowed to set. 
2.8.3 SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
Gel electrophoresis was performed using the Electrophoresis cell apparatus for mini gels 
(Bio-Rad, UK).  The units were assembled, and the middle chamber filled with running 
buffer (25mM Tris, 190mM glycine and 0.1% (w/v) SDS adjusted to pH 8.3). The comb 
was removed and 700µg of the protein samples were carefully loaded in each well. A 
pre-stained protein marker (NEB, UK) was also loaded to determine protein size. The 
outer chamber of the unit was also filled with the running buffer depending on the 
number of gels following the manufacturers’ recommendation. The gels were run at 





2.8.4 Transfer of proteins on to membranes 
For protein transfer onto a membrane, gels were prised from the casting trays and the 
stacking gel removed. The separating gel, which contains the protein samples was 
assembled in a sandwich of sponges, filter papers, gel and polyvinylidene difluoride 
(PVDF) membrane on a cassette in the following order (Figure 2.4). 
 
     
 
 
Gels were transferred on to a polyvinylidene difluoride (PVDF) membrane (Thermo 
Scientific). The membrane was activated in absolute methanol for 20secs, thereafter, 
held in 1 x cold (4oC) tris/glycine/methanol transfer buffer (25mM Tris, 190mM glycine 
and 20% methanol). Following assembly of the components on the cassette, the cassette 
was placed in the transfer tank containing cold transfer buffer. A magnetic stirrer and 
an ice pack were placed in the tank to maintain the cold temperature. Transfers were 
done in 4 hours. 
2.8.5 Immunoblotting 
Post-transfer, membranes were blocked in a 5% non-fat dry milk and 1xTBST solution 
for a minimum of 1 hour. This is to prevent unspecific binding of the antibody to 
membranes. Thereafter, the membrane was incubated at 4oC overnight in the primary 
antibody of choice (Table 2.2). 
 
Figure 2.4: Diagram illustrating sandwich assembly for transfer of proteins 














Membranes were washed (3x) in appropriate volume of 1x tris-buffered saline with 
Tween-20 (TBST) (20mM Tris pH 7.5, 150mM NaCl, 0.1% Tween20). Each wash lasting 
5mins each. This was followed by incubation with a horseradish peroxidase (HRP) linked 
secondary antibody (Cell signalling) at room temperature for 1 hour. Unbound 
secondary antibodies were removed by repeated washes (3x) in 1 x TBST, each wash 
lasting about 5mins. About 500µl of HRP-substrate (Millipore, UK) was dispensed on to 
the membrane for 2mins prior to image acquisition. Image acquisition from membranes 
was performed using the LI-COR Odyssey FC imaging system (USA) at chemi function for 
2mins. 
 
2.9 SRPK1 siRNA knockdown 
 
2.9.1 Cell culture and preparation 
All cell lines, TK6, K562 and Kasumi-1 cells were cultured in a T25 cell culture flask 
respectively for cells to be 80% confluence.  Cells were then harvested and spun down 
to discard the growth media. For each cell line, 5x105 cells were collected and washed 
in 1 x PBS followed by centrifugation at 106 x g for 5minutes. The supernatant was 
aspirated and discarded. Each cell line was re-suspended in 800µl of OptiMEM media 
(Gibco, UK) and transferred into a 6-well plate and incubated at 5% CO2 at 37oC. 
Antibody/ 
Specie 































200µg/ml 1:2000 BD 
Biosciences 
 
Table 2.2: Antibodies used for western blotting. Sources and working 




2.9.2 siRNA Transfection 
A cocktail of Lipofectamine RNAiMAX (7.5µl) (Thermo Fischer Scientific, UK) and 
OptiMEM media (100µl) was prepared. One hundred microlitre of 
Lipofectamine/OptiMEM cocktail was added to the SRPK1 siRNA (Eurofins, Genomics, 
UK) which was reconstituted in OptiMEM media to a final concentration and volume of 
100nM and 100µl, respectively. The entire mixture was incubated at room temperature 
(RT) for 20 minutes. Two hundred microlitre of siRNA/Lipofectamine/OptiMEM was 
added to each well and then left to incubate for 4 hours. Thereafter, each well was 
topped up with 1ml of appropriate tissue culture media and allowed to further incubate 
at 370C for 48hrs from the time of transfection. 
A similar protocol was applied to controls using a scrambled sequence of siRNA, which 
had previously been described by Karakama et al., (2010) and listed in Table 2.3. 
 
 
siRNA Targeted                            Sequence    Source 
SRPK1 5’-UUAAUGACUUCAAUCACUCCAUUGC-3’  





       
2.10  Statistical Analysis 
 
All statistical analysis was performed using GraphPad Prism version 7.0. Error bars 
represent mean ± 95% confidence interval (CI). Number of experimental repeats equals 
three (n=3). Except where stated, one-way ANOVA was used for analysis. The Tukeys 
and Dunnett’s test was employed for posthoc test within a treatment group where data 
assumes Gaussian distribution. Where distribution was not normal, Kruskal’s Wallis test 
was used to test for the difference between two groups and the Student t-test for pair-
wise comparison. Normality test was performed using the D’Agostino-Pearsons 
normality test which also computes the Skewness and Kurtosis, examining the symmetry 
Table 2.3: siRNA sequences used for knockdown and target.  





of the data relative to normal distribution. The confidence level was taken at 95%CI and 



























The serine/arginine-rich protein kinase-1 (SRPK1) like other protein kinases interacts 
with other proteins in order to transmit cell signalling.  SRPK1 phosphorylates the SR-
protein family of splice factors; its most studied substrate is SRSF1 (Plocinik et al., 2011; 
Gonçalves et al., 2014). Phosphorylation of the SR-protein by SRPK1 plays an important 
role in the regulation of pre-mRNA splicing, translation and non-sense mediated RNA 
decay (Graveley et al., 1998; Plocinik et al., 2011;). Studies suggest that knockdown of 
SRPK1 or inhibition of its catalytic activities results in reduced phosphorylation of SRSF1 
and other SR-protein, hence a shift in pre-mRNA splicing and changes in cell behaviour 
(Nowak et al., 2010; Goncalves et al., 2014; Mavrou and Oltean, 2016). SRPK1 
interaction with SRSF1 has been shown to affect the alternative splicing of caspase 9 
(Shultz et al., 2011) and vascular endothelial growth factor (VEGF-A), the latter 
controlling the ratio of pro and anti-angiogenic isoforms in a renal epithelial cell, colon 
and prostate cancer cells (Amin et al., 2011; Oltean et al., 2012; Mavrou et al., 2014). A 
previous study has also shown that SRPK1 interacts with activated protein kinase-B 
(Akt/PKB) through PHLPP, an Akt phosphatase and PI3 (Zhou et al., 2012). These 
pathways are upstream of several oncogenic signalling such as the mTOR and are known 
to regulate cell growth, upregulated proliferation, survival, differentiation, and protein 
synthesis. The PI3/Akt pathway through the mTOR-EGF signalling is known to affect pre-
mRNA splicing by modulating the interaction between SRPK1 and Hsp70 and Hsp40 
chaperone proteins (Zhou et al., 2012). 
Interestingly, over-expression and dysregulation of SRPKs have been shown to promote 
cell proliferation in several cancers including leukaemia. In particular, overexpression of 
SRPK1 was found in acute lymphoblastic leukaemia (ALL) and chronic myeloid leukaemia 
(CML) (Siqueira et al., 2015). Inhibition of SRPK1 using SRPIN340 resulted in reduced cell 
viability (Siqueira et al., 2015).  Additional research is needed to understand in greater 




The aim of this chapter is, therefore, to establish whether SRPK1 inhibition using SPHINX, 
a specific and more potent inhibitor (compared to an older analogue SRPIN340) of SRPK1 
causes changes in cell growth and viability as well as on the alternative splicing of a panel 
of cancer-associated genes. 
 
3.2  Results 
 
3.2.1 Validation of SPHINX and effect of SRPK1 inhibition with SPHINX on TK6 cell 
viability and growth 
 
First, the potency of SPHINX was determined by treating PC3 cell line with 10μM SPHINX 
for 48hrs. Similar experiment has been performed by Mavrou and colleagues (2014) 
suggesting that SRPK1 inhibition reduces tumour growth in vivo in orthotopic prostate 
cancer (PCa) mouse model. Result obtained from this experiment also showed that 
SRPK1 inhibition in PCa cells, PC3, reduces PC3 cell viability and growth in vitro (Figure 
3.1A-B). It was observed that SRPK1 protein levels were significantly reduced as well as 
















Figure 3.1.  Effect of SRPK1 inhibition with SPHINX on PC3 cell viability and growth. 
PC3 cells treated with 10μM of SPHINX for 48hrs. A. Percentage cell viability in PC3 
cells compared SPHINX treatment to DMSO (**P=0.0096). B. Cell number 
significantly decreased in PC3 cell (****P≤0.0001) when SPHINX was compared to 












To investigate the effect of SRPK1 on the growth and viability of TK6 cells, 2 x 106 of the 
cells were seeded and treated with up to 10μM of SPHINX for up to 72hrs. Cells were 
counted at 24hr interval using trypan blue and an automated cell counting chamber and 
result compared to the DMSO control treatment. 
Results showed a slight reduction in cell viability between the DMSO control and the 
SPHINX treatment at higher concentrations (1μM and 10μM). This was not found to be 
significant (P≥0.05). However, when the cell viability was compared between time 
points, there was a significant (P=0.041) apparent increases in cell viability between 
48hrs and 72hrs (Figure 3.3A). 
A B 
Figure 3.2.  Levels of SRPK1 and phospho SR-proteins in PC3 cells.  A. Immunoblot showing 
levels of SRPK1 in PC3 cells. B. Reduced phosphorylation of SR proteins when SPHINX 











Since no significant decrease in TK6 cell viability was observed, cell growth following 
SPHINX treatment was then examined. TK6 cells continued to grow with cell numbers 
doubling (up to 4 x 106) by 72hrs. There was also no difference when the treated group 
was compared to the DMSO control, proliferation rate significantly increased (P< 
0.0001) with time (Figure 3.3B). This suggests that SPHINX had no effect of TK6 cell 
growth and viability. 
A 
B 
Figure 3.3.  Effect of SRPK1 inhibition with SPHINX on TK6 cell viability and growth.TK6 
cells were treated with increasing concentrations (10nM, 100nM, 1μM and 10μM) of SPHINX 
for up to 72hrs. A. Percentage cell viability was significant (P ≤ 0.041) between 48hrs and 
72hrs. Treatments were compared to DMSO for each time point (n = 3). B. TK6 cells showed 





3.2.2 Effect of SRPK1 inhibition with SPHINX on K562 cell viability and growth 
Different leukaemic cell lines will respond differently to treatment depending on their 
type and the inherent mutations they have acquired (Siqueira et al.,2015). Chronic 
myeloid leukaemia cell line, K562 cells was also investigated for the effect on viability 
and growth following SPHINX treatment with concentrations up to 10µM for 72hrs. Like 
TK6 cells, K562 cells were also counted every 24hrs to investigate changes in cell growth 
and viability. There was no significant percentage decrease in cell viability when the 
SPHINX treated cells were compared to the DMSO cells for each concentration (Figure 
3.4A). Further analysis factoring in time showed an apparent percentage increase on cell 
viability between time points such that viability between 24hrs vs 48hrs and 24hrs vs 
72hrs significantly increased (P ≤ 0.05).  
Investigations into SPHINX effect on K562 cell growth also suggested there was no effect 
as K562 cell continued to grow and proliferate even at higher concentration of SPHINX 
(Figure 3.4B). K562 cell growth significantly increased with time suggesting that SPHINX 




























3.2.3 Effect of SRPK1 inhibition with SPHINX on Kasumi-1 cell viability and growth 
The effect of SRPK1 inhibition using SPHINX on Kasumi-1 (AML) cells was also 
investigated to see whether or not AML cells will react differently from the CML (K562) 
and lymphoblast (TK6) cell.  Results showed significant percentage decrease in cell 
viability with Kasumi-1 cells at higher concentrations of 1µM and 10µM of SPHINX 
inhibition when compared to DMSO control (Figure 3.5A). Decrease in cell viability at 
1μM was observed at 48hrs and 72hrs. At 10μM, Kasumi-1 cell viability continued to 
decrease with time. This suggests that Kasumi-1 cell viability may be affected by SRPK1 
inhibition at higher concentrations. 
Cell number in Kasumi-1 cells was also reduced at higher concentrations of 1μM and 
10μM but only at 72hrs was this effect significant (Figure 3.5B). Having observed an 
apparent decrease in both cell viability and growth in Kasumi-1 cells suggests that 
Kasumi-1 cells are more sensitive to SRPK1 inhibition. 
 
B 
Figure 3.4. Effect of SRPK1 inhibition with SPHINX on K562 cell viability and growth. 
K562 cells were treated with increasing concentration (10nM, 100nM, 1μM and 10μM) 
of SPHINX for up to 72hrs. A. Represent percentage in cell viability. Significant 
differences and percentage reduction in cell viability are observed between 24 and 48hrs 
(P ≤ 0.05) and 24hrs and 72hrs (P ≤ 0.01). Treated cells were compared to DMSO for each 
time point. B. K562 cells showed significant increases in cell number (**=P ≤ 0.01 and 

















Figure 3.5.  Effect of SRPK1 inhibition with SPHINX on Kasumi-1 cell viability and growth. 
Kasumi-1 cells were treated with increasing concentrations (10nM, 100nM, 1μM and 10μM) 
of SPHINX for up to 72hrs. Analysis compared DMSO treated cells with SPHINX treatment at 
each time point. A. A significant decrease in cell viability was observed at higher 
concentrations (1μM; **P=0.006 and ***P=0.0002 respectively) and (10μM; *P=0.013; 
***P<0.0001; 0.0001 respectively). B. Only at higher concentrations at 72hrs, was a reduced 





3.2.4 Effect of SRPK1 inhibition on caspase 3/7 activity in leukaemic cells 
 
3.2.4.1 Effect of SRPK1 inhibition on caspase activity in TK6 cells 
 
To further confirm that inhibition of SRPK1 does not affect TK6 cell viability and growth, 
the activities and expression of cleaved caspase 3 were studied. Caspase 3 is known as 
the apoptosis executioner and its activation is a product of both the intrinsic and 
extrinsic pathway (Brentnall et al., 2013). Hence, the choice of its investigation. TK6 cells 
were treated with increasing concentrations of SPHINX for 72hrs. Post-treatment, cells 
were harvested separately and processed following the methods, which have already 
been described in chapter 2.5. TK6 cells showed no significant difference in caspase 3 

























         
 
     












Figure 3.6. Measurement of caspase 3/7 activity in TK6 cells. (A) Cells were treated with increasing concentrations of SPHINX for 72hrs. (B) 
Percentages of apoptotic cells in TK6 cells. (C) Examination of TK6 cell morphology for caspase 3/7 activity. I. Micrograph represents Hoechst stain 
of the total cell at excitation between 420-495nm band width bypass. Arrows (green) represents necrotic cells marked by swelling of the cell and 





Lymphoblastic TK6 cells were stained with cleaved caspase 3/7 fluorescent dye and 
viewed under the microscope equipped with a fluorescent lamp. Since cells were in 
suspension culture, it was difficult to accurately view the same field. Therefore, cells 
were spun on to a microscope slide post staining with cleaved caspase 3/7 and 
counterstained using Hoechst fluorescent dye.  Micrograph of the Hoechst dye (Figure 
3.6 CI) represents the total cell found in a single field viewed per slide. Whereas Figure 
3.6CII represent the total number of cells positive for caspase 3/7 in the corresponding 
field as the Hoechst. The percentage number of cells positive for caspase 3/7 relative to 
the total number of corresponding cells was calculated in TK6 cells and result found no 
apparent increase in caspase 3/7 positive cells with increasing concentration of SPHINX 
and when compared to the DMSO control (Figure 3.6B). This is further evidence that 
SPHINX has no effect on TK6 cell viability. 
 
3.2.4.2 Effect of SRPK1 inhibition on caspase activity in K562 cells 
 
The CML cell line, K562 also did not display a change in cell viability measured via cell 
count using trypan blue. It was further investigated if the result is consistent by 
measuring the level of apoptotic activities in K562 cells treated with SPHINX. 
Spectrophotometric detection of the chromophore p-nitroaniline, which corresponds to 
the level of caspase 3 activity within the cell was found to be increased at the highest 
concentration of 10μM/ml, but this was not found to be statistically significant. 
Examination of the cleaved caspase 3/7 fluorescent dyes (Figure 3.7C) showed the 
general cell morphology (I) and the caspase 3/7 positive cells (II). When the positive cells 
were counted, and percentages taken in relation to the total cell number per field view, 
there appeared to be an increase in the percentage of positive cells as SPHINX 
concentrations increased. This was also found not be significant when compared to the 








                
 














Figure 3.7. Measurement of caspase 3/7 activity in K562 cells. (A) Cells were treated with increasing concentration of SPHINX for 72hrs. (B) Percentages 
of apoptotic cells in K562 cells. (C) Examination of K562 cell morphology for caspase 3/7 activity. I. Micrograph represents Hoechst stained. Arrows (green) 





3.2.4.3   Effect of SRPK1 inhibition on caspase activity in Kasumi-1 cells 
Kasumi-1 cells appeared to be more sensitive to SPHINX treatment and showed a 
decrease in cell viability and proliferation which was found to be significant at higher 
concentrations.  To further investigate whether the decrease in Kasumi-1 cell viability is 
due to cells death via apoptosis, the level of caspase 3 activity was measured (Figure 
3.8). A significant percentage increase in caspase 3 activity was observed. The level of 
activity was found to increase progressively with SPHINX concentration (Figure 3.8A). 
 
                  
 











Figure 3.8.  Measurement of caspase 3/7 activity in Kasumi-1 cells. (A) Cells were treated with increasing concentration of SPHINX for 72hrs. A significant 
difference in caspase 3 activity was found at concentrations of 10nm to 10µM (*P= 0.044; 0.038; 0.024; 0.025 compared to DMSO. (B) Percentages of 
apoptotic cells. Significant increase in caspase 3/7 positive cells were observed at higher concentrations of 100nM and 10µM (*P= 0.01; **P= 0.009; **P= 
0.006) when SPHINX treated group were compared to the DMSO control. (C) Examination of Kasumi-1 cell morphology for caspase 3/7 activity. Cells 
treated with varying concentrations of SPHINX for 72hrs were stained cleaved caspase 3/7 fluorescent dye. I. Micrograph represents Hoechst stained. 
Arrows (green) represents necrotic cells and (orange) apoptotic cells.  II. Corresponding image viewed at a green (FITC) band width. Arrows indicate 




The level of caspase 3 activity was further confirmed using fluorescent dye which was 
able to pick up cleaved caspase 3/7. Micrograph (Figure 3.8CI) of Kasumi-1 cells treated 
with increasing concentrations of SPHINX for 72hrs presented with cells with abnormal 
morphology, which appear to be distorted and hyper-fluorescent; an indication of 
chromatin fragmentation. Concentrations of 100nM- 10µM also showed fragments of 
particles, which are probably a product of the broken-down cells.  When the percentage 
of caspase 3/7 positive cells were analysed in relation to the total number of cells per 
field view, the number of positive cells increased with concentration (Figure 3.8CII) 
when compared to the DMSO control. This result further suggests that the inhibition of 
SRPK1 in the AML cell, Kasumi-1, results in cell death by apoptosis and indicated that 
SRPK1 could be playing a crucial role in Kasumi-1 cell growth and viability and hence the 
propagation of the disease.  
 
3.3 Effect of SPHINX on levels of SRPK1, VEGF and alternative splicing of 
a panel of apoptotic genes in TK6 cells  
 
Studies have shown that nearly 95% of all human genes are alternatively spliced, and 
the process is disrupted in cancer cells (Wang et al., 2008). Aberrant splicing in most 
cancers is known to be responsible for cancer of progressive phenotype seen in prostate 
cancer, basal-like and triple negative breast cancer, which further determine the 
response of these cancer cells to treatment (Mavrou et al., 2014; van Roosmalen et al., 
2015). Inhibition of SRPK1 has been shown to result in splicing in favour of the anti-
angiogenic phenotype of VEGF165b in cancer cells, podocytes and vascular disease 
(Amin et al., 2011; Oltean et al., 2012; Mavrou et al., 2014). It has also been shown that 
SRPK1 through SRSF1 is able to alter splicing of caspase 9 favouring pro-apoptotic (9a) 
isoform (Shultz et al., 2011). Therefore, the effect of SRPK1 inhibition on splicing in 
leukaemic cells was investigated since inhibition was seen to affect cell viability and 









3.3.1  Effect of SPHINX on SRPK1 expression  
 
TK6 cells were treated with increasing concentrations of SPHINX for up to 48hrs and 
total RNA extracted. Complementary DNA (cDNA) was synthesised using the reverse 
transcription method and amplified by PCR using appropriate primers. Conditions for 
amplification are described in the method section (chapter 2.7.4). 
To examine a potential auto-regulatory effect, levels of SRPK1 expression was 
measured. There was no significant change in SRPK1 levels when treatment was 
compared to control (Figure 3.9 A-C). 
                        
                           




Figure 3.9. SRPK1 levels in SPHINX treated TK6 cells. Cells were treated with increasing 
concentration of SPHINX for 48hrs. PCR was performed using SRPK1 specific primers. (A) 
TK6 β-actin controls for 24hrs and 48hrs. Representative PCR result for 24hrs and 48hrs 







3.3.2 Effect of SPHINX on VEGF alternative splicing 
Previous work has shown that inhibition or knockdown of SRPK1 in cancer cells resulted 
in a change in VEGF splicing to a more anti-angiogenic isoform, VEGF165b. We 
investigated if the inhibition of SRPK1 in TK6 cells resulted in a switch in splicing. No 
switch in VEGF splicing was observed (Figure 3.10B-C).  
        
 
             
 








Figure 3.10. Alternative splicing of VEGF in SPHINX treated TK6 cells. Cells were treated 
with increasing concentrations of SPHINX for 48hrs. PCR was performed using VEGF 
specific primers. B. Representation of PCR amplicon sizes for 24hrs and 48hrs.  C. 
Densitometry for VEGF amplicon normalized to β-actin. DMSO was compared to each 





3.3.3  Effect of SPHINX on Bclx alternative splicing 
To confirm that inhibition of SRPK1 in TK6 cells with increasing concentration of SPHINX 
does not result in increased apoptosis, hence reduced cell viability, as previously 
observed, changes in Bclx splicing was investigated. No change in splicing of Bclx was 
observed. There was a higher level of anti-apoptotic Bcl-xl to pro-apoptotic phenotype 
Bcl-xs and this was not altered by SPHINX (Figure 3.11B-C). 
                   
               
                            






Figure 3.11.  Alternative splicing of BCLx in SPHINX treated TK6 cells. Cells were 
treated with increasing concentrations of SPHINX for 48hrs. PCR was performed using 
Bclx specific primers. B. Representation of PCR amplicon sizes for 24hrs and 48hrs. C. 
PCR image quantification showing percentage of splice inclusion (PSI-Ψ) in Bcl-xl/xs 







3.3.4  Effect of SPHINX on Apaf-1 alternative splicing 
Splice ratio of Apaf-1xl/1s showed no significant difference when treated cells were 
compared to the controls. Level of pro-apoptotic Apaf-1xl appears to be consistent 
between treated group and control (Figure 3.12B-C) 
                     
 






Figure 3.12.  Alternative splicing of Apaf1 in SPHINX treated TK6 cells. Cells were treated 
with increasing concentrations of SPHINX for 48hrs. PCR was performed using Apaf1 specific 
primers. Representation of PCR amplicon sizes for 24hrs and 48hrs (B). C. Densitometry 







3.3.5  Effect of SPHINX on caspase 9 alternative splicing 
When caspase 9 was investigated for a switch in splicing in TK6 cells following SRPK1 
inhibition with SPHINX, there was also no change in splicing observed. There was an 
apparent increase in caspase 9a pro-apoptotic isoform at higher concentrations 
(100nM-10µM) at 48hrs. This was not found to be statistically significant when 
compared to the DMSO control (Figure 3.13B-C). 
                     
            




Figure 3.13.  Alternative splicing of caspase 9 in SPHINX treated TK6 cells. Cells were treated 
with increasing concentrations of SPHINX for 48hrs. PCR was performed using caspase 9 
specific primers. (B) PCR amplicon sizes for caspase 9 at 24hrs and 48hrs C. Densitometry 
showing caspase 9a/b PSI-Ψ values for 24hrs and 48hrs. DMSO vs treatment at 48hrs 100nM-







3.4 Effect of SPHINX on protein levels of SRPK1, SRSF1 and on the 
phosphorylation of SR protein in TK6 cells. 
 
3.4.1  Effect of SPHINX on SRPK1 protein levels  
There was no change in SRPK1 levels when compared to DMSO control or between 24hrs 
and 48hrs (Figure 3.14) in TK6 cells. 
     


















Figure 3.14 SRPK1 protein levels in SPHINX treated TK6 cells. Western blot images for 
SRPK1 in TK6 cells treated with SPHINX for up to 48hrs with corresponding β-actin. No 




3.4.2  Effect of SPHINX on SRSF1 protein levels 
SRSF1 is phosphorylated by SRPK1, however, it is also conceivable that the effect of 
inhibition of SRPK1 may (indirectly) alter total SRSF1 protein levels. To investigate this, 
an immunoblot for total SRSF1 was performed. At 48hrs, there seemed to be an 
apparent reduction in total SRSF1 protein level at the 1µM and 10µM concentrations 
which was found to be statistically significant when SPHINX treatment was compared to 
DMSO (Figure 3.15A-B). 
 






Figure 3.15 SRSF1 protein levels in SPHINX treated TK6 cells. A. Western blot images for 
SRSF1 in TK6 cells treated with SPHINX for up to 48hrs. B. Densitometry of SRSF1 protein 
level normalized to β-actin. Significant reduction in SRSF1 levels was found at higher 






3.4.3  Effect of SPHINX on SR protein phosphorylation 
Since previous studies have shown that SRPK1 inhibition results in reduced 
phosphorylation of SR-proteins including SRSF1, phosphorylation of SR-proteins was 
examined in leukaemic cells. An immunoblot was performed using the phospho-
antibody which pick up phospho-epitopes of SR-proteins. Levels of the SR-protein were 
not found to be significantly different in TK6 cells (Figure 3.16).              
                   














Figure 3.16 Protein levels of phospho-SR proteins in SPHINX treated TK6 cells. 





3.5 Effect of SPHINX on mRNA levels of SRPK1, VEGF and alternative 
splicing of a panel of apoptotic genes in K562 cells  
 
3.5.1 Effect of SPHINX on SRPK1 expression 
The effect of SPHINX on SRPK1 mRNA levels in K562 cells was observed following 
treatment. There were indications of significant changes in SRPK1 expression at higher 
concentrations of SPHINX at 48hrs compared to time-matched DMSO controls (Figure 
3.17B-C). 
 
                                                                                                








Figure 3.17. SRPK1 levels in SPHINX treated K562 cells. Cells were treated with increasing 
concentrations of SPHINX for up to 48hrs. PCR was performed using SRPK1 specific 
primers. (A) β-actin loading controls at 24hrs and 48hrs. (B) Amplicons of SRPK1 at for 
24hrs and 48hrs C. Densitometry analysis of SRPK1 expression showing significant 




3.5.2  Effect of SPHINX on VEGF alternative splicing 
The Inhibition of SRPK1 had no effect on total levels of VEGF expression (Figures 3.18A-
B). 
             















Figure 3.18. Alternative splicing of VEGF in SPHINX treated K562 cells. Cells were 
treated with increasing concentration of SPHINX for up to 48hrs. PCR was performed 
using VEGF specific primers. A. Representation of VEGF PCR amplicon sizes for 24hrs 
and 48hrs showing band intensity and size. B. Densitometry for VEGF amplicon 





3.5.3  Effect of SPHINX on Bclx alternative splicing 
Result showed two distinct Bclx isoforms (xl and xs) with no switch in splicing to its anti-
apoptotic, Bcl-xl or pro-apoptotic, Bcl-xs (Figure 3.19B). 
 
 
                           
     
 














Figure 3.19. Alternative splicing of Bclx in SPHINX treated K562 cells. K562 cells were 
treated with increasing concentrations of SPHINX for up to 48hrs. B. Bclx PCR amplicon 




3.5.4  Effect of SPHINX on Apaf-1 alternative splicing 
There was a significant change in Apaf1 alternative splicing following SRPK1 inhibition in 
K562 cells at 24hrs when SPHINX treatment was compared to DMSO. No change in 
splicing was observed at both time points (Figure 3.20 B). 
 
                     
 


















Figure 3.20. Alternative splicing of Apaf1 in SPHINX treated K562 cells. K562 cells 
were treated with increasing concentrations of SPHINX for up to 48hrs. B. Apaf1 PCR 




3.5.5 Effect of SPHINX on caspase 9 alternative splicing 
Two distinct caspase 9 isoforms (9a/b) are expressed in K562 cells. Following inhibition 
of SRPK1 in K562 cells, there was no switch in splicing. Levels of caspase 9a were 
significantly reduced in SPHINX treated group when compared to DMSO control (Figure 
3.21C). 
                         
    







Figure 3.21. Alternative splicing of caspase 9 in SPHINX treated K562 cells. K562 cells 
treated with increasing concentrations of SPHINX for up to 48hrs. B. Representation of 
caspase 9 PCR amplicon sizes for 24hrs and 48hrs showing band intensity and sizes C. 
Percentage splice inclusion (PSI-Ψ) for caspase 9a/9b. SPHINX treatment compared to 







3.6 Effect of SPHINX on protein levels of SRPK1, SRSF1 and on the 
phosphorylation of SR-protein in K562 cells. 
 
3.6.1 Effect of SPHINX on SRPK1 protein levels 
To investigate the effect of SRPK1 inhibition on SRPK1 protein levels and SR-protein 
phosphorylation, immunoblotting was performed. Protein levels of SRPK1 were found 
to be increased at concentrations of 10µM at 24hrs and 48hrs when compared to DMSO 
control (Figures 3.22A-C). 
         








Figure 3.22 Protein levels of SRPK1 in SPHINX treated K562 cells. Densitometry for SRPK1 
protein level normalized against β-actin. A. Result showing increased SRPK1 protein levels 
following higher concentrations of SPHINX for 24hrs and 48hrs (***P= 0.0008 and 
****P<0.0001 respectively). B. and C. showing western blot images for SRPK1 with 







3.6.2 Effect of SPHINX on SRSF1 protein levels 
Protein levels of SRSF1 appeared to increase at higher concentrations of SPHINX 
inhibition at 24hrs but not at 48hrs. These differences were not found to be significant 
(Figures 3.23A-C). 
       
 









Figure 3.23 Protein levels of SRSF1 in SPHINX treated K562 cells. A. Densitometry for 
total SRSF1 protein level normalized to β-actin. B. and C. Western blot images for 







3.6.3 Effect of SPHINX on SR protein phosphorylation 
An investigation into the effect of SPHINX on levels of SR-protein phosphorylation was 
also investigated in K562 cells. Interestingly, unlike the TK6 cells, levels of SRSF6 in K562 
cell were nearly undetected both in the treatment group and controls (Figure 3.24). This 
might be an indication of the different abundance of each splice factor in different cell 
lines. Levels of phospho SRSF4 and SRSF5 were found to be reduced at higher 
concentrations at 48hrs with no change in phosphorylation observed in SRSF11 (Figure 
3.24). 










Figure 3.24 Protein levels of phospho-SR proteins in SPHINX treated K562 cells. 
Densitometry of phospho-SR protein level normalized with β-actin. pSRSF4 and pSRSF5 




3.7 Effect of SPHINX on the level of SRPK1, VEGF RNA and alternative 
splicing of a panel of apoptotic genes in Kasumi-1 cells  
 
3.7.1 Effect of SPHINX on SRPK1 expression 
  
Results by Siqueira et al., (2015) indicates that each cell line responds differently to 
SRPK1 inhibition despite having a common origin from the white blood cell. This may be 
related to the unique mutations that each cell line has acquired, how quickly cells are 
able to get rid of factors, which are considered alien to the cells, and the functional 
importance of SRPK1 in the cell. In Kasumi-1 cells, SRPK1 levels appear to decrease with 
increasing concentration of SPHINX (Figure 3.25B-C).  
 
 






























Figure 3.25. SRPK1 RNA levels in SPHINX treated Kasumi-1 cells. Cells were treated with 
increasing concentrations of SPHINX for up to 72hrs. PCR was performed using SRPK1 specific 
primers. A. Representation of β-actin PCR amplicon sizes at 24hrs, 48hrs and 72hrs. B. SRPK1 






3.7.2 Effect of SPHINX on VEGF alternative splicing 
Levels of total VEGF was unchanged at 24hrs with increasing concentration of SPHINX 
inhibition. At 48hrs and 72hrs, total VEGF levels were significantly different from the 
controls with levels at 72hrs showing an apparent increase. This was not however dose 
dependent. No alternative splicing event was observed, specifically the anti-angiogenic 
VEGF165b isoform, which was not detected by standard PCR (Figure 3.26A-B). 
       
 









Figure 3.26. Alternative splicing of VEGF in SPHINX treated Kasumi-1 cells. Cells were 
treated with increasing concentrations of SPHINX for up to 72hrs. A. Representation of 
VEGF PCR amplicon sizes for 24hrs, 48hrs and 72hrs B. Densitometry for total VEGF 
normalized to β-actin.  Significant changes were observed in VEGF at 48hrs (P<0.05) and 






3.7.3 Effect of SPHINX of Bclx alternative splicing 
Levels of Bclx showed an apparent change in splicing towards Bcl-xs pro-apoptotic 
isoform in treated groups when compared to controls (Figure 3.27B).  
                    
 









Figure 3.27. Alternative splicing of Bclx in SPHINX treated Kasumi-1 cells. Cells were treated 
with increasing concentrations of SPHINX for up to 72hrs. PCR was performed using Bclx 
specific primers. B. Representation of Bclx PCR amplicon sizes for 24hrs, 48hrs and 72hrs C. 
PSI-Ψ values for Bcl-xl/xs PSI-Ψ values. Statistical analysis for DMSO versus SPHINX for 24hrs 








3.7.4 Effect of SPHINX on Apaf1 alternative splicing 
There was no significant change in Apaf1 alternative splicing at 24hrs to 72hrs time 
points. Although, there was less expression of the pro-apoptotic isoforms at 24hrs and 
48hrs especially at 10µM concentration. (Figure 3.28B-C). 
              
  










Figure 3.28. Alternative splicing of Apaf1 in SPHINX treated Kasumi-1 cells. Cells were 
treated with increasing concentrations of SPHINX for up to 72hrs. PCR was performed 
using Apaf1 specific primers. B. Representation of Apaf1 PCR amplicon sizes for 24hrs, 







3.7.5 Effect of SPHINX on caspase 9 alternative splicing 
Caspase 9 alternative splicing was affected by SRPK1 inhibition using SPHINX. Isoforms 
of caspase 9 were found to be decreased at higher contractions of SPHINX. Levels were 
found to be significantly different when compared to DMSO control (Figure 3.29B-C). 
          
    
 





Figure 3.29. Alternative splicing of caspase-9 in SPHINX treated Kasumi-1 cells. Cells were 
treated with increasing concentrations of SPHINX for up to 72hrs. PCR was performed using 
caspase 9 specific primers. B. Representation of caspase 9 PCR amplicon sizes for 24hrs, 
48hrs and 72hrs. C. Percentage splice inclusion (PSI-Ψ) for caspase 9a/9b. Statistics 
comparing DMSO and SPHINX treatment for 24hrs (***P=0.0004, *P=0.012; **P=0.005), 







3.8 Effect of SPHINX on protein levels of SRPK1, SRSF1 and on the 
phosphorylation of SR-protein in Kasumi-1 cells. 
 
3.8.1 Effect of SPHINX on SRPK1 protein levels 
Further studies were performed to understand what the effect of inhibiting SRPK1 in 
Kasumi-1 cells will be on the expression of SRPK1 at the protein level. There was no 
apparent change in SRPK1 protein levels in treated Kasumi-1 cells. Kasumi-1 cells 
appeared to express SPRK1 at a high level, owing to the high intensity of the bands 
(Figure 3.30). 
                   













Figure 3.30. Protein levels of SRPK1 in SPHINX treated Kasumi-1 cells. Western blot 
analysis on Kasumi-1 protein extracts using anti-SRPK1 antibody. Image showing protein 





3.8.2 Effect of SPHINX on SRSF1 protein levels 
Following the inhibition of SRPK1, levels of total SRSF1 in Kasumi-1 cells were measured. 
Total SRSF1 levels were increased across treatment and controls. Similar levels were 
found between SPHINX treatments and time matched DMSO controls.  There was also 
no change observed between time points when compared (Figure 3.31A & B). 
             





Figure 3.31. Protein levels of SRSF1 in SPHINX treated Kasumi-1 cells. Western blot 
analysis on Kasumi-1 protein extracts using anti-SRSF1 antibody. A. Densitometry showing 
protein levels of SRSF1 with no difference seen between treatment or time points. B. 
Image showing protein band visualized on PVDF membrane with corresponding β-actin 







3.8.3 Effect of SPHINX on SR-protein phosphorylation  
Phosphorylation of serine-arginine protein in Kasumi-1 was investigated following 
SRPK1 inhibition using SPHINX. The SR splice factors are a key substrate whose activities 
are dependent on the ability of SRPK1 to phosphorylate these proteins (Aubol et 
al.,2016). There was an apparent decrease in SRSF4 phosphorylation at higher 
concentrations of 1µM and 10µM when compared to time matched DMSO controls. 
Treatments at higher SPHINX concentration of 1µM and 10µM at 72hrs showed 
decrease phosphorylation in pSRSF6 levels. (Figure 3.32). Only with the 10µM 
concentration at 24hrs was the level of pSRSF11 found to be significantly reduced. 
Phosphorylation of pSRSF11 at 48hrs and 72hrs remained unchanged between treated 
group and controls. No significant differences were observed in pSRSF5 and pSRSF2 
phosphorylation at 48hrs and 72hrs following SRPK1 inhibition.  
 






Figure 3.32. Protein levels of phospho-SR protein in SPHINX treated Kasumi-1 
cells. Representative western blot image showing levels of SR protein 
phosphorylation, and time-matched β-actin loading control following inhibition 





3.9  Discussion 
 
3.9.1 Effect of SPHINX on SRPK1 protein and SR protein phosphorylation in leukaemic 
cells 
All three cell lines used in this study appear to express SRPK1 (Figure 3.14;3.22 and 3.30). 
SRPK1 protein remained unchanged in treated TK6 and Kasumi-1 cells when compared 
to the DMSO control. However, in K562, increased SRPK1 protein level (Figure 3.22) 
were observed at concentrations of 10µM SPHINX without a corresponding increase 
observed in RNA levels (Figure 3.17). Studies which have investigated transcription to 
translation ratio have also found conflicting results. While Lundberg et al., (2010) and 
Wilhelm et al., (2014) found a correlation between transcriptomes and proteomes in 
cell lines and tissues respectively, others (Nagaraj et al., 2011; Edfors et al., 2016) have 
concluded that protein and RNA levels do not correlate, and either cannot serve as proxy 
to predict the abundance of the other. This, they have attributed to the complexity in 
regulation and post-modification changes of these -omics at different stages.  Another 
study on colorectal cells found that knockdown of AKT2 and AKT3 affected expression 
of Rac1b only at the protein level and attributed differences in Rac1b RNA and protein 
to post-splicing effects on the RAC1 gene (Goncalves et al.,2014). These modifications 
may account for the observed result. The unchanged protein levels in TK6 and Kasumi-
1 and the increase observed in K562 suggests that the differential expression of SRPK1 
could be cell line dependent. It was also observed that SPHINX altered levels of the splice 
factor SRSF1 as well, particularly in K562 cells (Figure 3.23). This was consistent with the 
report of Goncalves et al., (2014) which observed that inhibition of SRPK1 using 25μM 
SRPIN340, an earlier analogue of SPHINX on colorectal cancer cell line. significantly 
reduced protein levels of total SRSF1 and pSRSF1 but not SRPK1 protein levels when 
compared to the DMSO control. Thus, in evaluating the effects of SPHINX treatment 
going forward, it will be necessary to consider that it might, directly or indirectly alter 
the expression of its target and the target’s substrates. 
Levels of phosphorylation of SR-proteins varied between cell lines following SPHINX 
treatment. Levels of pSRSF4 decreased in TK6 and Kasumi-1. In K562 cells, it appeared 
significant only at higher concentrations.  No apparent change in pSRSF6 levels was 
observed in TK6 whereas, in Kasumi-1 cells, it appeared to change at higher 




Kasumi-1 cells at 24hrs. Levels of pSRSF5 were unaffected in TK6 and Kasumi-1 cells; a 
significant reduction was observed at higher concentrations of SPHINX at 48hrs. pSRSF2 
could only be detected in Kasumi-1 cells with a variable degree of expression at different 
time points. With the caveat that the detection of phospho-SR proteins by western 
blotting is not strictly quantitative and therefore only indicative of changes, two 
conclusions are possible: one, that SPHINX broadly, and as expected, causes a reduction 
in levels of phospho-SR proteins; and two, the effectiveness of SPHINX on specific SR-
protein may be cell type dependent. 
The effect of SRPK1 inhibition on phosphorylation of SR protein has been widely studied, 
this study found consistent results with another study, which showed that SRPK1 
inhibition following interaction with HPV viral protein E1^E4 (a fusion protein processed 
to form the E4 viral protein), results in variable reduction in the phosphorylation of SR 
proteins with the pSRSF4 being the most affected (Prescott et al., 2014). An earlier study 
reported differential phosphorylation of SR protein in sorbitol-treated HeLa cells with 
resultant alternative splice site selection in the conserved early region 1A (E1A) of 
adenovirus due to altered cellular distribution of SRPK1 following SRPK1 knockdown 
(Zhong et al., 2009). Increased phosphorylation of SR proteins with a corresponding 
increase in mRNA and protein levels of SRPK1 and CLK1 has been observed in hypoxic 
cells, an effect which was reversed with siRNA knockdown of both kinases 
(Jakubauskiene et al., 2015), suggesting the effect of SRPK1 on SR protein 
phosphorylation. 
3.9.2 Leukaemic cell growth, viability and apoptosis following SRPK1 inhibition 
Cancer therapeutic agents are generally compounds screened for their ability to 
increase cytotoxicity of human cancer cells. The overall aim is to develop therapeutic 
agents that can modulate or inhibit specific molecular targets identified as being 
essential for tumour growth (Oltersdorf et al., 2005; Tse et al., 2008).  The aim of this 
chapter was to investigate the effect of SRPK1 inhibition with the compound SPHINX on 
leukaemic cancer cell lines. Lymphoblast cells (TK6), CML (K562) and AML cells Kasumi-
1 were used as model cell lines for this experiment.  
The inhibition of SRPK1 found no change in TK6 and K562 cell viability and growth (Figure 




concentrations of SPHINX, which were also time dependent (Figure 3.5). In terms of 
apoptosis, colorimetric assay and fluorescent examination in Kasumi-1 showed 
percentage increase in cleaved caspase 3 and caspase 7 activity (Figure 3.8). Although, 
K562 showed increased caspase 3/7 activity at the highest concentration of 10µM after 
72hrs, this was not found to be significant (Figure 3.7). This suggests that sensitivity to 
drug could differ from one cancer to another, even though, they have a common origin 
(blood). It also further explains why certain drugs can be used for the management of 
one type of cancer but not the other.  
Consistent with these findings is a study (Siqueira et al., 2015) investigating the effect of 
SRPK1 inhibition using SRPIN340 (an earlier version of SPHINX and less specific inhibitor 
of SRPK1) that showed that cells were sensitive to SRPK1 inhibition. It further reports 
that of all the representative cell lines, (i.e. cells of myeloid and lymphoid origin), the 
HL-60 cell line of myeloid origin was the most sensitive with increased apoptosis and 
reduced cell viability. Since both Kasumi-1 and HL-60 are cells derived from peripheral 
blood of acute leukaemic phases, this suggests that SRPK1 might be critical in the 
propagation of acute phases of leukaemia.  
Published studies on other cell lines have found conflicting results on the effect of 
inhibiting SRPK1 in cells. While Mavrou et al., (2014) found no effect on cell growth, 
proliferation and migration in the prostate cancer cell lines PC3 and DU145, Gammons 
et al., (2016) reported a decrease in melanoma tumour growth in vivo but no effect on 
cell growth, proliferation or migration was observed on in vitro cell culture.  This 
suggests a selective effect of the SRPK1 inhibitors on cell biology. 
Yildiez (2018) in his experiment in hepatocellular cancers suggested that drug sensitivity 
is dependent on cell-specific genetic mutations and the effectiveness of the non-
homologous end joining mechanism of DNA repair. It is, therefore, possible that the 
different mutations present in these cell lines, (Kasumi-1 t(8; 21); K562 t(9; 22)(q34; 
q11); (Kang et al., 2016) could be responsible for their sensitivity to SRPK1 inhibition and 
the selective effect of SRPK1 inhibitors on cell biology. Further to this, because this study 
was done on a population of cells, Nipel et al., (2017) suggested that heterogeneity in 
cell population has a significant impact on cell response as the assumption that cells in 





3.9.3 Effect of SPHINX on alternative splicing of a panel of apoptotic genes 
Small molecule inhibitors are being developed to provide new avenues in cancer 
therapy. These small molecules are generally designed to target specific proteins and 
bind to extracellular, cell surface ligands as well as intracellular proteins. Most of these 
drugs inhibit critical cancer targets and block signal transduction pathways (Lavanya et 
al., 2014).  Published work has shown that inhibition of SRPK1 resulted in altered VEGF 
splicing in podocytes in favour of its anti-angiogenic isoform, VEGF165b with a resultant 
decrease in angiogenesis (Nowak et al., 2010).  
To further explore splicing patterns following SRPK1 inhibition, a panel of genes (VEGF-
A, Bclx, Apaf1, and caspase 9) were investigated in leukaemic cell lines. This study 
determined whether SPHINX might alter the expression of SRPK1 itself (in a feedback 
loop). No effect on overall SRPK1 expression was observed (Figure 3.9).  Whereas total 
VEGF in TK6 and Kasumi-1 at 48hrs significantly decreased at higher concentrations 
(Figure 3.10 & 3.26), levels in Kasumi-1 increased at 72hrs with no change seen in K562 
upon treatment with SPHINX. This study was unable to detect the VEGF anti-angiogenic 
isoform which other study has detected in tumour growth in PC3 mouse xenografts and 
the PC3 cell line (Mavrou et al., 2015). It is possible that more sensitive assays, such as 
western blotting and ELISA, using a specific antibody targeting VEGF165b isoform and a 
suitable control such as podocyte cells or VEGF165b plasmid would give better 
indication of the VEGF165b isoform since PCR is semi-qualitative. 
 
No clear effect on Bclx, Apaf1 and caspase 9 alternative splicing was observed in all cell 
lines with the dominant isoforms being highly expressed. When levels of these isoforms 
were compared to the DMSO control, an increase in Bcl-xs was observed in Kasumi-1 
(Figure 3.27B). Also, a transient shift in Apaf1 splicing to Apaf-1xl isoform at 24hrs and 
48hrs was observed at higher concentration of 1µM and 10µM in Kasumi-1 cells (Figure 
3.28) but not in TK6 and K562 cells. The caspase 9a isoform was increasingly expressed 
in the SPHINX treated group in K562 and Kasumi-1 cells but not in TK6 when compared 
to the DMSO control. The increasing level of caspase 9a, a pro-apoptotic isoform of 
caspase 9 is consistent with increased caspase 3/7 activity in Kasumi-1 cells and at higher 
concentrations in K562 (Figure 3.7 & 3.8) which matched the decreased percentage in 




could be a downstream target of SRPK1 inhibition and highlights the possible role of the 
caspase pathway in maintenance of AML clones.  
The degree of mRNA processing is known to differ from cell to cell and depends partly 
on the rate of transcription which is not constant (Ingolia et al., 2011). There have been 
reports in which transcriptional changes feed back to regulate mRNA synthesis and 
structure (Namy et al., 2006; Yanagitani et al., 2011). Such transcriptional changes and 
the degree of mRNA processing may explain the differences in mRNA levels in these cell 
lines.  
SRPK1 overexpression, which was also observed at protein levels in this experiment, has 
been reported in several cancers including colon and breast malignancy where elevated 
levels decrease cell apoptosis (Lin et al., 2014; Mavrou et al., 2015).  
SRSF1 has been shown to regulate caspase 9 splicing in non-small lung cancer (NSCLC) 
and cell lines such as Hela cells, H838 and HBEC3-KT cells through interaction with RNA 
cis-element such as C9-I6/ISE and C9-E6/ESE that determines the choice of the splice 
site in caspase 9 (Shultz et al., 2011). It may be appropriate to infer that the levels of 
caspase 9a observed in this study is an indirect effect of SRPK1 inhibition since SRSF1 is 
a key substrate of SRPK1. The same study identified increased caspase 9a/b ratio in 
NSCLC following inhibition of phosphatidylinositol 3-kinase (PI3K/Akt), a pathway which 
has been shown to be activated by SRPK1 (Chang et al.,2015).  Apaf1 binding to pro-
caspase 9 is required for its activation in the intrinsic pathway (Anichini et al., 2006), 
studies have suggested that increased expression of Apaf-1xl isoform correlates to 
cancer cell survival and resistance to apoptosis (Shakeri et al., 2017). One study suggests 
that the balance between Apaf-1xl/s is required to overcome drug resistance and 
increase apoptosis in tumour cells (Benites et al., 2008). It has also been suggested that 
both hypo- and hyper-phosphorylation of SR proteins alter mRNA splicing significantly 
(Zhong et al., 2009). The variability in splicing observed remains inconclusive as to 
whether it is a direct effect of SRPK1 inhibition via SR protein phosphorylation. Assays 
such as qPCR and western blotting which are more quantitative and with a suitable 







Chapter 4  





Treatment of blood cancers is a very challenging task. There is an ongoing need to 
develop new and effective drugs. The management of leukaemic conditions such as CML 
and AML continues to be challenging. Imatinib mesylate (Gleevec) is the first drug (first 
generation) developed for targeted therapy of BCR-ABL positive CML; and azacytidine, 
a hypo-methylation agent is the first drug of choice for the treatment of AML (O’Brien 
et al., 2003; Tallman et al.,2019). Several generations, up to the third generation of the 
likes of imatinib such as Ponatinib (Iclusig) have been developed (O’Hare et al., 2009). 
Even though each new generation of these drugs has increased potency and efficacy, 
they are known to have severe side effects which could lead to patients withdrawing 
from the treatments. Side effects can also lead to the development of secondary 
diseases such as embolism, diabetes, stroke, congestive heart failure and secondary 
cancers that could potentially kill the patient (Aichberger et al., 2011; Gugliotta et al., 
2015). As newer generation of drugs becomes more focused, targeting specific 
mutations, unique to each of these cancers, it is still the case that targeting these 
pathways can be responsible for the severe side effects (Bagnyukova et al., 2010). 
Another challenge with chemotherapy regimen is the ability of patients to meet certain 
criteria such as presenting at a particular phase of the disease, never been exposed to 
certain drugs and having specific cytogenetic or chromosomal abnormalities to be 
eligible for a specific treatment. To overcome some of these therapy-related problems, 
it has been suggested that a combination of potential treatment regimen will increase 
treatment efficacy due to broad target and reduce side effects resulting from high dose 
(Cheng et al., 2011; Jabbour and Kantarjian, 2018). 
The aim of this chapter is to evaluate the consequence of co-inhibition of the splice 
factor kinase, SRPK1 and CLK1 combined with conventional chemotherapeutic agents 
used in the treatment of CML and AML. It is hoped that combining this treatment could 




4.2 Results  
 
4.2.1 Effects of Imatinib on K562 cell viability and growth 
To understand the effect of imatinib on cell viability, K562 cells were treated with 
increasing concentrations of imatinib mesylate up to 20μg/ml for 72hrs using a method 
that has earlier been described in chapter 2.4. Treatment of K562 with imatinib show 
that imatinib can reduce K562 cell viability in a dose-dependent manner, with time, 
when compared to the DMSO control. (Figure 4.1A). 
 



























Not only was cell viability decreased in a dose-dependent manner, a reduction in K562 
cell proliferation, and hence, cell growth was also observed, which was highly significant 
(P<0.0001) especially at 48hrs and 72hrs (Figure 4.1B).  
At 72hrs, for imatinib doses at 10μg/ml and 20μg/ml, less than 20% of the cells were 
viable and cell number decreased significantly. Therefore, these doses were considered 
very toxic to the cells and were not used in future experiments. Furthermore, 
considering that there was a need to extract RNA and proteins from these treated cells 
for further experiments, this would have been very difficult owing to the low cell 
number. For further experiments, cells were treated with no more than 5μg/ml of 
imatinib mesylate. This was considered as 3μg/ml is the clinically relevant dose and 
represent the peak serum concentration of imatinib when administered at FDA 
recommended a standard clinical dose of 400mg/day (Rezende et al., 2013).  
Figure 4.1. Effect of increasing concentration of imatinib mesylate on K562 cell 
viability and growth. Two million (2 x 106) cells were seeded over 72hrs with cell 
count performed every 24hrs. A. Percentage cell viability in K562 cells up to 72hrs.  
20µg imatinib treatment at 24hrs (P=0.001). At 48hrs and 72hrs (P<0.0001). B. 
Reduction in cell growth/cell number was observed with 5µg/ml, 10µg/ml and 
20µg/ml imatinib at 24hrs (P≤0.001). The cell number further reduced at all drug 
concentration for 48hrs and 72hrs (****P<0.0001) when treated group were 





4.2.2 Effect of combined SRPK1 inhibition and imatinib on K562 cell viability and 
growth 
The effect of imatinib on K562 cell viability and an appropriate concentration range was 
confirmed. Further experiments were then aimed at combining imatinib treatment with 
SRPK1 inhibition using SPHINX at 10μM concentration. This aim was to investigate 
whether there is any added advantage to imatinib treatment in achieving increased cell 
death in CML at lower doses. 
Therefore, cells were treated with either 10μM SPHINX, 3μg/ml and 5μg/ml imatinib 
alone or a combination of both for up to 72hrs. Results showed a significant decrease in 
cell viability when groups treated with SPHINX or in combination with imatinib were 
compared to DMSO controls (Figure 4.2A). However, further analysis to determine 
whether combined treatment with imatinib and SPHINX significantly differ from either 
SPHINX or imatinib alone found no significant changes in cell viability (Table 4.1A-B). 
Similar results were also obtained with the cell growth (Figure 4.2B) except for the 24hrs 
time point were only 5μg/ml imatinib and combination of imatinib with SPHINX differed 










               
 















Figure 4.2. Effect of combined SPHINX and imatinib mesylate on K562 cell viability and 
growth. Two million (2 x 106) cells were seeded over 72hrs with cell count performed every 
24hrs. A. Reduced in cell viability observed with imatinib and imatinib + SPHINX combined 
treatment at each time points when compared to DMSO control (****P<0.0001). B. 
Reduced cell growth/cell number was observed in 5µg/ml imatinib and imatinib + SPHINX at 
24hrs (*P=0.03 and **P=0.002 respectively) and at 48hrs and 72hrs (****P<0.0001) 



















4.2.3 Effect of combined SRPK1, CLK1 inhibition with imatinib on K562 cell viability 
and growth 
It has been established that both SRPK1 and CLK1 are required for the phosphorylation 
of SR-protein. One study suggests that, whereas, SRPK1 which has both nuclear and 
cytoplasmic presence is responsible for phosphorylation dependent transport of SR 
protein from the cytoplasm to the nucleus, CLK1, which is nuclear localized, is 
responsible for SR protein mobilization from speckles to the site of active pre-mRNA 
splicing (Aubol et al., 2016). Further studies have also suggested that both kinases 
interact in the nucleus via the CLK1 N-terminal to complete the functional task of SR 
protein phosphorylation in the nucleus. This is such that nuclear SRPK1 is responsible 
for the release of SR proteins, which have been mobilized at active splice site by CLK1 
which also regulates SRPK1 levels in the nucleus (Aubol et al., 2014; 2016). Thus, the 
Table 4.1A: K562 cell viability analysis for imatinib and imatinib 
combined with SPHINX 
Statistical analysis comparing cell viability on K562 cell treated with imatinib 
mesylate vs imatinib + SPHINX. Confidence interval (CI) at 95% for mean 
difference (-4.95, 16.84); T-value = 2.35; P = 0.144 (paired t-test). No significant 
statistical difference was observed in K562 cell viability when imatinib treated 
group was compared to imatinib and SPHINX combination.                        
Table 4.1B: K562 cell growth analysis for imatinib and 
imatinib combined with SPHINX 
 
Statistical analysis comparing cell viability on K562 cell treated with imatinib 
mesylate vs imatinib + SPHINX. Confidence interval (CI) at 95% for mean 
difference (-0.1932, 0.2732); T-value = 0.74; P= 0.537 (paired t-test). No 
significant statistical difference was observed in K562 cell number when 




effect of inhibiting both SRPK1 and CLK1 in leukaemic cell line K562 was studied to see 
if inhibition of both kinases will increase the rate of cell apoptosis and if additional 
combined treatment with imatinib will have an added advantage. Results of the analysis 
showed that double kinase inhibition of SRPK1 and CLK1 in addition to imatinib 
treatment resulted in a significant decrease in cell viability when compared to either 
SRPK1 or CLK1 inhibition alone at all-time points except for 3µg/ml imatinib treatment. 
At 48hrs, all combined treatment also differed significantly from imatinib and SPHINX 
combination and TG003 (CLK1 inhibitor) and SPHINX combination respectively (P<0.05) 
(Figure 4.3A).  
Similar results were also obtained when the effect on K562 cell growth was observed. 
The rate of K562 cell growth significantly reduced in all combined treatment than the 
single kinase inhibition/treatment or the controls. No significant change was observed 
when both kinases (SRPK1 and CLK1) were inhibited or with individual kinase inhibition 
combined with imatinib (Figure 4.3B). 



















4.2.4 Effect of azacytidine on Kasumi-1 cell viability and growth 
Kasumi-1 cells were also treated with azacytidine, a first line drug of choice in AML. FDA 
approved dose of 75mg/m2 IV or IM results in a peak serum concentration of 750ng/ml 
(FDA, 2007), which was considered the clinically relevant dose in this experiment. 
However, doses up to 1.5μg/ml were used to determine the effect of azacytidine on 
Kasumi-1 viability. A dose and time-dependent decrease in Kasumi-1 cell viability was 
observed when compared to the treatment controls (Figure 4.4A). 
Figure 4.3. Effect of combined SPHINX and TG003 with imatinib mesylate on K562 cell 
viability and growth. Two million (2 x 106) cells were seeded over 72hrs with cell count 
performed every 24hrs. A. Cell viability in treated cells. Cell viability differs significantly 
between SPHINX+TG003+Imatinib treated group when compared to the single treatment 
(untreated, DMSO, SPHINX and TG003) (****P<0.0001) for 24hrs and 72hrs. At 48hrs, 
untreated, DMSO, SPHINX and TG003 also differ significantly (****P<0.0001) in addition to 
Imatinib + SPHINX treatment (P≤0.03). A comparative analysis of time points also showed 
significant difference (P≤0.01) between start point and other time points. B. Reduced cell 
growth/cell number was also observed between SPHINX+TG003+imatinib treated group and 
the single treatments (****P<0.0001) for 48hrs and 72hrs, and (**P=0.004, ****P<0.0001 





           
 











Figure 4.4. Effect of increasing concentration of azacytidine on Kasumi-1 cell 
viability and growth. Two million (2 x 106) cells were seeded over 72hrs with cell count 
performed every 24hrs. A. Result showing the percentage viability in Kasumi-1 cells up to 
72hrs(****P<0.0001) when compared to the DMSO control. B. Time points also showed 
significant difference in cell number at 24hrs vs 72hrs and 24hrs vs 72hrs at ****P<0.0001 







When the effect of azacytidine on cell growth was observed, only at higher doses of 
750ng/ml and 1.5µg/ml was there a significant decrease in cell growth at 24hrs. 
However, at 48hrs and 72hrs, all azacytidine treatment showed a significant decrease in 
cell growth and hence proliferation in a dose-dependent manner (Figure 4.4B). 
4.2.5 Effect of SPHINX and azacytidine on Kasumi-1 cell viability and growth 
To determine whether there is any beneficial effect in combining SRPK1 inhibition and 
azacytidine treatment in the management of AML patients, Kasumi-1 cells were treated 
with either 10µM SPHINX or 750ng/ml azacytidine or a combination of both. There were 
indications of a beneficial effect as cell treated with a combination of SPHINX and 
azacytidine showed a significant decrease in cell viability. This was compared to the 
untreated and DMSO controls or SPHINX only treatment at each time points. Only at 
48hrs was azacytidine treatment significantly different from the combined treatment 
(Figure 4.5A). There was a difference between the combined treatment and the controls 















       
 
          











Figure 4.5. Effect of combined SPHINX and azacytidine on Kasumi-1 cell viability and 
growth. Cells were seeded over 72hrs with cell count performed every 24hrs. Cells were 
treated with SPHINX + azacytidine or SPHINX or azacytidine alone. A. Control, DMSO and 
SPHINX treated group showed increase in cell viability at 24hrs (****P<0.0001 and **P= 
0.004) and 72hrs (****P<0.0001 and **P=0.004). Cells at 48hrs showed similar result in 
addition to the azacytidine treated group ****P<0.0001; *P= 0.01 and **P= 0.004). Values 
when time was compared were ****P<0.0001 for 24hrs vs 72hrs and *P= 0.02 48hrs vs 
72hrs.  B. Cell growth was observed to increase in controls when compared to the SPHINX+ 





4.2.6 Effect of combined SPHINX and TG003 with azacytidine on Kasumi-1 cell 
viability and growth 
The effect of combined CKL1, SRPK1 inhibition with azacytidine on Kasumi-1 cell viability 
was investigated to determine if there was a beneficial outcome in the response of an 
AML cell line. the combination of azacytidine with SPHINX and TG003 showed a 
significant decrease in cell viability against single treatments and azacytidine combined 
with individual kinase inhibitor except with cells treated with SPHINX and TG003 at 
24hrs. At 48hrs, azacytidine and TG003 and SPHINX and TG003 were not statistically 
different whereas, at 72hrs, all single treatments, except azacytidine, showed no 
difference when compared to the combined treatment (Figure 4.6A). Cell growth was 
found to be increased in the untreated and DMSO controls only at 48hrs and 72hrs and 
this differed significantly when compared to cell growth in the azacytidine with SPHINX 












        
 










Figure 4.6. Effect of combined SPHINX and TG003 with azacytidine on Kasumi-1 cell viability 
and growth. Cells were seeded over 72hrs with cell count performed every 24hrs. Cells were 
treated with inhibitors (SPHINX or TG003) alone, inhibitor and azacytidine or in combination. 
A. At 24hrs, all treatment except SPHINX+TG003 showed a significant difference in cell 
viability when compared to the group treated with inhibitors and azacytidine (***P≤0.0005). 
Only azacytidine + SPHINX and SPHINX + TG003 did not differ significantly with inhibitors and 
azacytidine at 48hrs (P≥0.05) and at 72hrs, only the single treatment significantly differs from 
the inhibitors and azacytidine (****P<0.0001 and *P= 0.01 respectively). At time points, 
****P<0.0001 for 24hrs vs 72hrs and *P= 0.02 48hrs vs 72hrs.  B. Cell growth was observed 
to increase in controls when compared to the inhibitors + azacytidine treatment (*P<0.05) at 






4.2.7 Effect of combined SPHINX and chemotherapeutic drug on leukaemic cell 
biology 
4.2.7.1 Examination of the effect of combined SPHINX and imatinib on K562 cells 
 
Further investigation on the effect of combined imatinib and SRPK1 inhibition using 
acridine orange, fluorescent dye, showed that combining imatinib with SPHINX 
significantly increased (P≤0.0001; 0.0014) cell apoptosis when compared to the controls 
and SPHINX only treatment, which was consistent with the cell viability and growth in 
K562 cells. Interestingly, it was observed that more cells were driven to apoptosis when 
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Figure 4.7. Effect of combined SPHINX and Imatinib on K562 cell morphology. Representative micrograph of K562 cells stained with acridine 
orange fluorescence dye.  Cells were treated with either SPHINX, imatinib or in combination of both for up to 72hrs. A. Percentages of 
apoptotic cells. Significant decrease in cell apoptosis was observed in all group when compared to combined imatinib and SPHINX treated 
group (****P≤0.0001). B. Image viewed at a green (FITC) band width of about 510-560nm. Normal cells with intact nucleus and cytoplasm 




4.2.7.2 Effect of combined SPHINX and azacytidine on caspase 3/7 activity in Kasumi-1 
cells 
 
Experiment was performed to further understand the effect of azacytidine and SPHINX 
combined treatment on Kasumi-1 cells by investigating caspase 3/7 activity. Increased 
level of caspase 3/7 activity was observed in all treatments except for the controls. The 
level of caspase-3 activity did not differ significantly when the combined SPHINX and 
azacytidine was compared to SPHINX or azacytidine group except for the controls. 
Suggesting no added benefit (Figure 4.8A).
 
                        












Figure 4.8. Examination of caspase 3/7 activity in Kasumi-1 cells. (A) Post-treatment, cells were labelled with a known substrate; DEVD-p-
NA. Combined SPHINX + azacytidine cells significantly increased in caspase 3 activity when compared to untreated (**P=0.006) and DMSO 
(**P=0.008) control. (B) Percentage increase in apoptotic cells in combined SPHINX + azacytidine treatment compared to untreated (P=0.031) 
and DMSO (P=0.030) controls (C). I. Hoechst stain of the total cell at excitation between 330-380nm band width bypass. Arrows (green) 
represents necrotic cells and (orange) apoptotic cells.  II. Corresponding image viewed at a green (FITC) band width of 490-590nm. Caspase 




Examination of the activities of caspase 3/7 on Kasumi-1 cell (Figure 4.8B & C) showed 
results which were consistent with caspase 3 activity (Figure 4.8A) where only the 
controls significantly differed when compared to the SPHINX and azacytidine combined 
treatment. Although, there was an apparent increase in cell death in cells treated with 
combined SPHINX and azacytidine than SPHINX or azacytidine only. This was not found 
to be significant.  
            
4.3 Effect of SPHINX and imatinib on levels of SRPK1, VEGF and 
alternative splicing of a panel of apoptotic genes in K562 cells  
 
Experiments were performed to determine the effect of combined SPHINX and imatinib 
treatment on alternative splicing of genes. Hypothesis for this aspect of the study states 
that combining SPHINX and imatinib will lead to splicing in a panel of apoptotic genes in 
favour of pro-apoptotic isoforms than treatment with SPHINX or imatinib treatment 
alone.  To test this hypothesis, PCR were performed using methods already described in 
chapter two. 
 
4.3.1 Effect of combined SPHINX and imatinib on SRPK1 expression 
 
Using appropriate primers, it was first observed whether combining SPHINX with 
imatinib will have any effect on SRPK1 mRNA levels. No significant changes in SRPK1 
expression were observed (Figure 4.9B). 





              




4.3.2 Effect of combined SPHINX and imatinib on VEGF alternative splicing 
VEGF was amplified to check for alternative splicing event (specifically, expression of the 
pro- and anti-angiogenic VEGF arising from 3’ splice site in exon 8) and levels of total 
VEGF. There was no difference in total VEGF level neither was there any splicing event 
observed. (Figure 4.10). 
 
       




Figure 4.10. VEGF levels in combined SPHINX and imatinib treated K562 cells. Cells were 
treated with either SPHINX, Imatinib or a combination of both for up to 72hrs. 
Representation of VEGF PCR amplicon (199bp) for 24hrs, 48hrs and 72hrs. n=3. 
 
Figure 4.9. SRPK1 levels in combined SPHINX and imatinib treated K562 cells. Cells were 
treated with either SPHINX, Imatinib or a combination of both for up to 72hrs. A. 
Representation of β-actin amplicons for experimental time points;24hrs-72hrs. B. SRPK1 





4.3.3 Effect of combined SPHINX and imatinib on Bclx alternative splicing 
       
 






Figure 4.11.  Alternative splicing of Bclx in combined SPHINX and imatinib treated K562 
cells. Cells were treated with either SPHINX, Imatinib or a combination of both for up to 
72hrs. B. Representation of PCR amplicon for 24hrs, 48hrs and 72hrs. C. Densitometry 







Splicing events were studied by observing gene involved in the apoptotic pathway. Bcl-
x was studied to check whether combined treatment with SPHINX and imatinib would 
result in a splice switch to the pro-apoptotic isoform Bcl-xs. There was no significant 
change in the splice ratio of Bcl-xl and Bcl-xs (Figure 4.11). 
 
4.3.4 Effect of combined SPHINX and imatinib on Apaf1 alternative splicing 
Apaf1 amplification suggests an alteration in alternative splicing. At 24hrs, levels of Apaf-
1s, the pro-apoptotic isoform was found to be reduced compared to the pro-apoptotic 
isoform. Levels of the pro-apoptotic isoform were the same for both treatment and 
controls. However, at 48hrs and 72hrs, they were found to be the same in the controls 
while levels of Apaf-1s were also increased tending towards a switch to a pro-apoptotic 
phenotype when compared to images acquired at 24hrs (Figure 4.12B). However, 
quantification of PCR amplicons showed no change in splice ratio between Apaf-1xl/1s 
(Figure 4.12C). 
 
             











4.3.5 Effect of combined SPHINX and imatinib on caspase 9 alternative splicing 
Caspase 9 was examined to see if combining SPHINX with imatinib would lead to the 
expression of the pro-apoptotic caspase 9a isoform. Interestingly, unlike Apaf1, which 
did not show a complete switch in splicing, caspase 9 showed an apparent switch to pro-
apoptotic caspase 9a at 48hrs and 72hrs (Figure 4.13B). Densitometry of the PCR 
amplicon also indicated a switch in splicing with more inclusion of caspase 9a isoform in 
treatment including imatinib (Figure 4.13C). Since this switch was observed in the 
imatinib and combined imatinib and SPHINX but not in the SPHINX only treatment, it is 
unlikely that this switch resulted from SPHINX alone. Hence, suggesting that a 
combination of SRPK1 inhibition (using SPHINX) and imatinib treatment may not be 
beneficial in driving more cells to apoptosis in a CML cell line model. 
 
Figure 4.12.  Alternative splicing of Apaf1 in combined SPHINX and imatinib treated 
K562 cells. Cells were treated with either SPHINX, Imatinib or a combination of both for 
up to 72hrs. B. Representation of PCR amplicon for 24hrs, 48hrs and 72hrs. C. 





           
             






Figure 4.13.  Alternative splicing of caspase 9 in combined SPHINX and imatinib treated 
K562 cells. Cells were treated with either SPHINX, Imatinib or a combination of both for 
up to 72hrs. B. Representation of PCR amplicon for 24hrs, 48hrs and 72hrs. C. 
Densitometry showing percentage of splice inclusion (PSI-Ψ) in caspase-9a/9b isoforms 








4.4  Effect of combined SPHINX and azacytidine on mRNA levels of 
SRPK1, VEGF and alternative splicing of a panel of apoptotic genes in 
Kasumi-1 cells  
 
4.4.1  Effect of combined SPHINX and azacytidine on SRPK1 expression 
Experiments were performed to also investigate the combined effect of SRPK1 inhibition 
using SPHINX and azacytidine on SRPK1 overall expression in Kasumi-1 cells. With the 
caveat that standard PCR is not quantitative, the data suggest no change in overall SRPK1 
expression (Figure 4.14B). 
    
 
 






Figure 4.14. SRPK1 levels in combined SPHINX and azacytidine treated Kasumi-1 cells. Cells 
were treated with either SPHINX, azacytidine or a combination of both for up to 72hrs. A. 
Representative image for β-actin for experimental time points. B. SRPK1 PCR amplicon 






4.4.2 Effect of combined SPHINX and azacytidine on VEGF alternative splicing 
Alternative splicing event and levels of VEGF in Kasumi-1 cells indicate no change in VEGF 
expression level (Figure 4.15). At 48hrs, one experimental repeat showed an indication 
of a splicing event yielding a faint amplicon with a size of 65bp which corresponds to 
VEGF165b anti-angiogenic isoform. However, it was difficult to confirm this result as a 
repeat experiment aimed at reproducing the same result was not successful.   
   














Figure 4.15. VEGF expression in combined SPHINX and azacytidine treated Kasumi-1 cells. 
Cells were treated with either SPHINX, azacytidine or a combination of both for up to 72hrs. 




4.4.3 Effect of combined SPHINX and azacytidine on Bclx alternative splicing 
The ratio of Bcl-xl to Bcl-xs was broadly unaffected. Levels of highly expressed anti-
apoptotic Bcl-xl were predominant (Figure 4.16B). It was however interesting to note 
the very low levels of Bcl-xs in Kasumi-1 cells (Figure 4.16B). This provides further 
evidence that levels of gene expression differ from one cell type to another. 
   
                      
 















Figure 4.16. Alternative splicing of BCLx in combined SPHINX and azacytidine treated 
Kasumi-1 cells. Cells were treated with either SPHINX, azacytidine or a combination of 
both for up to 72hrs. B. Representation of PCR amplicon for 24hrs, 48hrs and 72hrs for 




4.4.4 Effect of combined SPHINX and azacytidine on Apaf1 alternative splicing 
There was no change in levels or alternative splicing events in Apaf1 when compared to 
the controls. This difference was not found to be statistically significant. (Figure 4.17B-
C). 
                  
                    








Figure 4.17. Alternative splicing of Apaf1 in combined SPHINX and azacytidine treated 
Kasumi-1 cells. Cells were treated with either SPHINX, azacytidine or a combination of both 
for up to 72hrs. B. Representation of PCR amplicon for 24hrs, 48hrs and 72hrs. C. 





4.4.5 Effect of combined SPHINX and azacytidine on caspase 9 alternative splicing 
Levels of caspase 9 appear unaffected with the highly expressed 9a isoform being 
consistent and showed no difference between the treatments and controls (Figure 
4.18B-C). 
                            
            
 





Figure 4.18. Alternative splicing of caspase 9 in combined SPHINX and azacytidine treated 
Kasumi-1 cells. Cells were treated with either SPHINX, azacytidine or a combination of both 
for up to 72hrs. B. Representation of PCR amplicon for 24hrs, 48hrs and 72hrs. C. 







4.5 Effect of combined SPHINX and TG003 with imatinib mesylate on the 
expression of SRPK1, CLK1, VEGF and alternative splicing of a panel 
of apoptotic genes in K562 cells  
 
4.5.1 CLK1 alternative splicing following inhibition with TG003 in K562 cells 
As previously discussed, CLK1 may affect the function of SRPK1 as both kinases 
complement the activity of the other in the phosphorylation of SR proteins, their 
preferred substrate (Aubol et al., 2014). Therefore, the effect of inhibiting both kinases 
together was examined. Chronic myeloid leukaemic cells, K562 were treated with 
increasing concentration of TG003, a specific inhibitor of CLK1. The effect of CLK1 
inhibition on its alternative splicing was then observed. Primers used were forward 
primers in exon 3 and exon 4 and two reverse primers on exon 5 of CLK1. A combination 
of these primers would detect alternative splicing events within these regions. Inhibition 
of CLK1 results in increased exon 4 retention at higher concentration of 10µM and 50µM 
(Figure 4.19B-C), with a significant difference when TG003 treatments were compared 
to DMSO control. This result was also matched with less intron 4 retention at the same 
higher concentration of 10µM at 24hrs and 10µM and 50µM at 48hrs and 72hrs 














                                                                                                   
 









            














Figure 4.19. Alternative splicing of CLK1 following inhibition with TG003 in K562 
cells. K562 cells were treated with increasing concentrations of TG003 for up to 
72hrs. PCR was performed using CLK1 specific primers. A. representative image for 
β-actin for experimental time points. B. PCR amplicon for CLK1/∆CLK1 exon 4 skipping 
at 24hrs, 48hrs and 72hrs and illustration of alternative splicing events in CLK1 
showing retention of exon 4. C. Densitometry showing percentage of splice inclusion 
(PSI-Ψ) for CLK1 exon 4. P-values for DMSO versus treatment at 24hrs 
(****P<0.0001), 48hrs (P=0.02; 0.01; 0.009; P<0.0001) and 72hrs(****P<0.0001). D. 
PCR amplicon for 24hrs, 48hrs and 72hr showing intron 4 retention and illustration 
of alternative splicing event in CLK1x showing retention of intron 4. E. Densitometry 
showing percentage of intron 4 retention for 24hrs-72hrs. DMSO was compared to 
TG003 concentrations at 24hrs (**P= 0.004; *P=0.01; *P=0.03; **P=0.003), 48hrs 






4.5.2 Effect of combined SPHINX and TG003 with imatinib on SRPK1 expression in 
K562 cells 
Levels of SRPK1, where both SRPK1 and CLK1 kinase was inhibited in addition to imatinib 
treatment was not found to be different from the controls or all other treatment (Figure 
4.20B-C). 
     
                   







Figure 4.20. SRPK1 levels in combined SPHINX and TG003 with imatinib mesylate treated 
K562 cells. K562 cells were treated with either Imatinib, SPHINX or TG003 inhibitor, a 
combination of both inhibitors and all three treatments for up to 72hrs. A. Representative 
image for β-actin for the experimental time points. B. SRPK1 amplicons for 24hrs, 48hrs and 





4.5.3 Effect of combined SPHINX and TG003 with imatinib on CLK1 alternative splicing 
K562 cells 
Since the effect of CLK1 inhibition on its own splicing is known, experiments were then 
performed to see how CLK1 splicing is affected by other treatments including combining 
CLK1 and SRPK1 inhibition in addition to imatinib treatment. At 24hrs, there was more 
exon 4 retention in the TG003 and TG003 and imatinib treated cell. However, at 48hrs 
and 72hrs, all treated group with CLK1 inhibition using TG003 either singly or in 
combination with other treatment showed increased retention of exon 4 (Figure 4.21A-
B). Further to this, a corresponding result was also observed with less intron 4 retention 
(Figure 4.21C-D). This suggests that inhibiting CLK1 and SRPK1 in addition to imatinib 
treatment may not have any added advantage to CLK1 activity in CML cell model. 
 
 
     









                                         
         













Figure 4.21. Alternative splicing of CLK1 in K562 cells following combined SPHINX and 
TG003 with imatinib mesylate treatment. K562 cells were treated with either Imatinib, 
SPHINX or TG003 inhibitor, a combination of both inhibitor and all three treatments for 
up to 72hrs. A. Representative of PCR amplicon for 24hrs, 48hrs and 72hrs. illustration 
of alternative splicing events in CLK1 showing retention of exon 4. B. Densitometry 
showing percentage of splice inclusion (PSI-Ψ) in CLK1 for exon 4 when other 
treatments were compared to combined SPHINX+TG003+Imatinib at 24hrs, 48hrs and 
72hrs. C. Representation of PCR amplicon for 24hrs, 48hrs and 72hr showing levels of 
intron 4 retention and illustration of alternative splicing event in CLK1. D. Densitometry 
showing percentage of intron 4 retention in CLK1 and significant levels observed when 




4.5.4 Effect of combined SPHINX and TG003 with imatinib on VEGF alternative 
splicing in K562 cells 
There was also no difference in VEGF expression between treatments, neither was 
there any alternative splicing event observed (Figure 4.22). 
   
 




4.5.5 Effect of combined SPHINX and TG003 with imatinib on Bclx alternative splicing 
in K562 cells 
Alternative splicing in Bclx was studied using appropriate primers. There was no change 
in Bclx splicing across all treatments including the controls. The dominant isoform Bcl-








Figure 4.22. VEGF levels in combined SPHINX and TG003 with imatinib treatment in 
K562 cells. K562 cells were treated with either Imatinib, SPHINX or TG003 inhibitor, a 
combination of both inhibitor and all three treatments for up to 72hrs. Representation 




                
                             











Figure 4.23.  Alternative splicing of Bclx in K562 cells following combined SPHINX and 
TG003 with imatinib treatment. K562 cells were treated with either Imatinib, SPHINX 
or TG003 inhibitor, a combination of both inhibitor and all three treatments for up to 
72hrs. PCR was performed using Bclx specific primers. B. Representation of PCR 
amplicon (Bcl-xl, 351bp) and (Bcl-xs, 162bp) for 24hrs, 48hrs and 72hrs. C. Densitometry 







4.5.6 Effect of combined SPHINX and TG003 with imatinib on Apaf1 alternative 
splicing in K562 cells 
PCR amplicons for Apaf1, on visual examination, appear to express equal level for 
both isoforms at 24hrs, but with a reduction in Apaf-1s level in the SPHINX and TG003 
and its combination with imatinib at 48hrs. However, at 72hrs, the levels seem to 
vary with treatment, maintaining higher levels of Apaf-1xl and Apaf-1s levels in the 
controls, SPHINX and TG003 treated groups. Treatment with imatinib, Imatinib and 
TG003 and the combined SPHINX, TG003 and imatinib treatment showed a reduction 
but equal levels of both Apaf-1xl and Apaf-1s isoforms (Figure 4.24B). Image 
quantification of the bands showed varying ratio with each treatment at 48hrs and 
72hrs. (Figure 4.24C).  
 
                  













4.5.7 Effect of combined SPHINX and TG003 with imatinib on caspase 9 alternative 
splicing in K562 cells 
The levels of caspase 9 were investigated to see whether inhibiting SRPK1 and CLK1 in 
addition to imatinib treatment would result in a complete switch in splicing to the pro-
apoptotic caspase 9a since earlier treatments with imatinib alone resulted in a switch 
but non-significant change in splice ratio between 9a/9b (Figure 4.25B). Figure 4.25C 
shows levels of caspase 9a and 9b levels for 24hrs-72hrs. Reduced levels and an 
apparent change in splicing was observed at 48hrs and 72hrs in groups with imatinib. 
This result was consistent with the previous experiment indicating imatinib but not 
SPHINX or TG003 potentially being responsible for the induction of pro-apoptotic events 




Figure 4.24. Alternative splicing of Apaf1 in K562 cells following combined SPHINX and 
TG003 with imatinib mesylate treatment. K562 cells were treated with either Imatinib, 
SPHINX or TG003, a combination of both inhibitor and all three treatments for up to 
72hrs. B. Representative of PCR amplicons (Apaf-1xl, 430bp) and (Apaf-1s, 301bp) for 
24hrs, 48hrs and 72hrs. C. Densitometry showing percentage of splice inclusion (PSI-Ψ) 






                     
                








Figure 4.25. Alternative splicing of caspase 9 in K562 cells following combined 
SPHINX and TG003 with imatinib mesylate treatment. K562 cells were treated 
with either Imatinib, SPHINX or TG003 inhibitor, a combination of both 
inhibitor and all three treatments for up to 72hrs. B. Representation of PCR 
amplicon (caspase 9a, 742bp) and (caspase 9b, 292bp) for 24hrs, 48hrs and 
72hrs. C. Densitometry showing percentage of splice inclusion (PSI-Ψ) in 
caspase-9a/9b isoform. Statistics comparing SPHINX+TG003+Imatinib with 







4.6 Effect of combined SPHINX and TG003 with azacytidine on the 
expression of SRPK1, CLK1, VEGF and alternative splicing of a panel 
of apoptotic genes in Kasumi-1 cells  
 
4.6.1 Effect of combined SPHINX and TG003 with azacytidine on SRPK1 expression 
 
The effect of SRPK1 and TG003 inhibition in addition to treatment with azacytidine in 
Kasumi-1 was also investigated to see if combined treatment would influence RNA 
processing in AML treatment potentially indicating a better therapeutic outcome. 
Changes in levels of SRPK1 was examined to see if a combination of this treatment would 
result in any change in SRPK1 RNA when compared to the use of each inhibitor or drug 
alone. Results showed no change in SRPK1 levels (Figure 4.26B-C). 



























Figure 4.26. SRPK1 levels in combined SPHINX and TG003 with azacytidine treatment 
in Kasumi-1 cells. Kasumi-1 cells were treated with either azacytidine, SPHINX or 
TG003 inhibitor, a combination of both inhibitor and all three molecules for up to 
72hrs. A. Representation of loading control, β-actin (206bp) for 24hrs, 48hrs and 72hrs. 
B. SRPK1 PCR amplicon for 24hrs, 48hrs and 72hrs. C. Densitometry showing levels of 





4.6.2 Effect of combined SPHINX and TG003 with azacytidine on VEGF alternative 
splicing in Kasumi-1 cells 
Levels of total VEGF was also investigated for the changes and to see if treatment would 
result in a switch in splicing to VEGF anti-angiogenic isoform VEGF165b which has been 
shown to slow down disease progression through inhibition of neovascularization 
(Mavrou et al., 2014). There were no significant changes in total VEGF levels, neither 
was there any splicing event seen. (Figure 4.27). 
 
              
 




4.6.3 Effect of combined SPHINX and TG003 with azacytidine on Bclx alternative 
splicing in Kasumi-1 cells 
The apoptotic gene Bclx was studied to see if there was a change in splicing to the pro-
apoptotic isoform Bcl-xs. The dominant isoform was seen to be highly expressed and no 





Figure 4.27. VEGF levels in combined SPHINX and TG003 with azacytidine treatment 
in Kasumi-1 cells. Kasumi-1 cells were treated with either azacytidine, SPHINX or TG003 
inhibitor, a combination of both inhibitor and all three treatments for up to 72hrs. 




                 
           
               
 






Figure 4.28. Alternative splicing of Bclx following combined SPHINX and TG003 
with azacytidine in Kasumi-1 cells. Kasumi-1 cells were treated with either 
azacytidine, SPHINX or TG003 inhibitor, a combination of both inhibitor and all three 
molecules for up to 72hrs. B. Representation of PCR amplicon (Bcl-xl, 351bp) and 
(Bcl-xs, 162bp) for 24hrs, 48hrs and 72hrs. C. Densitometry showing percentage of 








4.6.4 Effect of combined SPHINX and TG003 with azacytidine on Apaf1 alternative 
splicing 
The levels of Apaf1 appear to be unaffected at 24hrs and 48hrs, anti-apoptotic isoform, 
Apaf-1xl seem to have a higher level of expression. While at 72hrs, cells treated with 
azacytidine, TG003 and azacytidine, SPHINX and TG003 and all three combined 
treatment showed reduced but equal levels of both isoforms. 
     
               




Figure 4.29. Alternative splicing of Apaf1 following combined SPHINX and TG003 
with azacytidine in Kasumi-1 cells. Kasumi-1 cells were treated with either 
azacytidine, SPHINX or TG003 inhibitor, a combination of both inhibitor and all three 
molecules for up to 72hrs. B. Representation of PCR amplicon (Apaf-1x, 430bp) and 
(Apaf-1s, 301bp) for 24hrs, 48hrs and 72hrs. C. Densitometry showing percentage of 







4.6.5 Effect of combined SPHINX and TG003 with azacytidine on caspase 9 alternative 
splicing in Kasumi-1 cells 
Levels of caspase 9 appear unaffected across the treatment with caspase 9a isoform 
being more expressed (Figure 4.30B-C).  
                  
              
 








Figure 4.30. Alternative splicing of caspase-9 following combined SPHINX and TG003 
with azacytidine in Kasumi-1 cells. Kasumi-1 cells were treated with either azacytidine, 
SPHINX or TG003 inhibitor, a combination of both inhibitor and all three molecules for 
up to 72hrs. PCR was performed using caspase 9 specific primers. B. Representative PCR 
amplicon for caspase 9a, (742bp) and caspase 9b, (292bp) for 24hrs, 48hrs and 72hrs.C. 





4.6.6 Effect of combined SPHINX and TG003 with azacytidine on CLK1 alternative 
splicing in Kasumi-1 cells 
Kasumi-1 cells showed more CLK1 exon-4 inclusion in all treatment involving TG003 at 
24hrs and 48hrs. At 72hrs time point, except for the TG003 only treatment, all others 
involving TG003 in addition to the azacytidine only treatment had more exon 4 inclusion. 
(Figure 4.31A-B). Similarly, levels of CLK1 intron 4 retention varied between treatment 
(Figure 4.31C). 
 
          































Figure 4.31. Alternative splicing of CLK1 following combined SPHINX and TG003 with 
azacytidine in Kasumi-1 cells. Kasumi-1 cells were treated with either azacytidine, 
SPHINX or TG003 inhibitor, a combination of both inhibitor and all three molecules for 
up to 72hrs. A. Representative PCR for (CLK1 268bp) and (ΔCLK1 187bp) for 24hrs, 
48hrs and 72hrs. B. Densitometry showing percentage of exon 4 splice inclusion (PSI-






4.7 Effect of combined SPHINX and TG003 with imatinib on SRPK1 
expression and on SRSF1 and other SR-protein phosphorylation in 
K562 cells 
 
4.7.1 Effect of combined SPHINX and TG003 with imatinib on SRPK1 protein 
expression in K562 cells 
Studies into the effect of inhibiting SRPK1, CLK1 and imatinib treatment on K562s has 
shown that these have very little effect on the level and alternative splicing. We next 
examined the effect of the inhibitors on SRPK1 and CLK1 protein levels as there is 
evidence; at least in the case of CLK1 that expression of the splice factors themselves 
changes through presumed auto-regulatory mechanisms (Uzor et al., 2018). Protein 
levels of SRPK1 were found to alter when a comparison was made between the cells 
treated with SPHINX, TG003 and imatinib to all other treatments, only the controls and 
single kinase inhibition was found to show a significant change in SRPK1 protein level at 
24hrs and DMSO and TG003 at 72hrs (Figure 4.32A-B). This result was consistent with 
the data suggested by the standard PCR experiment.  
 
 






           
 






4.7.2 Effect of combined SPHINX and TG003 with imatinib on SRSF1 protein 
expression in K562 cells 
Like the levels of SRPK1, levels of total SRSF1 protein levels at 24hrs were found to be 
higher in the controls, SPHINX, TG003 and imatinib treatment than in the combination 
treatments. At 48hrs levels of the controls, combined SPHINX and imatinib and SPHINX 
and TG003 were higher compared to the combined treatment group. Whereas at 72hrs, 
SRSF1 levels were higher in the controls, SPHINX and TG003 treatment (Figure 4.33). It 
was expected that the total SRSF1 level will be unaffected by SRPK1 or CLK1 inhibition 
because both kinases are only known to act on the phosphorylated epitope.  
           
 
B 
Figure 4.32. SRPK1 Protein levels in combined SPHINX and TG003 with imatinib in 
K562 cells. Western blot analysis on K562 protein extracts using anti-SRPK1 antibody. 
K562 cells were treated with either SPHINX; or TG003, a combination of both inhibitor 
and in addition to Imatinib.  A. Densitometry showing protein levels of SRPK1 with 
increased SRPK1 protein level in the single treatment at 24hrs (P= 0.02, 0.006,0.04, 
and 0.03 respectively) and the DMSO and TG003 group at 72hrs (P<0.05) when 
compared to SPHINX+TG003+IM treated group. B. Image showing protein band 











4.7.3 Effect of combined SPHINX and TG003 with imatinib on CLK1 protein expression 
in K562 cells 
It was only at 72hrs did CLK1 levels in K562 cells treated with SPHINX, TG003 and 
imatinib significantly differ from the control but not with all other treatment (Figure 
4.34A). Like with SRPK1, CLK1 proteins levels appear to be unaffected following CLK1 
inhibition. In contrast, imatinib treatment results in a reduction in CLK1 protein levels as 
all treatment including imatinib showed an apparent decrease (Figure 4.34B). This was 
also an interesting finding knowing that imatinib could affect signalling pathway that 
results in changes in CLK1 expression. This was not the focus of this study; further 
investigation is necessary to understand what role CLK1 and changes in CLK1 levels in 
response to chemotherapy could be playing in CML progression and treatment 
outcome.  
Figure 4.33. Total SRSF1 protein levels in combined SPHINX and TG003 with imatinib 
in K562 cells. Western blot analysis on K562 protein extract using anti-SRSF1 antibody. 
K562 cells were treated with either SPHINX or TG003, a combination of both inhibitor 
and addition to Imatinib.  Image showing protein band visualized on PVDF membrane 




                 
 
 











Figure 4.34. CLK1 protein levels in combined SPHINX and TG003 with imatinib in 
K562 cells. Western blot analysis on K562 protein extract using anti-Clk1 antibody. 
K562 cells were treated with either SPHINX or TG003, a combination of both 
inhibitor and in addition to Imatinib. A. Densitometry showing protein levels of CLK1 
with only the control at 72hrs showing a significant difference (*P=0.02). B. Image 
showing protein band visualized on PVDF membrane with corresponding β-actin 




4.7.4 Effect of combined SPHINX and TG003 with imatinib on SR-protein 
phosphorylation in K562 cells 
Examination of phosphorylation serine/arginine proteins in K562s showed varying levels 
of phosphorylation with each treatment measured using an antibody specific to 
phospho-SR epitopes. Representative image blots are shown in Figure 4.35 
corresponding to each time point. There were indications of reduced phosphorylation 
in all treatments involving imatinib, and group treated with a combination of SPHINX 
and TG003 especially at 72hrs. Since SRPK1 and CLK1 are critical in the phosphorylation 
of SR proteins, it was expected that inhibition of either kinase will result in reduced 
expression of SR phospho-epitope. This was not the case, especially at 72hrs.  
Figure 4.35. Protein levels of phospho-SR protein in combined SPHINX and TG003 with 
imatinib in K562 cells. Western blot analysis on K562 protein extract using 1H4 pan 
antibody. K562 cells were treated with either SPHINX or TG003 a combination of both 
inhibitor and in addition to Imatinib. Western blot image showing protein levels for 
phospho-SR family proteins at 24hrs (I), 48hrs (II), and 72hrs (III). Results are suggestive 
of reduced phosphorylation of SR proteins in treatments with imatinib and combined 
SPHINX with TG003. Images were visualized on PVDF membrane with corresponding β-






4.8 Effect of combined SPHINX and TG003 with azacytidine on SRPK1 
expression and on SRSF1 and other SR-protein phosphorylation in 
Kasumi-1 cells 
 
4.8.1 Effect of combined SPHINX and TG003 with azacytidine on SRPK1 protein 
expression in Kasumi-1 cells 
Contrary to the effect of imatinib on SRPK1 in K562s, azacytidine has no effect on levels 
of SRPK1 protein expression in Kasumi-1 cells. Combining Inhibition of SRPK1 and CLK1 
with azacytidine results in a significant reduction in SRPK1 levels at 48hrs when 
compared to other treatment. However, at 72hrs, levels only differed with TG003, 
azacytidine and combined SPHINX and azacytidine (Figure 4.36A&B). Even though the 
combination of SPHINX and TG003 with azacytidine was not significantly different from 
the SPHINX and TG003 combination, there are indications that azacytidine may have a 
potential effect on levels of the SRPK1 oncoprotein. 
 





























Figure 4.36. SRPK1 Protein levels in combined SPHINX and TG003 with azacytidine in 
Kasumi-1 cells. Western blot analysis on Kasumi-1 protein extract using anti-SRPK1 
antibody. Kasumi-1 cells were treated with either SPHINX or TG003, a combination of 
both inhibitor and in addition to azacytidine. A. Densitometry showing increased protein 
level of SRPK1 at 48hrs in all treatment which differs significantly (****P≤0.0001; 
**P=0.008 and **P=0.002) from the SPHINX+TG003+azacytidine group except for 
SPHINX+TG003 treatment. At 72hrs (*P<0.05; **P=0.007 respectively) in the TG003, 
azacytidine and SPHINX+ azacytidine group. B. Images are representation of PVDF 






4.8.2 Effect of combined SPHINX and TG003 with azacytidine on SRSF1 protein 
expression Kasumi-1 cells 
Figure 4.37 are immunoblotting of total SRSF1 protein in Kasumi-1 cells following 
treatment with several compounds. Levels of total SRSF1 were found to be reduced at 
24hrs treatment with combined SPHINX and azacytidine and combination of all three 
treatment. An apparent increase in total SRSF1 was observed in the controls, SPHINX, 
azacytidine and TG003 and azacytidine when compared to SPHINX, TG003 and 
azacytidine combination. At 48hrs and 72hrs, levels of SRSF1 appear to be reduction in 
total SRSF1 splice factor in combined TG003 and azacytidine, SPHINX and TG003 and 
SPHINX, TG003 with azacytidine combination which appears to be time dependent. The 
latter displayed the lowest levels at all time points. 
 











Figure 4.37. Total SRSF1 protein levels in combined SPHINX and TG003 with azacytidine 
in Kasumi-1 cells. Western blot analysis on Kasumi-1 protein extract using anti-SRSF1 
antibody. Kasumi-1 cells were treated with either SPHINX or TG003, a combination of 
both inhibitor and in addition to azacytidine. Images are representation of protein levels 





4.8.3 Effect of combined SPHINX and TG003 with azacytidine on CLK1 protein 
expression in Kasumi-1 cells 
Examining the levels of CLK1 in Kasumi-1 cells showed a trend which is both treatment 
and time dependent. There was an apparent decrease in CLK1 with the combined 
treatments at 24hrs and 48hrs. Furthermore, at 72hrs, combined SPHINX, TG003 and 
azacytidine resulted in low levels of CLK1, compared to all other single and combined 
treatment (Figure 4.38). 















Figure 4.38. CLK1 protein levels in combined SPHINX and TG003 with azacytidine 
in Kasumi-1 cells. Western blot analysis on Kasumi-1 protein extract using anti-CLK1 
antibody. Kasumi-1 cells were treated with either SPHINX or TG003, a combination 
of both inhibitor and in addition to azacytidine. Images shows level of CLK1 proteins 





4.8.4 Effect of combined SPHINX and TG003 with azacytidine on SR-protein 
phosphorylation in Kasumi-1 cells 
Phosphorylation of the serine-rich splice factors is the key function of SRPK1 and CLK1. 
Protein blots for SR proteins showed significant decrease in phosphorylation in groups treated 
with TG003 and azacytidine, SPHINX and TG003 and a combination of all three compounds. 
These were more Phosphorylation of SRSF4 at 24hrs increased in the controls, SPHINX, 
TG003 and azacytidine but not in groups with combined treatment when compared to 
combined SPHINX, TG003 and azacytidine (Figure 4.39).  
At 48hrs and 72hrs, reduced phosphorylation was observed in TG003 and azacytidine 
and SPHINX and TG003 combination of all three treatments. Phosphorylation of pSRSF11 
for SPHINX and TG003 at 24hrs, TG003 and azacytidine and SPHINX and TG003 at 48hrs, 
and at 72hrs, SPHINX and TG003 was reduced.  
Levels of pSRSF5 were different across each treatment. Except for SPHINX and TG003 
treatment and a combination of all three treatments, levels were observed to rise after 
24hrs. Levels of pSRSF2 were similar to those found in pSRSF5.  
Figure 4.39. Protein levels of phospho-SR protein in combined SPHINX and 
TG003 with azacytidine in Kasumi-1 cells. Western blot analysis on Kasumi-
1 protein extract using SR-antibody (1H4). For statistical analysis, all 
treatments were compared to the combined SPHINX+TG003+azacytidine 
treatment. Representative Western blot images for SR protein blot showing 
levels of phosphorylation of SR proteins and corresponding β-actin loading 








4.9.1  Effect of combined SPHINX and TG003 with imatinib on K562 cell viability and 
growth 
CML is a myeloproliferative disorder characterized by a balanced translocation t(9;22) 
(q34; q11). This results in the formation of BCR-ABL oncoprotein, a constitutively active 
tyrosine kinase that promotes cellular growth and proliferation. Imatinib, a tyrosine 
kinase inhibitor, is a first-generation drug and a first line drug for the management of 
CML targeting the ATP-binding site of the fusion protein. Previous studies have shown 
that treatment of CML with imatinib results in decreased cell proliferation and cell death 
due to apoptosis (Husaini et al., 2017). 
To observe first-hand the effect of imatinib on the K562 cell line, cells were treated with 
increasing concentrations of imatinib up to 20μg/ml (Figure 4.1). Results obtained were 
consistent with previous research which recorded increased cell death and reduced cell 
proliferation in CML cells treated with imatinib or its analogue, dasatinib (Roussidis et 
al., 2004; Lu et al., 2017). Contrary to this finding, an earlier study (Roseé et al, 2003) 
found no correlation between imatinib treatment and cell death in K562 possibly due to 
experimental design, as the cells used were synchronized and arrested at the G1/S phase 
and treated with 1µM imatinib for up to 48hrs. Another study has shown that imatinib 
is able to inhibit cell growth and proliferation in platelet derived growth factor receptor 
positive (PDGFR+) ovarian cancer (Matei et al., 2004) and in colon cancer, with cell cycle 
arrest at G1/S phase (Samei et al., 2016). The increased cell death observed in K562 cells 
even at low doses of imatinib confirms the effectiveness of imatinib in CML treatment. 
Combining imatinib treatment and SRPK1 inhibition using SPHINX in K562 cells showed 
no further decrease in cell viability and growth. However, the result was consistent with 
the reduced cell viability in imatinib only treated cells This finding was unexpected. 
However, with a further assay, using acridine orange fluorescent dye to study cell 
apoptosis in combined imatinib and SPHINX treatment, it was observed that there were 
fewer apoptotic cells in the combined treatment than imatinib treatment alone. This 
brings into question if there is an indirect effect of SPHINX on the targets of imatinib, 




A study has shown that both imatinib and SPHINX or its analogue (SRPIN340) are able to 
interact with the PI3/Akt pathway (Zhou et al., 2012; Wang et al., 2014). It is therefore 
possible that SPHINX interaction with PI3/Akt activates rather than inhibits downstream 
target pathways responsible for cell survival. This will require further study on the 
structure of both molecules to understand what relationship exists between them. 
4.9.2  Effect of combined SPHINX and TG003 with azacytidine on Kasumi-1 cell 
viability and growth 
 
The use of azacytidine (a cystidine analogue with DNA hypo-methylation properties) in 
the management of AML was suggested in patients with unfavourable cytogenetics or 
myelodysplasia-related changes who are ineligible for stem cell transplant (NICE, 2018).  
Treatment with azacytidine has a clear activity but treatment does not result in a 
significant increase in overall survival (OS) (Dombret et al., 2015).  
Using the Kasumi-1 cell line as a model for AML, the effect of azacytidine on Kasumi-1 
cell viability and growth was observed. With a clinically relevant dose of 750ng/ml of 
azacytidine, concentrations up to 1.5µg/ml of azacytidine were used. Decreasing cell 
viability and reduced cell growth was recorded.  
Since treatment with azacytidine is not without side effects, which is a consequence of 
most chemotherapeutic agent, its combination with SPHINX was investigated with the 
thought that an increase in cell death would inform reduction in clinical doses. Kasumi-
1 cell viability was decreased in the combined treatment when compared to controls 
and SPHINX treatment (Figure 4.5A). However, for cell growth, the combination 
treatment was only reduced relative to the untreated and DMSO controls but was not 
significantly reduced relative to SPHINX or azacytidine treatments alone (Figure 4.5B). 
Additional assays measuring caspase 3/7 activity showed increased caspase activity with 
the combined treatment but did not differ significantly with the SPHINX or azacytidine 
treatment alone. This study observed no change in cell viability and growth with 
additional inhibition of CLK1. Suggesting that combined treatment with azacytidine, 
SPHINX and TG003 may have no additional benefit in AML treatment than combining 
azacytidine and SPHINX or azacytidine and CLK1 alone. 
With a lack of data comparing the effect of small molecules such as SPHINX and CLK1 




Research comparing the effect of combining azacytidine and romidepsin (AR) with 
interferon-α (IFN-α) on tumour progression and metastasis found that the addition of 
interferon potentiates the anti-proliferative, pro-apoptotic and metastasis activity of 
azacytidine and romidepsin alone in colorectal cancer (CRC) and CRC stem cells (CSCs) 
(Buoncervello et al., 2015). This combination was also known to affect the ERK1/2 and 
Akt pathway (Buoncervello et al., 2015). An earlier study has suggested a better 
outcome when immune therapy is combined with a conventional chemotherapeutic 
agent by induction of immunogenic cell death and increased T-cell recognition of 
tumour cells (Galluzzi et al., 2012). 
4.9.3 Effect of combined SPHINX and TG003 with imatinib on the expression of SRPK1, 
CLK1, VEGF and alternative splicing of a panel of apoptotic genes in K562 cells. 
The earlier results (Figure 3.17) demonstrated that inhibition of SRPK1 in K562 cells 
showed a fluctuating level of SRPK1 mRNA such that levels increased at 24hrs but 
decreased at 48hrs. Further experiments combining SRPK1 with imatinib treatment 
found no further change in levels of SRPK1, with levels remaining unaffected with 
additional inhibition of CLK1(Figure 4.20). This suggests that combined treatment offers 
no potential benefit where the aim is not just to inhibit the activity but also to reduce 
SRPK1 protein levels.  
SRPK1 has been described as a constitutively active kinase and considered to be resilient 
to inactivation due to its activation loop not requiring intra-protein interaction to stay 
active (Ngo et al., 2007). This could explain the unaffected levels of SRPK1 in leukaemic 
cells as preliminary studies in this research carried out on the prostate cancer cell line 
PC3, observed a significant decrease in SRPK1 mRNA and protein levels following SRPK1 
inhibition. 
Results obtained were consistent with previous studies which showed that inhibition of 
CLK1 results in more exon 4 inclusion and less intron 4 retention in an auto-regulatory 
loop (Uzor et al., 2018). This change in CLK1 splicing was observed only at concentrations 
of 10µM and 50µM TG003. When CLK1 inhibition was combined with either SPHINX or 
imatinib treatment or a combination of all treatments, only treatment involving TG003 
continued to show more exon 4 inclusion, whereas only at 72hrs did all treatments 




upregulation of CLK1 and its alternative splicing towards full-length CLK1 both in hypoxic 
conditions (Bowler et al., 2018), and in osmotic and heat shock conditions (Uzor et al., 
2018). There are indications that most tissues express both full-length and truncated 
forms of CLK1. However, there is a shift in how much of each isoform is expressed in the 
presence of stress (Ninomiya et al., 2011; Uzor et al., 2018).  Analysis of both exon 4 and 
intron 4 has shown that compared to intron 4, exon 4 is flanked by weak splice 
recognition sites and therefore will require strong ESE such as SRSF1 (Schwartz et al., 
2008; Uzor et al., 2018). The need for effective splicing towards catalytically active full 
length CLK1 continues to suggest its auto-regulation as an adaptative mechanism to 
maintain its function in adverse and disease conditions.  
Results presented here confirm that the autoregulation of CLK1 through its alternative 
splicing, observed following TG003 treatments in prostate cancer cell lines, can be 
reproduced in leukaemic cell lines. There is no strong evidence, however, of SPHINX 
causing a similar change to SRPK1 protein levels, and therefore, the effects measured 
are presumably due to an inhibitory effect on SRPK1 enzyme activity. 
Compared to previous studies (Nowak et al., 2009; Mavrou et al., 2014; Batson et al., 
2017) this study was unable to observe changes in VEGF splicing towards the anti-
angiogenic isoform VEGF165b in three leukaemic cell lines, neither did any single kinase 
inhibition nor a combination of any two or more compounds find any change in splicing. 
This suggests that VEGF165b isoform could be selectively expressed in certain cell types. 
A study (Song et al., 2012) also suggests that the BCR/ABL mutation self-regulates VEGF 
expression through HIF-1α activation of STAT3 on the VEGF promoter in leukaemic 
cancer. This auto-regulatory ability of VEGF may account for the levels of total VEGF 
observed. 
No change was observed in Bclx alternative splicing in combined imatinib and SPHINX 
treatment or in addition to CLK1 inhibition. Similarly, no change was observed in Apaf1 
alternative splicing with increased PSI (Ѱ) value indicating higher expression of Apaf-1xl 
anti-apoptotic isoform. Treatment with imatinib and imatinib TG003 combination 
expressed equal ratio of Apaf-1xl/1s at 72hrs. Like Apaf1, caspase 9 showed an apparent 
switch in splicing to caspase 9a upon treatment with imatinib or in combination with 
other inhibitory molecules. Combining imatinib with both kinase inhibitors had no 




in Apaf1 and caspase 9 continues to support the ability of imatinib to initiate alternative 
splicing and apoptosis in K562 cells (Liu et al., 2012 and 2015). 
4.9.4  Effect of combined SPHINX and TG003 with imatinib on protein levels of SRPK1, 
SRSF1, CLK1, and on the phosphorylation of SR protein in K562 
It has been observed that inhibition of SRPK1 using SPHINX had no effect on SRPK1 and 
total SRSF1 in the K562 CML cell line. The degree of the effect on SR protein 
phosphorylation in K562 varied from one SR protein to another, with reduced phospho-
epitope as expected following increasing concentrations of SPHINX (Figure 3.24). 
This study was expanded to investigate what effect a combination of SRPK1 and CLK1 
inhibition, in addition to treatment with imatinib, would have on individual protein 
kinase expression and on phosphorylation of SR proteins. The research group confirms 
previous work (Uzor et al., 2018; Bowler et al., 2018) in which CLK1 is found to auto-
regulate its expression in response to stress. Protein levels of CLK1 were elevated in 
treatments involving TG003 without imatinib in K562 cells. Interestingly, this increase is 
accompanied by an increase in SRSF1 supporting findings that suggest SRSF1 as the ESE 
required for CLK1 auto-regulation (Schwartz et al., 2008; Uzor et al., 2018); increased 
catalytically active CLK1 mRNA equals increased CLK1 protein. Furthermore, increased 
SRPK1 protein levels were observed even with a combination of TG003 with SPHINX 
which inhibits SRPK1. These results put together, suggests that CLK1 regulates SRPK1 
levels, and both CLK1 and SRPK1 are responsible for SR protein function (Aubol et al., 
2016 and 2018).  It is also possible that SRPK1 undergoes auto-regulation, and a further 
complication is that its nuclear presence is controlled by CLK1 (Aubol et al., 2016). 
Interestingly, except for combined imatinib and SPHINX treatment, all other treatments 
with imatinib combinations showed a time-dependent decrease in protein levels of 
SRPK1, SRSF1 and CLK1 at 48hrs and 72hrs. Since imatinib is specific for targeting the 
tyrosine kinase BCR-ABL, it can be inferred that through a downstream signalling 
pathway of BCL-ABL such as mTOR/Akt, imatinib is able to regulate protein synthesis of 
SRPK1, CLK1 and SRSF1 (Kharas et al., 2008). One study suggests that Akt, which is a 
target of imatinib can induce auto-phosphorylation of SRPK1, increasing SRPK1 nuclear 
import and subsequent SR protein phosphorylation (Zhou et al., 2012) indicating a direct 




observe that imatinib can reduce the levels of total SRSF1 through a mechanism, which 
is not known. This finding will need further investigation. 
Examining the effect on SR protein phosphorylation, fluctuating levels of 
phosphorylation within the SR protein family was observed. An apparent reduction in 
phosphorylation was observed where treatments were combined at the 72hrs time 
point. This was consistent with the levels of SRPK1 and CLK1 levels earlier observed. 
Overall, combining imatinib treatment and both kinase inhibition suggests a potential in 
the regulation of SR protein kinases, SRPK1 and CLK1 (Figure 4.32 & 4.34) and their 
substrate, SRSF1 (Figure 4.33) in CML. This in the broad sense will regulate aberrant 
splicing and pathways such as the PI3K/Akt which are targets of the SRPK1-CLK1-SR 
protein axis necessary for progression of CML.  
4.9.5 Effect of combined SPHINX and TG003 with azacytidine on the expression of 
SRPK1, CLK1, VEGF and alternative splicing of apoptotic genes in Kasumi-1 cells 
Statistics have shown that many adult patients with AML will go into a refractory phase 
or relapse from the disease (Breems et al., 2005). With the success achieved in the use 
of small molecule inhibitors for the treatment of multiple tumours such as 
gastrointestinal stromal tumour and CML (Luger, 2010; Demetri et al., 2002; O’Brien et 
al., 2003), the shift in research is the need to develop a therapeutic agent with a lasting 
positive outcome for patients in this category. 
This study has shown that SPHINX, and likewise, azacytidine, affect Kasumi-1 cell viability 
and growth. Further study expanded on this to see how a combination of both molecules 
in addition to CLK1 inhibition affects mRNA levels and splicing. Levels of SRPK1 and VEGF 
were unaffected when SPHINX was combined with azacytidine or with additional 
inhibition of CLK1. At 48hrs in the SPHINX and azacytidine combination, a smaller 
amplicon band (65bp) was observed, suspected to be VEGF165b isoform (Figure 4.15). 
This was inconclusive as the result was not reproducible. CLK1 showed more exon 4 
inclusion and less intron 4 retention in all groups involving TG003 treatment. Contrary 
to the levels of CLK1 intron 4 observed in K562, Kasumi-1 cells overall appear to express 
less of CLK1 intron 4 isoform. This observation was made considering the low levels 
observed in the untreated and DMSO controls. It does follow that different cells will 




might be common in acute phases of leukaemia as a previous study has observed 
similarly low levels of this isoform in MOLT 4, an acute lymphoblastic leukaemia cell line 
(Uzor et al., 2018). Choice of splice site involving binding of the ESE such as SR proteins 
on the alternative exons has been shown to promote exon inclusion (Han et al., 2011). 
This might be the case with Kasumi-1 mRNA splicing.    
Furthermore, no change was observed in Bclx, Apaf1 and caspase 9 alternative splicing 
following combined SPHINX and azacytidine, or in addition to CLK1 inhibition. This can 
be accounted for by mutation and copy number changes in genes encoding spliceosome 
proteins such as SRSF2, U2AF1 and SF3B1 in AML shown to affect maintenance and 
stability of leukaemic stem cell (LSC) clones and propagation of AML (Crews et al., 2016; 
Papaemmanuil et al., 2016). These proteins interact with pre-mRNA, and when mutated, 
splice site recognition is altered, which results in more intron retention and exon 
skipping. This correlates with the splicing event observed in these genes as the larger 
isoforms were highly expressed. Results observed with Bclx also suggest that the cell 
death observed in Kasumi-1 cells may have resulted from pathways other than the 
intrinsic pathway in which Bclx is involved, while a reduced but equal ratio of both Apaf1 
isoforms could be responsible for the induction of apoptosis rather than a complete 
switch from one isoform to the other. Since levels of Apaf1 in the combined treatment 
appear the same with azacytidine and with combined SPHINX and TG003 inhibition, it is 
unlikely that combining all three treatment may have an added advantage (Figure 4.29B-
C) 
4.9.6  Effect of combined SPHINX and TG003 with azacytidine on of SRPK1, SRSF1, 
CLK1, protein expression and phosphorylation of SR protein in Kasumi cells 
A previous study has shown increased sensitivity of myeloid cells to SRPK1 inhibition 
using the small molecule inhibitor SRPIN340 when compared to leukaemic cancers of 
lymphoid origin (Siqueira et al., 2015), suggesting that Kasumi-1 cells, which belongs to 
the same category, could be more sensitive to treatment.  
The result from this study has also suggested similar sensitivity with Kasumi-1 cells as a 
model when compared to K562 and TK6 cells where no effect on protein expression was 
observed following inhibition with SPHINX and TG003. Contrary to K562 cells, where 




than SPHINX or TG003, in Kasumi cells, a reduction was observed with treatment 
combination of TG003 and azacytidine, SPHINX and TG003 and a combination of both 
kinase inhibitor with azacytidine. Results were found to be consistent with time except 
for SRPK1 levels at 24hrs (Figure 4.36). Since SRPK1 and CLK1 phosphorylate SR-proteins, 
including SRSF1, it was expected that inhibition of both kinases would result in an 
increased expression of total SRSF1 rather than a decrease. The reduced expression of 
SRSF1 observed when SPHINX, TG003 and azacytidine were combined indicates a 
prospect of the potential benefit a combination of these compounds could play in the 
reduction of oncogenic splice factor SRSF1 in tumour cells. These results also suggest a 
cell-specific and cell-dependent effect of one kinase over another. Furthermore, the 
similarity in the protein levels of SRPK1 and CLK1 continue to confirm existing 
publications on the role SRPK1 and CLK1 in SR protein phosphorylation, and the 
regulation of SRPK1 by CLK1 (Zhou et al., 2012; Aubol et al., 2016).  
Phosphorylation of SR proteins; pSRSF4, pSRSF6, pSRSF11, pSRSF5 and pSRSF2 appear 
to also follow the trend observed in SRPK1, SRSF1 and CLK1 when the cells were treated 
with a combination of TG003 and azacytidine, SPHINX and TG003 and a combination of 
both kinase inhibition with azacytidine. Reduced phosphorylation was observed when 
all three treatments were combined and consistent with time, especially at 48hrs and 
72hrs. This confirmed the role of SRPK1 and CLK1 in SR protein phosphorylation. Also, 
since multiple SR proteins act on a set of ESEs, the degree of one SR protein expression 
over the other may result in competitive binding between SR proteins. The consequence 
which will either enhance or repress the binding of another SR protein (Pandit et al., 
2013). The implication of this result outcome is that combined targeting of SRPK1 and 











5 Comparative assessment of the effect of SRPK1 inhibition and 
SRPK1 siRNA knockdown in leukaemic cell lines. 
 
5.1 Introduction  
 
The serine-arginine protein kinase-1 (SRPK1) plays an essential role in various cancer and 
its progression (Mavrou et al., 2014; Roosmalen et al., 2015). SRPK1 has been shown to 
be upregulated in several types of cancers (Han et al., 2017). It has been shown that 
knockdown of SRPK1 inhibited tumour growth in xenograft and altered splicing of VEGF 
to a more anti-angiogenic VEGFxxxb isoform (Gonćalves, et al., 2014; Mavrou et al., 
2014). Other studies have shown that targeting SRPK1 using siRNA resulted in reduced 
cell proliferation and altered expression of key regulators of apoptosis (Hayes et al., 
2007). In K562 and AML, SRPK1 knockdown has been shown to suppress cell growth, 
induce apoptosis and altered isoform levels of genes involved in leukaemogenesis and 
apoptosis such as MYB, BRD4, VEGF-A and BCL2 (Tzelepis et al., 2018; Wang et al., 2018). 
This chapter was aimed at investigating the effect of SRPK1 knockdown using small 
interfering RNA (siRNA) on TK6, K562 and Kasumi-1 cell models. 
5.1.1 SRPK1 siRNA knockdown in leukaemic cell lines     
Using siRNA, SRPK1 was knocked down in leukaemic cell lines; TK6, K562 and Kasumi-1 
cell. The target sequence of the siRNA has been previously used (Karakama et al., 2010) 
to successfully knockdown SRPK1 (described in chapter 2.9). To determine the effective 
concentration of siRNA for SRPK1 knockdown, leukaemic cell lines were transfected with 
increasing concentration of SRPK1 siRNA up to 100nM. Cell transfection time with the 
siRNA was four hours and total incubation time was 72hrs. Immunoblotting was used to 
determine the effective knockdown which showed significant SRPK1 knockdown in all 
cell lines. Concentration for siRNA knockdown was then maintained at 100nM for all cell 





                  




5.1.2 Effect of siRNA knockdown on leukaemic cell viability and growth 
The effect of SRPK1 knockdown on leukaemic cell viability and cell growth was studied. 
This was done by transfecting TK6, K562 and Kasumi-1 cells with siRNA. Cell counts and 
viability assays were performed after 72hrs. Results of cell viability and growth in 
Knockdowns, scrambled control and SPHINX treatments were compared to DMSO. 
Results suggest no change in TK6 cell viability. In K562 and Kasumi-1 cells, SPHINX and 
knockdown cells significantly decreased when compared to DMSO (Figure 5.2A).  
When cell growth for all cell line was investigated, TK6 cells showed changes in cell 
number even in the scrambled control whereas, K562 and Kasumi-1 cells showed a 
significant decrease in cell growth in SPHINX and knockdown cells when compared to 
DMSO. This indicates that knockdown of SRPK1 has an apparent effect on leukaemic cell 
growth and suggests that SRPK1 may be involved in regulating the growth and 
proliferation pathways of some of these cells (Figure 5.2B). 
Figure 5.1. Knockdown at protein level of SRPK1 in leukaemic cells using small 
interfering RNA. Representative blots for TK6, K562 and Kasumi-1 cells showing 




                  
 


















Figure 5.2. Comparative effect of SRPK1 inhibition and knockdown on leukaemic cell 
growth.  Leukaemic cells were either treated with 10µM SPHINX or transfected with 
100nM siRNA for 72hrs. A. TK6 cell viability were unaffected. SPHINX (P=0.012) and 
SRPK1-siRNA (P<0.0001) percentage viability differed with DMSO in K562 cells. 
Percentage decrease (****P<0.0001) in Kasumi-1 cell viability for SPHINX and SRPK1-
siRNA when compared to DMSO. B. TK6 cells (**P= 0.007; 0.002; 0.002) showed changes 
in cell growth. Cell number was reduced (*P= 0.03; ****P<0.0001) when compared to 
DMSO in K562 cell. For Kasumi-1 cells, a reduction (*P=0.042; ****P<0.0001) in cell 




5.2 Effect of SRPK1 siRNA knockdown on alternative splicing of a panel 
of genes in leukaemic cells 
 
5.2.1 Effect of siRNA knockdown on VEGF alternative splicing 
Levels of total VEGF showed no apparent difference between SPHINX treated cells and 
cells where SRPK1 were knocked down in TK6, K562 and Kasumi-1 cell. Both the treated 
group and control appear to be the same except for Kasumi-1 cells, where the VEGF in 
the SPHINX treatment and knockdown seem higher when compared to the controls. 
Alternative splicing of total VEGF to its anti-angiogenic isoform which has previously 
been reported (Mavrou and Oltean, 2016; Batson et al., 2017) following SRPK1 inhibition 
or knockdown was not detected (Figure 5.3B).  
                   
                     
 







Figure 5.3. Comparative effect of SRPK1 inhibition and knockdown on VEGF alternative 
splicing. Leukaemic cells were either treated with 10µM SPHINX or transfected with 
100nM siRNA. A. Actin control for all PCR amplification. B. Total VEGF PCR amplicon 






5.2.2 Effect of siRNA knockdown on Bclx alternative splicing 
Ratios of Bclx isoforms (xl/xs) remained unchanged following SRPK1 knockdown in all 
three cell lines (Figure 5.4A-B). Bclx splicing levels in the knockdown were like the 
SPHINX treatment and controls with the more abundant anti-apoptotic isoform Bcl-xl 
(351bp) being more highly expressed.  
            
 














Figure 5.4. Comparative effect of SRPK1 inhibition and knockdown on Bclx alternative 
splicing. Leukaemic cells were either treated with 10µM SPHINX or transfected with 
100nM siRNA or a scrambled control. A. PCR images for (Bcl-xl, 351bp) and (Bcl-xs, 
162bp) for TK6, K562 and Kasumi-1. B. Densitometry showing percentage of splice 




5.2.3 Effect of siRNA knockdown on Apaf1 alternative splicing. 
Knockdown of SRPK1 showed no apparent effect on Apaf1 splicing (Figure 5.5). 
 
            
 


























Figure 5.5. Comparative effect of SRPK1 inhibition and knockdown on Apaf1 
alternative splicing. Leukaemic cells were either treated with 10µM SPHINX or 
transfected with 100nM siRNA or a scrambled control. Representative PCR image for 





5.2.4 Effect of siRNA knockdown on caspase 9 alternative splicing. 
Knockdown of SRPK1 had no effect of caspase 9 alternative splicing. Quantitative 
analysis of gel electrophoresis indicates equal levels of both isoforms being expressed 
both in the controls and treated group (Figure 5.6A-B).   
 
         
 
 










Figure 5.6. Comparative effect of SRPK1 inhibition and knockdown on caspase 9 
alternative splicing. Leukaemic cells were either treated with 10µM SPHINX or transfected 
with 100nM siRNA or a scrambled control. A. Representation of PCR amplicon (caspase 9a, 
742bp) and (caspase-9b, 292bp) for TK6, K562 and Kasumi-1. B. Densitometry showing 





5.3 Comparative assessment of SRPK1 inhibition and SRPK1 
siRNA knockdown in leukaemic cells protein levels 
 
5.3.1 Effect of siRNA knockdown on SRPK1 protein levels  
Protein quantification indicated an effective knockdown of SRPK1 using siRNA. Levels of 
SRPK1 differed significantly between knockdown and DMSO (Figure 5.7A-B). 
          
                      






Figure 5.7. Comparative assessment of SRPK1 protein levels in SRPK1 inhibition and 
knockdown leukaemic cells. Cells were treated with either SPHINX or transfected with 
SRPK1 siRNA. A. Result showed significant knockdown of SRPK1 in the siRNA transfected 
cells for all cell lines. In TK6 (**P= 0.006).  K562 protein levels also differ (***P=0.0002) 
compared to DMSO. Knockdown of SRPK1 in Kasumi-1 (**P=0.003) when compared to 
DMSO. B. Images are representative of immunoblot with corresponding β-actin loading 




5.3.2 Effect of siRNA knockdown on SRSF1 protein levels  
Protein levels for total SRSF1 were found to be increased following knockdown of SRPK1 
in K562 cells, when compared to the DMSO control. Kasumi-1 and TK6 cells showed no 
difference in both the knockdown and SPHINX when compared to DMSO control (Figure 
5.8). 
  






















Figure 5.8. Comparative assessment of total SRSF1 protein levels in SRPK1 
inhibition and knockdown leukaemic cells. Western blot analysis on leukaemic cells 
protein extract using anti-SRPK1 antibody. Cells were treated with either SPHINX or 
transfected with SRPK1 siRNA. Representative immunoblots with corresponding β-





5.3.3 Effect of siRNA knockdown on SR protein phosphorylation  
Phosphorylation of SR protein following SRPK1 knockdown using siRNA was also 
investigated. Protein levels for pSRSF4 were found to be reduced in the knockdown 
group for all cell lines. In TK6 and K562 cells, reduced levels of phosphorylation 
significantly differed from the DMSO treated cells. Furthermore, in Kasumi-1 cells, both 
the SPHINX and knockdown cells showed a significant decrease in phosphorylation when 
compared to the DMSO. 
Immunoblotting using the 1H4 monoclonal antibody designed to identify phospho-
epitopes for the SR proteins showed that levels of pSRSF6 following SRPK1 knockdown 
was found to be reduced. Lower levels of phosphorylation were observed in the 
knockdown in TK6 and K562. While in Kasumi-1 cells, SPHINX and the knockdown cells 
significantly decreased pSRSF6 levels (Figure 5.9). 
Levels of pSRSF11 appear to be affected by the knockdown in TK6 and K562 cells (I & II) 
when compared to the DMSO control. In Kasumi-1, reduced phosphorylation of pSRSF11 
was observed in the SPHINX and knockdown cells when compared to DMSO (III).  
Reduced levels of pSRSF5 were observed in knockdown cells in all three cell lines these 
were found to be significantly reduced compared to the increased level seen in the 
untreated, DMSO and scrambled group. Similar levels were also observed for Kasumi-1 














 Figure 5.9. Comparative assessment of protein levels of phospho-SR 
protein in SRPK1 inhibited and knockdown leukaemic cells. Western 
blot analysis on leukaemic cells protein extract using anti-SRPK1 
antibody. Cells were treated with either SPHINX or transfected with 
SRPK1 siRNA. Representative western blot images (I-III) for SR-proteins 







5.4.1 Effect of SRPK1 knockdown on leukaemic cell viability and growth 
In a previous study, knockdown of SRPK1 in the CML cell line, K562 using siRNA has been 
shown to induce apoptosis and decrease K562 cell proliferation (Wang et al., 2018). 
Levels of apoptosis induction correlated with increased levels of cleaved caspase-3, 
cleaved PARP and p53 protein levels (Wang et al., 2018). A similar experiment carried 
out in renal cell carcinoma (RCC) and pancreatic tumour cells also observed growth and 
proliferation inhibition as well as suppression in the migratory and invasive ability of the 
cells (Hayes et al., 2007; Han et al., 2017).  
A further experiment was carried out firstly to confirm that the effects observed with 
SPHINX was an SRPK1-dependent effect and secondly, to observe whether leukaemic 
cells will behave differently if SRPK1 was knocked down using siRNA rather than 
inhibited with small molecules. Apart from TK6 cells where no change was observed in 
the cell viability, a significant decrease in cell viability was observed in K562 and Kasumi-
1 cells in SPHINX and knockdown cells when compared to DMSO. Furthermore, cell 
growth was significantly reduced in the SPHINX and knockdown cells when compared to 
DMSO controls in TK6, K562 and Kasumi-1 cells. This result is consistent with published 
work (Wang et al., 2018) and suggests that SRPK1 could be involved in CML and AML cell 
growth and disease progression. 
5.4.2  Effect of SRPK1 knockdown on alternative splicing of VEGF and a panel of 
apoptotic genes 
This study found no difference in VEGF levels between knockdown, SPHINX inhibition 
and controls. This suggests that knockdown of SRPK1 has no effect of VEGF in TK6, K562 
and Kasumi-1 model cell lines. No change was also observed with splicing of apoptotic 
genes in all three cell lines, with the dominant isoforms being highly expressed. Other 
studies have found changes in VEGF alternative splicing following inhibition or 
knockdown of SRPK1 in several cancers (Gammons et al., 2014; Gonçalves et al., 2014; 
Hatcher et al., 2018). Previous studies have reported altered expression of caspase and 
BCL2L apoptotic genes following transfection with small interfering RNA targeting SRPK1 




5.4.3  Effect of SRPK1 knockdown on the levels of SRPK1, SRSF1 protein and on 
phosphorylation of SR protein in leukaemic cells 
Consistent with the established role of SRPK1 in phosphorylation of SR proteins, levels 
of total SRSF1 were increased, whereas phosphorylation for pSRSF4, pSRSF6, pSRSF11 
and pSRSF5 were found to be reduced in knockdown cells. The levels of SR protein 
differed from the controls but not all SR protein showed a difference between the 
knockdown cells and the SPHINX treated cells. This suggests that there may not be a 
compensatory mechanism for SRPK1. So, whether inhibition or knockdown, the same 
effect will be observed on the phosphorylation of its substrate. Results suggest that 






6 Discussion of key findings, limitation of study and future 
work 
 
6.1 Summary of key findings  
 
Leukaemia is a malignant disorder that results from the abnormal proliferation of a clone 
of haematopoietic cells characterised by insensitivity of blood cells to growth regulation 
and apoptosis (Chu et al., 2012). According to CRUK, leukaemia is the 12th most common 
cancer in the UK with about 9,900 new cases of leukaemia reported in the UK each year 
(CRUK, 2018). The incidence rate is higher in males than in females. It is projected that 
the incidence rate of leukaemia will rise by 5% between 2014 and 2035 while the 
mortality rate will rise by 18%. Leukaemia prognoses differs significantly depending on 
whether it is acute or chronic, of myeloid or lymphoid cell type, age and time of diagnosis 
(CRUK). Despite advancements in understanding the molecular pathogenesis of 
leukaemia, and despite improvements in therapy and the introduction of novel drugs, 
most patients will relapse due to impaired haematopoiesis driven by clonal evolution of 
bone marrow stem cells (Martínez et al., 2005; Yilmaz et al., 2019).  
The serine/arginine-rich protein splice factor kinase-1 (SRPK1) belongs to a family of 
protein kinases, which phosphorylate specific amino acids of proteins rich in 
serine/arginine repeats (RS-domain). A study has shown that following activation of EGF, 
SRPK1 can induce substantial changes in the alternative splicing landscape through 
phosphorylation of SR proteins (Zhou et al., 2012). It is apparent that the role and 
expression of SRPK1 in different cancers is heterogeneous and therefore, its role in 
cancer is not yet fully understood (Zhou et al., 2013; Bullock and Oltean, 2016). 
A study in leukemic cells demonstrated that SRPK1 is highly expressed in erythroid and 
lymphoid cells and, there is an associated increased expression of SRPK1 to cell 
proliferation and tumour grade (Sanidas et al., 2010). Repression of SRPK1 in AML was 
shown to modify the choice of a splice site in VEGF and caspase 9 (Shultz et al., 2011; 
Oltean et al., 2012). In relation to VEGF, the mechanism is such that repression of SRPK1 




site in exon 8 during VEGF pre-mRNA splicing resulting in expression of anti-angiogenic 
VEGF (Shultz et al., 2011; Oltean et al., 2012).  
This thesis was aimed at targeting SRPK1 with a small molecular inhibitor as alternative 
mechanism in slowing the growth of leukaemic cells and augmenting existing 
conventional chemotherapeutic drugs. 
6.1.1 Effect of SPHINX on leukaemic cell viability and growth 
This study investigated what effect SRPK1 inhibition using SPHINX has on leukaemic cell 
viability and growth. It also investigated if combining SRPK1 inhibition with existing 
drugs will improve leukaemia treatment using three cell line models: the lymphoblastic 
cell line TK6, the chronic myeloid leukaemia cell line K562 and the acute myeloblastic 
leukaemia cell line Kasumi-1. 
Results from this study showed that inhibition of SRPK1 using SPHINX had no effect on 
TK6 and K562 cell viability and cell number at experimental concentrations. Kasumi-1 
cell viability and growth were significantly decreased and shown to be concentration 
dependent. The percentage decrease in cell viability observed was accompanied by an 
increase in caspase 3/7 activity, which are known to be indicators of apoptosis.  When 
SRPK1 was knocked down using siRNA in all three cell lines, K562 and Kasumi-1 but not 
TK6 showed a decrease in both cell viability and growth. Peripheral blood cells of 
myeloid origin have been shown to be more sensitive to SRPK1 inhibition (Siqueira et 
al., 2015). This suggests that SRPK1 could play a role in leukaemic cell survival, but its 
effect could also be cell specific. 
This study also confirms that both Imatinib mesylate (a tyrosine kinase inhibitor 
targeting the fusion protein Bcr/Abl in CML) and azacytidine (a DNA hypo-methylation 
agent used in AML therapy) are both effective in inducing cell death in CML and AML 
cell line models. However, when SPHINX was combined with either imatinib for K562 or 
with azacytidine for Kasumi-1, only in Kasumi-1 cells was an additive effect of increased 
cell death observed over cells treated with either SPHINX or azacytidine alone. 
Combining imatinib and SPHINX showed no additive effect in the percentage of cell 
death in K562 cells compared to imatinib treatment. A limitation to this aspect of the 
study is the lack of a suitable control in the microscopic investigation of apoptosis. A 




sulfonamide which inhibits caspase 3/7 activity by competitively binding to the active 
binding site and catalytic cysteine residue respectively (Lee et al., 2000; Yoshimori et 
al.,2004). The established apoptotic inducer apoptolidin, has been shown to be 
selectively cytotoxic on several cancer cell lines and non-cytotoxic on normal cells (Ghidu 
et al.,2008) and would have served as a good positive control. These would have 
validated the observed result especially in the untreated and DMSO controls where no 
caspase activity was observed. Owing to this caveat, it is possible that some leukaemic 
cancers could benefit from therapies that include inhibiting SRPK1; this ought to be 
looked at in much further depth in future research. 
6.1.2 Effect of SPHINX on alternative splicing of CLK1 and a panel of apoptotic genes 
The results obtained showed that alternative splicing in RNA levels of Bclx, Apaf1 and 
caspase 9, responded differently following inhibition of SRPK1 using SPHINX.  
SPHINX inhibition of SRPK1 favoured the increased expression of the anti-apoptotic Bcl-
xl isoform in all cell lines. Higher levels of Bcl-xl have been reported in several cancers 
including leukaemia where it confers a cell survival advantage in leukaemic cells (Boise 
et al., 1993; Takehara et al., 2001; Willimott et al., 2011). 
 
Like with BCL2L, APAF1 also encodes two isoforms; Apaf-1xl and 1s. Apaf-1xl which is 
the full-length isoform and anti-apoptotic in function was also found to be increasingly 
expressed in all cell lines except for Kasumi-1 cells at 10μM concentration at 24hrs. 
Studies have shown that an increased level of Apaf-1xl in cells prevents cell apoptosis 
and confers resistance to chemotherapeutic treatment (Benites et al., 2008). The study 
also suggests that an equal level of both isoforms rather than overexpression of either 
Apaf-1xl or 1s is required to initiate apoptosis in cells and overcome drug resistance 
(Benites et al., 2008). 
 
On the alternative splicing of caspase 9, caspase 9a the larger of the caspase 9 isoforms 
which is also known to be pro-apoptotic (Shultz et al., 2011) in function was increasingly 
expressed in TK6 cells and Kasumi-1 cells at higher concentrations of SPHINX inhibition. 
Conversely, K562 showed decreased levels of the pro-apoptotic 9a isoform. This finding 
indicates that caspase 9a could be involved in the apoptosis of some leukaemia cells. 




apoptosome and supressing (9b), or activation (9a) of the caspase enzyme cascade (Vu 
et al., 2013). A case-controlled study (Edathara et al., 2019) suggested that a 
polymorphism, CASP9-1263A>G, observed in a CML patient, enhanced the risk for 
developing CML while, Ex5 +32G>A exonic polymorphism, which results in the 
substitution of glutamine by arginine causes conformational changes in caspase 9 and 
therefore its affinity to Apaf-1. This change in caspase 9 affinity for Apaf-1 was observed 
to confer resistance to CML cells against apoptosis (Edathara et al., 2019). It also 
suggests that the choice of apoptotic pathway could be cell-specific since levels of 
caspase 9a matched the increased level of cell death in Kasumi-1 cells but not in the 
other two cell lines. 
 
On combining SPHINX with either imatinib or azacytidine, CLK1 showed increased exon 
4 retention and less intron 4 inclusion in treatments involving TG003. This shift in splicing 
is aimed towards higher expression levels of catalytically active CLK1 and its auto-
regulation in order to maintain its activity. It was also observed that the level of 
retention of intron 4 was lower in Kasumi-1 cells as compared to K562. There was no 
additional effect of combining SPHINX and azacytidine in the alternative splicing of Bclx, 
Apaf1 and caspase 9 when these were compared with the single treatments in Kasumi-
1 cells. Furthermore, in K562 cells, combining SPHINX and imatinib showed a change in 
alternative splicing towards increased expression of caspase 9a, an effect which could 
have been caused by imatinib since the same splicing event was not observed in the 
SPHINX only treatment.  A previous study (Liu et al., 2012) had observed a switch in Bclx 
to a pro-apoptotic isoform (Bcl-xs) in K562 cells following treatment with imatinib. The 
concentration of imatinib used however, was higher than the concentration used in this 
thesis.  
This aspect of the study was confronted with some challenges. First, PCR for the 
reference gene (β-actin) used as loading control and normalization of the gene of 
interest was performed on each batch of synthesized cDNA. This has the advantage of 
confirming the integrity of the cDNA after synthesis and a baseline for overall actin 
expression in the cell lines. It does have the disadvantage of not confirming the integrity 
of the cDNA in subsequent repeats. Even though cDNAs are known to be relatively 
stable, the cycle of freeze thawing, handling and temperature have an effect which was 




could be responsible for the second challenge, which is large variation in the confidence 
intervals observed during statistical analysis. As such, some of the PCR outputs were 
neither quantified nor normalized, and results presented were interpreted based on 
visual examination of the amplicon intensity, which could be subject to bias.  
 
6.1.3 Effect on protein levels of SRPK1 and SRSF1 and phosphorylation of SR-protein 
 
It is conceivable that the inhibition of SRPK1 might result in changes in its own 
expression as there are no published studies investigating the effect of SRPK1 inhibition 
on its own protein levels through such an auto-regulatory mechanism. Results from this 
thesis have shown that inhibition of SRPK1 in model cell lines using SPHINX suggest an 
increase in SRPK1 protein levels at higher concentrations in K562 but not in TK6 and 
Kasumi-1 cell lines. Exposing K562 cells to imatinib did appear to cause a reduction in 
SRPK1 levels, and this effect was not significantly augmented with SPHINX. In Kasumi-1 
cells, there was an obvious advantage over combining SPHINX and TG003 with 
azacytidine as cells in this group expressed less SRPK1 protein overall. In summary there 
is some evidence that i) there may be an auto-regulatory mechanism that needs to be 
investigated further and ii) established drugs such as imatinib appear to influence SRPK1 
expression presumably by interfering with regulatory or cell signalling pathways such as 
Rac signalling where it affects its splice selection of e3b with consequent decrease of 
Rac1b (Gonçalves et al., 2014) required to maintain SRPK1 expression. 
 
Protein levels of total SRSF1 appeared to be reduced at 48hrs in TK6 at higher 
concentrations but were unaffected in K562 and Kasumi-1 cells. This suggests that SRPK1 
activity might also influence the overall expression of its own substrates, perhaps 
through an alternative splicing mechanism. Protein levels of the splice factor kinase CLK1 
were found to be reduced in K562 cells in treatment with imatinib, imatinib and TG003 
and a combination of all three molecules. In Kasumi-1 cells, combining SPHINX and 
TG003 with azacytidine resulted in a significant decrease in CLK1 protein when 
compared to other treatments. This suggests that as well as affecting the expression of 
SRPK1 and SRSF1, treating leukaemic cell lines with these compounds also affects 




benefit, since elevated expression of these splice factor kinases is generally associated 
with a more proliferative phenotype (Karni et al., 2007; Anczuków et al.,2012). 
 
Phosphorylation of SR proteins was found to be significantly reduced and affected either 
in a concentration-dependent manner or at a time point in all three cell lines following 
SRPK1 inhibition with SPHINX. This was not surprising as these splice factors are SRPK1 
substrates and required for their activation (Gui et al., 1994), and confirmed that SPHINX 
was having the desired effect. Knockdown of SRPK1 was shown to affect the level of SR 
protein phosphorylation. Combining SPHINX (to inhibit SRPK1) with TG003 (to inhibit 
CLK1) with imatinib or azacytidine resulted in decreased SR protein phosphorylation 
when compared to the single treatments in K562 especially at 72hrs.  In the AML cell 
line, Kasumi-1, there was a marked decrease in SR protein phosphorylation in cells 
treated with SPHINX, TG003 and azacytidine. Increased SR protein phosphorylation and 
associated increases in SR protein activity is associated with a proliferative phenotype 
(Karni et al., 2007); therefore, the ability of SPHINX (especially in combination with other 
inhibitors) to reduce phosphorylation of SR proteins could prove beneficial in the 
treatment of AML. However, for an experiment lasting 72hrs, the half-life of the 
inhibitors and drugs used were not determined. Other factors such as drug handling, 
storage, light and temperature are known to affect shelf-life of drugs (Anderson and 
Scott, 1991; Singh et al., 2002). It is possible that some results which were not consistent 
were because of degradation of the drugs. For example in Figures 3.32, 4.36 and 4.39, 
where a decrease was observed at 24hrs while at 48hrs and or 72hrs, an increase was 
observed. 
Taken together, the results presented in this thesis do suggest that there may be benefit 
in targeting the splice factor kinase SRPK1 with SPHINX, perhaps in combination with 
existing drugs, and in combination with CLK inhibitors. Further research is needed to 











6.2 Future work 
 
6.2.1 Determine the broad effect of SRPK1 inhibition in leukaemic cells on the 
transcriptome 
Results presented in this thesis suggest that SRPK1 inhibition in the model cell lines (TK6, 
K562 and Kasumi-1) has a different effect on each cell line with Kasumi-1 cells being the 
most affected. It is possible that SRPK1 inhibition using SPHINX could influence other 
targets and pathways other than those investigated in this research. Tzepelis et al., 
(2016) have identified SRPK1 as a gene that could be targeted in AML following a CRISPR 
screen and pharmacological validation. Previous studies (Zhou et al., 2012; Wang et al., 
2014) have also found an effect of targeting SRPK1 on PI3/Akt pathways, which was not 
investigated in this study. As expected, we observed that SRPK1 inhibition affected 
phosphorylation of SR proteins, which are key in the splicing machinery. It would be of 
interest to determine the effect of SRPK1 inhibition, either alone or together with CLK 
inhibition, and together with established drugs on the transcriptome more widely. The 
most direct approach would be to use RNASeq and to examine the effect on the 
alternative splicing of a wide range of cancer-associated transcripts, associated with 
each of the hallmarks of cancer. As well as a broad analysis of alternative splicing, the 
alternative splicing of genes specifically associated with critical roles in each type of 
leukaemia could be examined. This type of research would also shed further light on the 
biological function of SRPK1. 
6.2.2 In vivo experiments to determine the effect of SRPK1 inhibition on tumour 
growth 
Siqueira et al., (2015) observed that peripheral blood cells of myeloid origin where 
Kasumi-1 cells belong are more sensitive to SRPK1 inhibition when compared to cells of 
lymphoid origin. Result obtained in this study were consistent with their findings with 
Kasumi-1 showing increased propensity to cell death following SPHINX inhibition and 
knockdown when compared to K562 and TK6 cells. It would be worth investigating if 
such a result could be replicated in vivo to confirm the previous reports of SRPK1 as a 
potentially druggable target in AML and, therefore, to move research forwards.  
It is worth mentioning at this point that two in vivo study attempts were made during 




could be replicated in vivo, specifically in mouse xenograft experiments. However, due 
to technical issues experienced, viable tumours did not form and so, the experiment was 
not completed. This study was unable to achieve growth of tumours in all the mice at 
the end of the approved period for such work. Owing to the time limit of this project, it 
was not possible to make another attempt. This will be a primary objective in future 
research, perhaps using a different leukemic cell line model that is more suitable for 
xenografting. 
6.2.3 Investigating the potential of targeting CLK1 in leukaemic cells 
The effect of inhibiting CLK1 with TG003 on SR protein phosphorylation and on its own 
alternative splicing was investigated in this project even though it was not the focus of 
the research. It was observed that CLK1 splicing particularly in CML cells following 
inhibition with TG003 resulted in more exon 4 retention and intron 4 skipping; this was 
not apparent in Kasumi-1 cells. It was observed that CLK1 protein was increased 
following its inhibition with TG003; when imatinib was combined with TG003, an 
additive effect was observed. It would be of great interest to investigate the effect of 
CLK1 inhibition on leukemic cells, either on its own, or in combination with SRPK1 
inhibition. It should be noted that TG003 is one of the first CLK inhibitors to be developed 
(in Masatoshi Hagiwara’s laboratory); it also inhibits CLK4, which is closely related to 
CLK1. More specific CLK inhibitors are being developed that could supersede TG003. It 
is conceivable that a potential novel therapy will be focused on inhibiting both SRPKs 
and CLKs together. There are, furthermore, other splice factor kinases such as the DYRKs 
(Becker and Joost, 1999); their role and targetability in leukaemia should also be 
considered.  
6.2.4 Effect of combining SPHINX with imatinib 
This research also observed some interesting results with imatinib.  It was observed that 
imatinib alone reduced cell viability as well as protein levels of CKL1, total SRSF1 and 
SRPK1 in CML.  In addition, imatinib appeared to affect the alternative splicing of caspase 
9 favouring pro-apoptotic caspase 9a. Interestingly, when imatinib was combined with 
SPHINX, the effect on SRPK1, CKL1 and total SRSF1 expression was less prominent. So, 
there are likely to be complex effects when SPHINX and imatinib are combined. In line 




PI3/Akt pathway (Wang et al., 2014). Future work will address in more detail the 
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